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CHAPTER I: GENERAL INTRODUCTION  
As integral part of the body, proteins are involved in all important biological 
processes. Consequently, the understanding of their role in physiological and 
pathophysiological processes led to an enormous request to exploit the potential of 
proteins as therapeutic agents. However, the large scale production of proteins for 
pharmaceutical applications was not possible until the mid 1970s, when the 
advances of recombinant DNA technology marked the beginning of modern 
biotechnology era. The first recombinant protein (Humulin®; marketed by Genentech 
and Eli Lilly) was approved in 1982, and nowadays, only 25 years later, 
approximately 20 % of new drug applications involve a protein as active compound. 
Most of them are used for the treatment of serious, life-threatening, and chronic 
diseases such as cancer, rheumatoid arthritis, hepatitis and others [166, 244].  
In comparison to low molecular weight drugs especially the high activity and 
selectivity of proteins often allow a better treatment of these diseases [231, 250]. 
However, due to their fragile, three-dimensional macromolecular structure proteins 
are susceptible to a variety of chemical and physical degradation pathways. 
Therefore, the development of suitable formulations in which the native structure and 
activity of proteins are maintained during preparation, delivery, shipping, and long-
term storage has become one of the most challenging tasks [129, 143, 250]. 
Unfortunately, proteins generally require parenteral administration for systemic 
delivery. One reason why non-parenteral application pathways are often restricted is 
the high molecular mass in combination with the polar characteristics of proteins. 
Consequently, proteins reveal a low permeability through biological membranes. 
Furthermore, proteases ubiquitously present at administration sites as well as the 
inherent instability of proteins hamper a non-invasive administration [98, 231]. 
Nevertheless, research is focussed on the improvement of the bioavailability through 
alternative routes of administration. These attempts recently led to the approval of 
pulmonary-delivered insulin [1]. However, still concerns remained, such as potential 
local side effects or anti-insulin antibody formation [231, 244].  
As the plasma half-lives of proteins are often very short, frequent injections or 
administration via infusions are required for maintaining therapeutic plasma levels. 
This is associated with poor patient compliance, side effects, or cost consuming 
hospitalisation [41, 73, 98, 231]. One way to overcome these restrictions is the 
optimisation of pharmacokinetic properties by mutagenesis or post-translational 
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engineering of therapeutical proteins, like the conjugation with poly(ethylene glycol) 
[245]. Apart from these options, the development of injectable, sustained release 
systems can be regarded as another promising strategy to improve protein delivery 
[41, 73, 98, 231]. 
Several systems, like microspheres, liposomes, as well as solid and in-situ forming 
implants, have been suggested as delivery technologies for proteins. Among the 
plethora of investigated synthetic and natural polymers, biodegradable poly(α-
hydroxy esters) and in particular poly(lactic acid), PLA, and poly(lactic-co-glycolic 
acid), PLGA, found most widespread use. Their popularity mainly stems from the fact 
that these polymers provide an excellent safety and biocompatibility record [80, 198, 
233].  
However, despite the early success of peptide-loaded microspheres and implants, 
the delivery of proteins appears to be more difficult and still no controlled release 
system for the delivery of proteins is launched [212]. The only protein-releasing depot 
device that reached the market in 1998 (Genentech´s Nutropin Depot®) was 
withdrawn 2004 [78].  
The limited success of polymeric delivery systems for the controlled release of 
pharmaceutical proteins can be explained with some inherent shortcomings of 
PLA/PLGA. Several detrimental effects on protein stability during device 
manufacturing as well as during storage and release were identified [169, 199, 212, 
233].  
In order to overcome these restrictions lipids (e.g., triglycerides, monoglycerides, and 
fatty acids) have been proposed as alternative matrix formers for controlled protein 
delivery systems [127, 144]. Being natural, physiological materials, lipids feature a 
superb biocompatibility [85, 180]. Moreover, compared to PLA/PLGA lipid matrix 
materials exhibited several potential advantages that might facilitate the preservation 
of the native protein structure during manufacturing, storage, and during release. 
This superiority was recently confirmed by Mohl and Winter. They introduced a 
tristearin-based implant system for the continuous release of interferon α-2a (IFN-α) 
over 1 month [153]. Importantly, IFN-α was released almost exclusively in its 
monomeric form and co-lyophilisation with hydroxypropyl-β-cyclodextrin (HP-β-CD) 
provided long-term stability of these formulations [151, 152]. 
However, little is known about the mechanisms controlling the liberation of IFN-α 
from lipidic implant systems so far. Therefore, one of the central aims of the present 
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work was the establishment of an understanding about the underlying release 
determining mechanisms.  
Furthermore, the developed lipidic device exceeded the size that would be commonly 
accepted for an implant administration. Consequently, different ways for the 
preparation of miniaturised lipidic implants were evaluated in the course of this 
thesis, too. All methods for the manufacturing of lipidic implant systems described in 
literature rely on the preparation with a self-made manufacturing apparatus which is 
operated manually and only in lab-scale. In order to overcome this limitation within 
the scope of this thesis, state of the art extrusion techniques were applied with 
respect to an ease of up-scaling.  
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1. OVERVIEW ON APPROVED CONTROLLED RELEASE SYSTEMS FOR PHARMACEUTICAL 
PEPTIDES 
The approved controlled release systems for pharmaceutical peptides can be divided 
into microspheres, solid implants, and in-situ forming implants [45, 198, 212]. 
Microspheres have a diameter of 1-100 µm and are suspended in an appropriate oily 
or aqueous liquid prior to injection. Solid implants commonly reveal a cylindrical 
geometry. Even if films and tablets have been realised experimentally, small 
cylindrical implants which offer the possibility to be deposited subcutaneously via a 
large gauge needle (trochar) are preferred. A small size of the device is further 
crucial to avoid irritations at the site of injection [198].  
Compared to microparticles, two main disadvantages are noted for implant systems:  
(1) the administration is more complicated and might be painful for the patient and  
(2) the administered doses are more limited [45, 198].  
Thus, countless publications are dealing with the development of polymeric 
microparticulate systems, whereas the literature describing implants for the delivery 
of proteins is sparse. On the other hand, implants inhere the possibility of a surgical 
removal, if adverse events necessitate an interruption of the therapy [41, 121]. 
Moreover, the versatility of implant shape and sizes permits the adjustment of drug 
release rates [102].  
Nowadays, two solid implant systems based on PLGA for the sustained delivery of 
goserelin acetate and buserelin acetate are commercially available (Zoladex® and 
Profact®Depot) [121].  
In order to facilitate the administration, in-situ forming implants have received 
attention. Eligard® based on the ATRIGEL® technology is a sustained release 
formulation for leuprolide acetate that is administered as liquid and forms a solid 
implant after s.c. or i.m. injection. In-situ forming is realised by dissolving the 
polymeric matrix material (e.g. PLA, PLGA) in a water-miscible, biocompatible 
solvent (e.g. dimethyl sulfoxide, N-methyl-2-pyrrolidone, or triacetin). Upon 
administration the polymer precipitates due to the displacement of the organic 
solvent upon contact to the tissue fluids. However, potential disadvantages of in-situ 
forming implants are (1) inconsistent shapes of the implant formed after injection into 
the body, (2) undesired burst effects, and (3) solvent toxicity [61]. 
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Figure 1: Cross section of the DUROS® implant system [254]. 
Apart from in-situ forming and solid implants based on PLGA osmotically driven 
implantable systems for peptides have been approved. ViadurTM is an adaptation of 
the DUROS® implant technology for the delivery of leuprolide acetate. The implant 
consists of a cylindrical titanium alloy reservoir capped at one end by a rate-
controlling membrane and capped at the other end by a diffusion moderator. Within 
the diffusion moderator an orifice, through which the drug release occurs, is located 
(Figure 1). The osmotic engine, containing sodium chloride, expands as the device is 
imbedded into water. Consequently, the pressure applied by the piston forces the 
drug formulation through the orifice. Leuprolide is delivered in a constant manner 
over 1 year. The external dimension of the implant is 4 mm in diameter and 45 mm in 
length [254].  
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2. CONCERNS ASSOCIATED WITH THE USE OF PLA/PLGA AS MATRIX FORMERS 
2.1. PROTEIN INSTABILITY DURING MANUFACTURING OF PLA/PLGA MICROPARTICLES 
This chapter is focussed on potential sources for protein destabilisation during the 
preparation of controlled release devices. Detrimental conditions for the formulation 
of particulate drug delivery systems based on PLGA are discussed exemplarily. 
Nevertheless, the destabilising situations depicted below will threat the protein 
stability in a similar way irrespective of the used matrix material and the kind of 
controlled release systems aimed to be produced.  
Table 1: Common techniques for the preparation of microparticles [258] 
chemical processes physical processes 
solvent evaporation and extraction
phase separation 
polyelectrolyte complexation 
interfacial polymerisation 
spray drying 
spray congealing 
supercritical fluid precipitation 
 
The broad spectrum of physical and chemical techniques applied for the formation of 
microparticles is summarised in Table 1. All techniques require the loading of an 
organic polymer solution with the protein. A few attempts were made to dissolve the 
protein directly in the organic polymer solution [162, 176, 259]. In most cases the 
loading of the protein was realised by dispersing an aqueous protein solution 
(emulsion method) or the solid protein powder (suspension method) in the organic 
polymer phase. Therefore, in the following chapter denaturating stresses associated 
with the emulsion and the suspension loading will be outlined. 
2.1.1. PROTEIN LOADING – EMULSION TECHNIQUE 
The most prominent technique to prepare microspheres is the double emulsion 
method which comprises the emulsifying of the aqueous protein solution in an 
organic solution of the polymer. This primary emulsion is then transferred into a 
second aqueous phase. The formation of a W/O/W emulsion is accomplished by 
intensive stirring, vortexing, or homogenisation. For particle hardening the polymer 
solvent needs to be removed which can be realised either by extraction with a water 
miscible solvent or by evaporation. Finally, the microparticles are washed and 
vacuum dried or lyophilised [258]. As alternatives to the double emulsion technique 
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the particle forming (after emulsification of the aqueous protein solution in the organic 
solvent) can be conducted, for example, by spray drying or by phase separation.  
However, irrespective of the technique applied for particle shaping protein 
denaturation and aggregation may take place due to the presence of water/organic 
solvent interfaces. Because of their amphiphile character proteins tend to adsorb at 
such interfaces and as a result, protein unfolding followed by non-covalent 
aggregation occurs [16, 156, 189, 190, 234]. In addition, Pérez and Griebenow 
reported the formation of an alternative unfolded species (U*) for lysozyme after 
adsorption. U* diffused from the interface back into the bulk solution which led to a 
continuous drop of the enzyme activity in the soluble fraction [168].  
Furthermore, the organic solvent might diffuse to a certain extend into the aqueous 
protein phase resulting in (1) an alteration of the ionic strength and/or (2) in direct 
binding of the organic solvent to the protein [199].  
Finally, proteins are exposed to large shear and cavitation stress during 
emulsification. In dependence on the applied homogenisation technique the mass 
transport to the surface and to water/organic interfaces increases. For instance, 
Morlock et al. reported that the formation of erythropoietin (EPO) aggregates was 
less pronounced when rotor/stator type homogenisers were used instead of 
ultrasound or vortex mixing [156]. The employment of sonication is particularly 
harmful since local temperature extremes as well as free radicals might be generated 
upon emulsifying [128].  
Several attempts to stabilise the protein during emulsification have been proposed. 
For instance, the usage of higher protein concentrations or carrier proteins minimised 
the relative fraction of the therapeutically protein adsorbed at the interface [156, 188]. 
Furthermore, the protein could be stabilised by the addition of sugars, polyols etc. via 
preferential exclusion. In addition, co-encapsulation of cyclodextrins was shown to 
improve the stability of EPO [156], ovalbumin, and lysozyme [188].  
2.1.2. PROTEIN LOADING – SUSPENSION TECHNIQUE 
This technique is based on the scientific knowledge that the conformational mobility 
of suspended proteins in aprotic, hydrophobic solvents is particularly restrictive [123]. 
Consequently, suspending the solid protein powder in the organic polymer solution 
causes less protein destabilisation than loading the protein as aqueous solution [43]. 
The particle forming can be performed with the methods mentioned in Table 1.  
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However, when water is required during the particle shaping step this will be 
associated with certain problems. In the case of the S/O/W method the solid protein 
is first suspended in the organic polymer solution. Afterwards, this suspension is 
emulsified in an outer aqueous phase for particle forming. Since proteins are 
hydrophilic they tend to leach from the polymer solution into the outer aqueous phase 
what accounts for low encapsulation efficiencies [169]. On the other hand, leakage of 
the outer aqueous phase into the organic solution will increase the flexibility of the 
protein. Consequently, the ability of unfolding is rising [148].  
In order to obviate both obstacles, non-aqueous encapsulation procedures such as 
the S/O/O method were introduced [169]. Here, the suspension of the protein powder 
in an organic polymer solution is added to a coacervating fluid, which is miscible with 
the polymer solvent but does not dissolve the polymer (e.g. silicone oil, vegetable oil, 
or light liquid paraffin). Thus, the polymer solvent is slowly extracted, followed by the 
concentration of the polymer until coacervated drug loaded droplets are formed. The 
final hardening of the particles is accomplished by pouring them into a second non-
solvent (e.g. aliphatic hydrocarbons) [212, 258].  
However, serious practical concerns arise with the S/O/O technique. The obtained 
microparticles tend to aggregate and scale-up is hardly realisable [258]. Furthermore, 
multiple solvents are applied and their residual contents may restrict the approval by 
the authority. Moreover, the particle size of the protein powder must be sufficiently 
small to avoid contact to the microparticle surface, which in turn would result in a 
large burst release [169]. 
A non-aqueous, cryogenic methodology led to the unique protein-containing PLGA 
depot system (Nutropin Depot®) that reached commercialisation. The sustained 
release formulation of zinc-complexed rhGH in PLGA microspheres resulted in a 
one-month effect after one single injection [10, 109]. However, in 2004 Nutropin 
Depot® was withdrawn from market by Genentech, claiming “significant resources 
required … to continue manufacturing and commercializing the product” as the main 
cause [78].  
This short overview on techniques used to produce microspheres illustrates that 
there are several severe stability problems associated with the encapsulation of 
pharmaceutical proteins into microspheres. Unfortunately, methods that provide 
acceptable protein integrity, such as the anhydrous procedures, are often very 
complicated. 
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Apart from protein destabilisation during manufacture a further drawback is frequently 
reported for microspheres: high burst release due to low encapsulation efficiencies 
[119, 130]. High initial release rates may lead to drug concentrations near or above 
the toxic level in vivo. Also the drug released during burst might be metabolized and 
excreted without being effective. Thus, high burst release is mostly undesired [103].  
2.2. PROTEIN INSTABILITY DURING RELEASE FROM PLA/PLGA MATRICES 
In addition to the destabilising effects identified during manufacturing several 
destructive conditions for proteins are generated within PLA or PLGA matrix systems 
during incubation [169, 198, 199, 212, 233].  
During release, the degradation of the polymer backbone entails a mass loss. 
Generally, this material loss is referred to as erosion. For degradable polymers two 
mechanisms have been proposed: surface or heterogeneous erosion and bulk or 
homogeneous erosion. In the case of surface erosion the cleavage of the polymer 
chains mainly occurs at the outermost area of the matrix. The polymer degradation is 
faster than the intrusion of water into the matrix, thus the erosion only affects the 
surface and not the inner part of the matrix (heterogeneous). In contrast, bulk erosion 
occurs when the degradation of the polymer is slow compared to the water uptake. 
The matrix is completely wetted before scission of the polymer begins. Finally, the 
polymer chains are cleaved throughout the device (homogeneous process) [79, 80].  
Obviously, the mechanism of degradation depends on the type of functional groups 
from which the polymer is built. Polymers comprising reactive functional groups such 
as polyanhydrides are predominantly subjected to surface erosion, whereas 
polymers containing less reactive groups for example poyl(α-hydroxy esters) tend to 
bulk erosion [79, 80].  
During the bulk erosion of PLA/PLGA matrices the generated degradation products 
are trapped within the matrices. Consequently, the incorporated proteins are faced to 
a completely altered microenvironment [169, 198, 199, 212, 233].  
Due to the accumulation of degradation products within the matrix the following 
causes for protein unfolding, aggregation, and chemical degradation have been 
identified: 
(1) a significant pH drop [74], 
(2) an increase of the osmotic pressure [28], 
(3) accumulation of reactive species [140]. 
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In order to overcome these stability problems the following attempts have been 
suggested: 
(1) neutralisation by the incorporation of basic salts (e.g. Mg(OH)2) [261]  
(2) accelerated leaching out of degradation products due to an increase of the 
porosity of the matrix [169].  
Another critical factor leading to potential deterioration of protein upon release is the 
hydration of the matrix. The presence of water increases the protein molecular 
mobility and consequently the occurrence of protein unfolding and irreversible 
aggregation. Typically, moisture induced aggregation is ascribed to a thiol-disulfide 
interchange [49, 50]. Furthermore, chemical reactions such as deamidation were 
reported as a result of water imbedding [131].  
Finally, interactions between the PLA/PLGA matrix and the protein have been 
identified as further cause for incomplete protein release. Mainly the protein is 
adsorbed due to unspecific hydrophobic contacts and due to electrostatic interactions 
[70, 233].  
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3. ALTERNATIVE MATRIX MATERIALS 
Based on the multitude of reports describing the problems associated with the use of 
PLG/PLGA devices, current research is focussed on both the search for possibilities 
to stabilise the incorporated protein against the detrimental conditions and on the 
evaluation of alternative matrix formers. Among them, hydrogels and lipid-based 
formulations have achieved particular interest within the past few years [98, 111, 127, 
144]. 
3.1. CONTROLLED RELEASE SYSTEMS BASED ON HYDROGELS  
Hydrogels are cross-linked hydrophilic polymers assembled to a three-dimensional 
network, which can take up a large amount of water without loosing structural 
properties. The obtained swollen and rubbery consistence is regarded to provoke 
minimal tissue irritations and less harmful conditions for incorporated proteins [121, 
237]. The pool of investigated polymers is vast, including natural polymers (collagen, 
alginate, chitosan) as well as synthetic polymers poly(ethylene glycol), poly(vinyl 
alcohol), poly(hydroxyethylmethacrylate) [237].  
Cross-linking can be accomplished either by the introduction of chemical linkers or by 
physical methods. However, chemical cross-linkers are often toxic and the 
proceeded chemical reaction might affect the entrapped protein. Thus, interest in 
physical cross-linking increased. During this procedure, non-permanent physical 
interactions between the polymer chains are initiated by an external trigger (e.g. pH, 
temperature, ionic strength) [92].  
Hydrogels are either formulated as microspheres or as in situ forming implants. In 
spite of the interest especially on microspheres based on dextran hydrogel [91, 237], 
so far little research is dedicated to the physicochemical characterisation of the 
proteins within these hydrogel microparticles. For instance, the cross-linking or 
hardening procedure might be a concern with respect to protein stability [111]. 
3.2. CONTROLLED RELEASE SYSTEMS BASED ON LIPIDIC MATERIALS  
Lipids have been referred to as “chemically heterogeneous group of substances, 
having in common the property of insolubility in water, but solubility in non-polar 
solvents”. More precisely the principal categories of lipids are: fatty acids, fatty acid 
salts, phospholipids, glycerides, waxes, glycolipids and sterols [220]. Due to this wide 
variety of compounds a diversity of lipid-based delivery platforms for peptides and 
proteins is described in literature. Based on the structural properties of the 
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predominant lipid, systems that rely on lipid bilayers and solid, matrix-like systems 
can be distinguished. 
Bilayer-based systems 
When placing amphiphilic polar lipids in water lipid bilayers are formed 
spontaneously, which arrange to various geometric structures and shapes [200]. The 
obtained three-dimensional structures, like liposomes and cubic phase gels, have 
been utilised as drug delivery vehicles for the sustained release of peptides and 
proteins. Studies on the application of liposomes as microreservoir for the sustained 
release of proteins involve traditional liposomes, such as unilamellar and 
multilamellar vesicles [216], as well as newly developed multivesicular liposomes. 
The latter are based on the DepoFoamTM technology. Multilamellar liposomes are 
structurally distinct from lamellar liposomes and consist of aggregated, water-filled 
polyhedral compartments separated by lipid bilayers [257]. For instance, 
subcutaneous injection of DepoLeridistim (DepoFoamTM encapsulated Leridistim, a 
chimeric growth factor containing IL-3 and G-CSF receptor agonist) prolongates the 
biological effect for up to 10 days [134].  
Alternatively, proteins have been incorporated into cubic phase gels. From these 
systems, release is regulated by diffusion through aqueous channels permeating the 
cubic phase. Incorporation into cubic phase provided protection of insulin against 
agitation induced aggregation. However, in-vivo delivery of insulin and desmopressin 
revealed limited liberation periods of 6-9 h [200]. Recently, the diameter of the 
channels was tailored to the hydrodynamic diameter of the incorporated drug. 
Nevertheless, protein delivery was still finished after approximately 12 days [46].  
Matrix-like systems 
In spite of their advantages, the described liposomes and cubic phase gels have no 
matrix−type character which often leads to short release periods terminated within 
several hours to a few days. In contrast, relatively hydrophobic lipids have been used 
in the solid state to provide sustained release from solid lipid nanoparticles, 
microspheres, microcapsules, and implants. 
Even though solid lipid nanoparticles (SLN) were suggested as delivery systems for 
proteins their hydrophobic nature and small sizes render high encapsulation yields 
very unlikely. For instance, only small quantities of lysozyme (50-500 µg 
protein/g lipid) were incorporated into SLNs comprising various lipids, even when a 
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special solubilisation technique was applied [4]. Rather than usage for prolonged 
release, SLN own potential for drug targeting after surface modification or as 
adjuvant for vaccines [195]  
On the basis of their outstanding importance as protein delivery system lipidic 
microspheres and implants will be discussed in detail below.  
3.2.1. LIPID MICROPARTICLES 
Lipid microparticles can be produced by the use of similar methods as described for 
polymeric microparticles (see Chapter I.2.1). However, the manufacturing protocol 
itself threatens the protein stability irrespective of the applied matrix material. 
Consequently, applying the double emulsion method would also involve the creation 
of detrimental interfaces and shear forces. Therefore, several alternative techniques 
using the advantage that lipids can be manufactured as molten liquid were 
developed.  
One of these microsphere preparation methods is the melt dispersion method. With 
this technique lipid microparticles were produced by emulsifying a drug loaded 
molten lipid into an aqueous, surfactant containing phase which is heated above the 
melting point of the lipid. Afterwards this emulsion is rapidly cooled down [18, 19, 48]. 
Using this technique Reithmeier et al. succeeded to encapsulate thymocartin, 
somatostatin, and insulin into glyceryl tripalmitate microparticles. The protein was 
loaded into the molten lipid either as aqueous solution (W/O/W) or as solid (S/O/W) 
[179, 180].  
Another preparation technique was introduced by Del Curto [55]. Gonadotropin 
release hormone agonist (Antide®) was co−melted with glyceryl monobehenate 
(Compritol E ATO®) or glyceryl monostearate (Imwitor 900®). The obtained matrix 
was micronised in a milling aperture cooled with liquid nitrogen. The developed 
microparticles based on Compritol E ATO® revealed testosterone suppression up to 
29 days in-vivo. However, the manufacturing procedure was limited by the solubility 
of the drug within the molten lipid. Due to the hydrophilic character of peptides and 
proteins monoglycerides were required as matrix material and still only low drug 
loadings of max. 2 % were realisable. Alternatively, the drug loading of the matrix 
was conducted by dissolving Antide® and the lipid in a benzyl−ethanol mixture. 
Afterwards, the solution was poured into petri dishes and the solvent was allowed to 
evaporate [55]. However, in this case the proposed method is restricted by the drug 
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solubility in the applied organic solvent. Thus, it remains questionable if this 
technique can be applied to other peptides and proteins.  
Lipid microparticles can also be obtained by atomisation of the protein loaded lipid 
melt in a cold stream of air (spray congealing). For instance, with this technique 
bovine growth hormone was encapsulated into lipid microparticles. After application 
to dairy caddy the milk production could be enhanced over a time frame of 2 weeks 
[30]. More recently, Göpferich and co−workers reported the encapsulation of insulin 
by a spray congealing procedure [145]. 
A supercritical fluid process for the coating of protein particles with lipids was 
introduced in 2001 by the group of Benoit [184, 185, 224]. Protein particles were 
dispersed in a supercritical solution of the lipid. Then, the pressure was decreased to 
reduce the solubility of the lipid within the supercritical CO2, which induced a 
precipitation upon the insoluble protein particles [224]. In order to obtain a uniform 
coating layer, the usage of heterogeneous lipid mixtures was preferable. Compared 
to pure triglycerides such materials revealed a reduced tendency to form separate, 
distinct crystals on the protein particles. The supercritical procedure was shown to be 
suitable for the coating of bovine serum albumin (BSA) particles with Gelucire® 50-02 
without affecting the protein structure. However, the obtained reservoir type 
microspheres delivered BSA within only 24 h [185] and were yet not capable for a 
sustained release . 
3.2.2. SUBTYPES OF LIPID BASED MICROPARTICLES   
Domb et al. introduced a special kind of microparticles, called lipospheres that are 
defined as water−dispersible solid microparticles composed of a hydrophobic fat core 
coated by a monolayer of phospholipid molecules [59]. Despite the aforementioned 
definition some authors used the term liposphere and lipid microparticle 
interchangeably. 
For the mucosal vaccination via the delivery of antibodies to the respiratory tract 
microparticles based on dipalmitoylphosphatidylcholin were prepared by spray 
drying. The developed microparticles exhibited a thin−walled porous morphology with 
a geometric diameter of around 7 µm [22, 23]. Thus, the developed system takes an 
intermediate position between microspheres and liposomes.  
In spite of some progress obtained so far, thorough investigations on protein integrity 
within lipid microspheres are rare. Data on drug integrity are only provided in the 
case of peptide encapsulation. Thus, it remains unclear whether techniques such as 
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the melt dispersion method really offer the benefit to encapsulate proteins without 
affecting their three dimensional structure. In particular the creation of water-molten 
lipid interfaces might cause similar problems as the double emulsion process outlined 
in Chapter I.2.1.  
But, considering the knowledge obtained with the preparation of polymeric 
microparticles it can be assumed that non-aqueous encapsulation approaches such 
as the spray congealing technique will display the potential of lipids as alternative 
matrix formers.  
3.2.3. LIPIDIC IMPLANTS 
3.2.3.1. MANUFACTURING BY COMPRESSION 
Lipidic implant systems are mostly prepared by compression of protein lipid blends. 
In contrast to polymeric implants (see Chapter I.4), the high compressibility of lipids 
allows the formation of solid matrices by traditional compression at mild conditions. 
Thus, several authors used this technique to demonstrate the suitability of lipids as 
carriers for pharmaceutical proteins. The first investigations rely on cholesterol as 
matrix material [115, 246]. Later on triglycerides, monoglycerides and fatty acids 
were applied, too [31, 214, 248]. In Table 2 an overview on implant systems prepared 
by compression is given. 
Table 2: Protein loaded lipid-based implant prepared by simple compression. 
author matrix composition / protein observation 
Kent 1984 [115] cholesterol, bovine growth hormone / insulin, 
preparation of macromolecular-loaded 
lipidic implants is possible 
Wang 1987 [247] cholesterol / insulin reduction of blood glucose levels over 24 days 
Wang 1989 [246] 
various fatty acids, fatty acid 
anhydrides, monoglycerides and 
triglycerides / insulin 
reduction of blood glucose levels in-
vivo over 43 days 
Cady 1991 [31] C10−C20 fatty acid salts of growth hormone releasing heptapeptide 
fatty acid chain length correlates with 
the daily release rate 
Khan et al. 1991 [117] cholesterol, lecithin / bovine serum albumin 
release in-vitro over up to 1 month, in-
vivo erosion of the implants within 
40 days 
Kaevichit and Tucker 
1994 [112] 
stearic acid / bovine serum 
albumin prolonged release over 60 h 
Steber 1995 [215] triglycerides partially coated with methacrylate / somatotropin, 
elevated blood levels of in-vivo for 
1 month 
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Vogelhuber et al. 2003 
[241] 
trimyristin / TAMRA-BSA, 
hyaluronidase 
release of bioactive hyaluronidase 
within 48 hours 
Mohl and Winter 
 [151-153] tristearin / IFN-α 
sustained release of monomeric IFN-α 
over 1 month 
Guse et al. 2006 [84] various triglycerides / lysozyme sustained release over 1 month 
Koennings et al. 2006 
[125] tripalmitin / interleukin-16 
sustained release over 18 days but 
integrity loss 
Apple et al.2006 [6] tripalmitin / insulin release of bioactive insulin 
Koennings et al. 2007 
[126] 
tripalmitin / lysozyme, brain-
derived neutrophilic factor (BDNF) 
60 % intact BDNF were released over 
one month  
Koennings et al. 2007 
[124] 
various triglycerides / lysozyme 
increased wettability of the matrix 
accounted for accelerated release 
rates 
 
All studies mentioned in Table 2 used compression to form the implant. However, the 
techniques applied to generate the lipid protein blend were quite different:  
(1) the solid protein was simply physically mixed with the lipid powder [112, 151-153, 
241, 246], 
(2) the solid protein was physically mixed with precipitated lipid powder [117], or  
(3) the protein was co-precipitated with the lipid powder [6, 84, 115, 125]. 
Khan et al. [117] revealed that the loading techniques influenced the erosion rates 
and thus, the release behaviour. Before compression, the lipids, namely cholesterol 
and lecithin, were co-precipitated from organic solvents. After solvent evaporation the 
lipidic co-precipitates were pulverised and mixed with BSA. Finally, the lipid protein 
blend was compressed. When chloroform was used as precipitating agent the  
co-precipitates revealed reduced erosion and release rates compared to pellets 
prepared by physically mixing [117].  
Recently, the group of Göpferich applied three alternative methods to co-precipitate 
protein and lipidic material: (1) the emulsion-compression method, (2) the 
suspension-compression method, and (3) the wetting-compression method.  
When applying the emulsion-compression method the aqueous solution of the 
protein was emulsified into a solution of the lipid in methylene chloride by vortex 
mixing. This emulsion is subsequently freeze dried and the obtained dry powder 
comprising the lipid and the protein is compressed. Recently, Guse et al. used the 
emulsion-compression method to load various triglyceride matrices with lysozyme 
[84].  
Chapter I: General introduction 17 
  
However, it has been shown extensively that the creation of water-organic solvent 
interfaces inheres several unfavourable conditions on protein stability. The protein 
denaturation and subsequent formation of higher order aggregates is claimed as one 
of the major cause for incomplete protein release from PLGA matrices (see Chapter 
I.2). Thus, it can be expected that the emulsification with an organic lipid solution 
might also affect the protein integrity. Indeed, Koennings et al. recently reported that 
the emulsion-compression method was unsuitable to maintain protein integrity. 
Protein aggregation was observed during the emulsifying of an aqueous lysozyme 
solution in an organic solution of tripalmitin [126]. 
Performing the suspension-compression method, the protein was suspended as solid 
powder in the organic lipid solution. This method was applied by Koennings et al. to 
encapsulate interleukin-18 (IL-18) into tripalmitin implants [125]. First, the protein had 
to be co-lyophilised with poly(ethylene glycol) 6000 (PEG) in order to obtain the solid 
IL-18 particles. After dispersing the protein powder in the lipid solution by 
ultrasonication, the suspension was frozen in liquid nitrogen, and the organic solvent 
was allowed to evaporate. Finally, the lipid-protein blend was ground in a mortar and 
compressed [125].  
The authors suggested that this procedure resulted in a more homogenous 
distribution of the protein within the lipid matrix compared to the simple physical 
admixture before compression. However, only 30 % of IL-18 were delivered from 
these implants and also increasing the amount of the porogen PEG 6000 from 2 % to 
7 % failed to improve the recovery rates. Furthermore, the fully bioactive IL-18 was 
only delivered within 24 hours; at later time points a progressive integrity loss was 
found. The protein stability after manufacturing was not investigated. Due to the 
progressive decrease of bioactivity during in-vitro incubation the authors concluded 
that the protein stability was compromised during release rather than during implant 
manufacture [125].  
By applying the wetting-compression method insulin was encapsulated in tripalmitin 
implants. Here, the lipid powder was admixed with a solution of insulin. After drying, 
the lipid-insulin blend was compressed. The biological activity of the released protein 
was investigated in a long-term cartilage engineering culture. In a two-week trial, 
biological effects of the released insulin on the cartilage constructs could be proven, 
indicating the preservation of the protein activity [6].  
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An excellent protein stability of IFN-α delivered from HP-β-CD was also reported by 
Mohl and Winter [151-153] Importantly, the implants were prepared in a less 
complicated way by the compression of physically mixed lipid and protein powders. 
This manufacturing technique was demonstrated to maintain the integrity of IFN-α. 
The addition of PEG 6000 into the lipidic implant ensured a sustained delivery of 
monomeric protein over 1 month [151-153].  
3.2.3.2. ALTERNATIVE MANUFACTURING TECHNIQUES FOR LIPIDIC IMPLANTS 
Up to now, only two studies are available reporting protein-loaded lipidic implants that 
were not prepared by compression techniques. Pongjanyakul et al. filled polyethylene 
tubes (internal diameter 2.5 mm) with a suspension of lysozyme in molten glyceryl 
palmitostearate (Precirol ATO 5). The tubes were closed and cooled to 45 °C with a 
rate of 14 °C/min. Afterwards, the solidified lipid was pushed out of the tubing and cut 
into implants with a length of 4 mm. Compared to implants prepared by compression 
the obtained pellets revealed a smoother surface with only a few pores. 
Consequently, the amount of totally liberated protein was reduced [174].  
Besides, Yamagata et al. suggested heat extrusion through a needle as 
manufacturing procedure for lipidic implants. In this report polyglycerol esters of fatty 
acids loaded with solid IFN-α powder were heated above their melting point and then 
forced through a stainless steel needle [255].  
Apparently, all methods described above, are based on a manufacturing method in 
lab-scale with the help of self-made equipment. So far no attempts have been made 
to prepare lipid-based delivery systems for proteins with up-scalable techniques such 
as twin screw extrusion.  
3.3. LIPIDS AS MATRIX MATERIAL – ADVANTAGES AND CONCERNS  
3.3.1. POSSIBLE ADVANTAGES OF LIPIDIC MATRICES 
Reithmeier et al. assessed the biocompatibility of lipid microparticles in comparison 
to PLGA microspheres by implanting both delivery forms subcutaneously into mice. 
After two days in both groups a weak proliferation combined with a slight infiltration of 
specific inflammatory cells was visible. The proliferation of the connective tissue was 
even more pronounced for PLGA microspheres. After 7 days the reaction of the 
connective tissue was finished in the lipid group, whereas the proliferation in the 
polymeric group still proceeded [179]. This excellent biocompatibility report for 
tripalmitin was confirmed several times later. For instance, after subcutaneous 
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implantation of cylindrical implants with a diameter of 2.0 mm no inflammatory 
reaction and only a slight encapsulation into connective tissue were observed [85]. 
Good biocompatibility was also demonstrated for implants based on alternative lipids, 
such as lecithin, cholesterol [243], and glyceryl monostearate (GMS) [3]. 
These studies indicate that an important prerequisite for the development of 
controlled release systems based on lipids is fulfilled: the biocompatibility has been 
shown to be comparable to that of approved polymeric systems.  
As outlined above, lipids inhere some unique properties that allow the development 
of gentle manufacturing procedures. For instance, the preparation of lipidic implants 
by compression was shown to maintain protein stability during implant 
manufacturing, storage, and release [151-153]. Furthermore, due to the low melting 
temperatures of lipids the processing of the melt is feasible, and consequently the 
application of organic solvents becomes redundant. A fact of importance, since 
residue solvent levels in pharmaceutical products are well known as a potential toxic 
risk and might thus hamper the approval by authorities [253].  
However, the outstanding benefit of lipids as matrix material might be that the protein 
is confronted to less detrimental conditions during the release period. As outlined in 
Chapter I.2, bulk erosion and the resulting accumulation of degradation products 
have been identified as a tremendous intrinsic problem of PLA/PLGA matrices 
comprising the protein stability during release. In contrast, matrices based on pure 
triglycerides revealed no swelling or erosion during in-vitro and in-vivo release [85, 
241]. As a result, lipophilic matrices might provide a less challenging environment for 
the incorporated protein during release. Indeed, compressed tristearin implants 
comprising IFN-α co-lyophilised with HP-β-CD revealed integrity of released INF-α 
and of INF-α trapped within the matrix [153]. In accordance with these findings the 
biological activity of hyaluronidase was maintained during the release period from 
triglyceride implants [241]. However, the incubation period of the latter example was 
very short (48 h). Moreover, Maschke et al. recently reported the formation of 
degradation products (desamidoinsulin and covalent insulin dimer) within tripalmitin 
microspheres during release [145]. In addition, the embedding of interleukin-18 into 
tripalmitin cylinders failed to conserve the biological activity [125]. In contrast to the 
implant system proposed for the delivery of IFN-α [153], both the described tripalmitin 
cylinders [125] and microspheres [145] did not contain an additional stabilising agent. 
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Consequently, it seems essential for the success of lipidic implants to include a 
protein stabiliser within the matrix. 
3.3.2. POSSIBLE PROBLEMS ASSOCIATED WITH THE USE OF LIPIDS 
3.3.2.1. POLYMORPHISM 
Almost all fats and fatty acids possess the ability to form different polymorphs. 
Dependent on the unit cell structures mono-acid saturated triglycerides are classified 
into three main crystallographic types. The least stable α-modification is 
characterised by a loosely packing of the hydrocarbon chains in a hexagonal unit cell 
structure. The intermediate β’-modification reveals an orthorhombic unit cell structure 
and the most dense packing is achieved with the stable β-form by a triclinic packing 
[77, 192].  
Thus, a polymorphic transformation might occur during the preparation of controlled 
release systems based on lipidic materials. Especially, when the manufacturing 
process comprises a melting or dissolution step, polymorphism needs to be 
considered since the crystallisation of lipids follows the so-called Ostwald step rule. 
Accordingly, the least stable α-form nucleates first, followed by a transition to the 
intermediate β’-modification, and, finally, the optimal packing is accomplished by a 
rearrangement to the β-form [192]. Consequently, the presence of less stable α- or 
β`-forms after manufacture will result in a polymorphic transformation to the more 
stable polymorphs upon storage. In the case of controlled release systems based on 
lipids such a rearrangement might account for changes in the release behaviour. 
For example, the preparation of lipid microparticles by the melt dispersion technique 
or by spraying processes (such as spray congealing or spray drying) resulted in the 
formation of the unstable α-form [64, 65, 179]. Since the transformation from the β´-
form to the β-polymorph is often associated with swelling or blooming of saturated 
triglyceride [77], the rearrangement to the β-modification was responsible for 
changes in the appearance and the texture of the microparticles upon storage. After 
production, microparticles comprising the lipid in the α−modification showed a 
smooth surface. In contrast, a grainy microstructure appeared after the 
rearrangement to the stable β-polymorph during storage [65].  
It is highly conceivable that the visible change of the lipidic matrix structure will be 
reflected in a modification of the release characteristics upon storage. Such an effect 
is for example recognized when using Gelucire® as matrix material [39, 191, 218]. 
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Gelucires are lipid-based excipients comprising a blend of mono-, di-, and 
triglycerides with mono- and diesters of fatty acids and poly(ethylene glycol). Due to 
the polymorphic transformation to a more stable form, large lipid crystals were 
generated disturbing the compact matrix and accounting for increased release rates 
[39].  
Furthermore, with the rearrangement of the α- to the β-modification the crystalline 
lattice becomes more perfect and the number of imperfections decreases. This may 
result in an expulsion of incorporated drug [158].  
Due to the multitude of problems associated with delivery devices comprising less 
stable polymorphs a melting or dissolution step should be avoided. However, when it 
is not possible to circumvent the formation of instable modifications, various 
strategies are imaginable to overcome the above mentioned drawbacks.  
By fluctuating the temperature around the melting point of the less stable modification 
the rearrangement to more stable forms could be accelerated. The application of a 
specific tempering process step might, furthermore, circumvent any blooming effects 
[77].  
Another attempt to fasten the polymorphic transformation of lipid microparticles was 
introduced by Steber with the addition of liquid or semi-softened fats to the solid lipid 
matrix [213]. In preliminary studies - which are beyond the scope of the present 
thesis - it was shown that a Miglyol®812 content of 15 % ensured immediate 
crystallisation of tristearin material to the stable β-polymorph even when the melt was 
cooled down with liquid nitrogen [95]. 
Apart from these approaches aiming at an accelerated polymorphic rearrangement 
also the opposite, namely the stabilisation of the less stable modification can be 
found in literature. For example, some emulsifiers e.g. lecithin and monoglycerides 
serve as anti-blooming agents since they possess the ability to incorporate into the 
crystal lattice, preventing or delaying the transformation to the ß-polymorph [77].  
3.3.2.2. DEGRADATION 
During in-vitro incubation [151, 240, 241] and after subcutaneous implantation [85, 
241] implants based on pure triglycerides revealed no erosion. This means that such 
large lipidic devices need to be removed by a surgical intervention after completed 
release.  
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In contrast, implants based on lecithin and cholesterol [117] or glyceryl monostearate 
[3] revealed an erosion after implantation. Thus, the admixing of such “erosion 
modifiers” might improve the erosion behaviour of triglyceride implants. Promising 
results into this direction have been reported by the addition of phospholipids. The 
admixing of 10 % distearoyl-phosphatidyl-choline (DSPC) to a tripalmitin implant 
formulation led to visible signs of degradation after subcutaneous implantation into 
mice. As higher levels of phospholipids induced an inflammatory reaction the addition 
of 10 % might offer a balance between acceptable biocompatibility and bioerosion 
[85]. 
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4. IMPLANTS – A CLOSER LOOK AT ALTERNATIVE MANUFACTURING POSSIBILITIES 
Lipidic implantable controlled release devices have been mostly prepared by 
compression. So far, alternative manufacturing protocols have attracted only 
marginal attention (see Chapter I.3.2). In contrast, dozens of preparation techniques 
for polymeric implant systems are described in literature, since research has been 
focused on these materials for a long time. The following chapter will therefore briefly 
introduce to the manufacturing possibilities which were successfully applied for the 
preparation of polymeric implants. 
4.1. COMPRESSION MOULDING  
Compression moulding refers to the formation of implants by compression of a 
polymer/drug blend above its glass transition temperature. Due to the thermoplastic 
behaviour of most polymers a large variety of implant shapes can be realised. For 
instance, Liu et al. developed a method to prepare complex reservoir-type PLGA 
capsules for the treatment of osteomyelitis. The release system was loaded in two 
distinct manufacturing steps. First, an antibiotic/polymer blend was compression 
moulded to form a hollow cylinder with a cover. In order to fuse the polymer particles 
the device was sintered above the glass transition temperature at 55 °C. Afterwards, 
the core of the cylinder was loaded with aqueous solution of recombinant bone 
morphogenetic protein (rhBMP-2). The cylinder sealing was achieved by ultrasonic 
welding. Thereby, the applied mechanical vibrations induced intermolecular friction 
within the polymer, that generated heat, sufficient high enough to melt PLGA and to 
fusion bond the parts of the cylinder [139].  
One potential advantage of the compression moulding technique is the avoidance of 
organic solvents. However, compared with other manufacturing processes this 
technique is more complicated and the potential of up-scaling remains questionable.  
4.2. SOLVENT CASTING 
Applying solvent casting, the matrix material is dissolved in an appropriate solvent. 
Afterwards the desired implant is formed by pouring the solution into moulds and 
evaporating the solvent. Therefore, the release rates do not only depend on the 
matrix formulation but also on the solvent characteristics, the mould material, and the 
solvent evaporation technique [263].  
Protein encapsulation can be achieved by emulsifying the aqueous protein in the 
organic polymer solution and subsequent solvent casting. Alternatively, the protein 
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solution itself can be solvent casted by pouring the aqueous protein solution into 
moulds. After drying, the protein pellet is wetted with the organic polymer solution 
[68].  
Since the solvent casting usually involves the dissolution of the carrier material in an 
organic solution, the protein drug has to incorporate either as aqueous solution or as 
lyophilisate. In particular the first scenario inheres several problems similar to that 
discussed for the preparation of microparticles (see Chapter I.2.1).  
4.3. EXTRUSION  
Most polymeric implants are prepared by extrusion [121]. Generally, extrusion 
describes a process during which the raw material is forced through an orifice or a 
die. For that purpose at least two main components are necessary: (1) a transport 
system that may impart a mixing function and (2) a die system, which forms the 
material. The pressure required for extrusion depends on the design of the die, on 
the extrusion rate, and in particular on the rheological characteristics of the 
formulation. With respect to the method used to adapt the viscosity, extrusion can be 
classified into molten systems (hot-melt extrusion) and semisolid systems. Semisolid 
systems are generated by dispersing a high portion of solid material in a liquid phase 
[219]. This technique is widely used to prepare granules or pellets, whereas for the 
preparation of parenteral controlled release devices mostly the hot melt extrusion 
technique is applied [121].  
Since PLA and PLGA fulfil the basic prerequisite of thermoplasticity, various peptides 
have been embedded into these matrices by hot melt extrusion. In order to enable 
the flow through the extruder die, the drug and the polymer have to be heated above 
the glass transition temperature. The obtained rods are cooled and cut to a specified 
length. Finally, sterilization of the implants can be accomplished by gamma-irridation 
[121]. 
According to their design, various extruder types can be distinguished. Among them 
ram and screw extruders are particularly capable for the production of controlled 
release systems [219].  
4.3.1. RAM EXTRUSION 
The setup of a ram extruder is schematically illustrated in Figure 2. The extruder 
consists of a barrel that is pre-filled with the powder mixture. By means of a piston (or 
ram) the material is forced through the die at the bottom of the barrel [219].  
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barrel
die  
Figure 2: Schematic setup of a ram extruder. 
The extrusion process can be divided into three phases: (1) compression, (2) steady 
state flow, and (3) forced flow. The first phase is characterised by a large 
displacement of the piston with little pressure increase leading to the compaction of 
the powder to a plug prior to extrusion. After the maximal density of the material is 
reached, the pressure increases until the material commences a continuous 
extrusion (steady state flow). Optimally, when the piston is very close to the die 
forced flow occurs (Figure 3) [219]. 
 
Figure 3: Typical force displacement plot for a ram extrusion [219]. 
The area under the steady state curve represents the work required for extrusion 
[219]. Pito et al., for instance, used this value to evaluate the extrudability of various 
saturated polyglycolysed glyceride formulations. It was shown that the melting 
temperature correlates well with the energy required to produce extrudates. 
Furthermore the applied force strongly depends on the die diameter, the length-to-
radius-ratio, and the extrusion rate [171]. 
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Compared to twin-screw extrusion, ram extrusion is a non-continuous procedure 
(unless more than one barrel is employed). Since only small amounts of substance 
are necessary, ram extrusion is mostly used in laboratory scale. In lab scale, also a 
very simple modification of the ram extrusion procedure is often applied – the 
extrusion through a needle. 
 
Ram extrusion has been performed with semisolid systems as well as with molten 
materials. An example for the latter technique is the preparation of BSA-loaded rods 
based on poly(orthoester) [90, 187]. Zhu and Schwendeman developed an extrusion 
process without the employment of heat [262]. The semi-solid system of protein 
powder suspended in an acetone PLGA solution was extruded through a needle into 
a silicon tube. Afterwards, the solvent was evaporated first at room temperature and 
then by vacuum drying for 24 h. Semi-solid extrusion was further utilised for the 
preparation of collagen mini-rods. Fujioka et al., for instance, prepared co-
lyophilisates of interferon and collagen, which were wetted with distilled water leading 
to a gel that could be forced through a nozzle [76].  
Semisolid extrusion apparently offers the advantage that heat is generated only by 
friction. Consequently, the risk of temperature induced denaturation is reduced 
compared to hot-melt extrusion. However, the employment of an aqueous solution as 
wetting agent may result in a highly concentrated protein solution in which the carrier 
material is dispersed. Thus, the possibility of molecule collisions followed by 
aggregation may increase [250].  
4.3.2. SCREW EXTRUDER 
The screw type extruder consists of at least one rotating screw inside a stationary 
cylindrical barrel. At the end of the barrel a die is connected to shape the implant 
[219].  
The extrusion channel can be divided into three distinct sections (Figure 4). Within 
the first zone, the feed zone, the extruder is loaded. After the feeding zone the 
transition zone follows. Within this zone the pressure increases due to the reduction 
of the thread pitch while maintaining a constant flight depth or due to the reduction 
flight depth while maintaining the thread pitch [25, 219]. Thus, a compression of the 
material takes place. Finally, the material arrives the metering zone as a 
homogeneous plastic melt suitable for extrusion. In this last section the pulsating flow 
is reduced and a uniform delivery rate through the die is achieved [219].  
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Figure 4: Component parts of a single screw extruder [25]. 
Because of the high extrusion rates that can be achieved with single- or twin-screw 
extruders, they are predominantly applied in the industrial manufacturing of implants 
[121].  
Based on this technology two commercially available release systems, Implanon® 
and NuvaRing®, were developed. Implanon® is administered subcutaneously to 
deliver a progestagen for a period of three years. The vaginal ring NuvaRing® is 
designed for the liberation of both a progestagen and an estrogen for a period of 21 
days. Since the carrier material polyethylene vinyl-acetate (EVA) is non-erodable, the 
implants need to be removed after the release period. In both systems the drug is 
delivered from a coaxial fibre. The fibre consists of a drug loaded core, which is 
enveloped with a thin polymer membrane. The steroids within the core polymer are 
either dispersed as solid crystals or molecularly dissolved. The co-axial fibres are 
prepared with the help of two single screw extruders that are connected with a 
spinning block. Core and membrane polymer are melted separately within one of the 
single screw extruders and delivered to a spinneret, where the coaxial fibre is formed 
[235, 236]. 
4.4. STABILITY ISSUES DURING IMPLANT MANUFACTURING 
During implant manufacturing proteins might be exposed to various unfavourable 
conditions and thus the question arises whether the protein suffer physical or 
chemical destabilisation.  
Protein destabilisation is highly expectable when the manufacturing procedure 
involves the creation of interfaces (see Chapter I.2.1).  
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Fortunately, various techniques such as compression and extrusion are feasible 
allowing the avoidance of water/organic solvent interfaces during production. 
Nevertheless, in the course of these methods the protein – dispersed as solid within 
the solid, molten, or dissolved matrix material – might be exposed to elevated 
temperatures and pressures. The approved implant systems (Zoladex® and 
Profact®Depot) comprise peptides. However, the sensibility of proteins against 
various stresses can be expected to be higher. Therefore, destabilisation that might 
occur during extrusion will be discussed in the following section. 
4.4.1. ELEVATED TEMPERATURES 
The free energy of unfolding ∆Gunfold of the native protein in aqueous solution typically 
shows a parabolic profile in dependence of the temperature. Consequently, most 
proteins are only stable in a certain temperature range and high or low temperatures 
out of this range may destabilise or denaturate a protein. Typically, ∆Gunfold  becomes 
negative at temperatures higher than 50-100 °C accounting for protein unfolding at 
elevated temperatures [38]. With increasing temperature interactions within the 
polypeptide backbone change: electrostatic interactions as well as hydrogen bonding 
are weakened, whereas hydrophobic interactions are strengthened [250]. The overall 
mobility of the polypeptide chain increases and thus the tendency for unfolding 
grows. The temperature at which 50 % of the protein is unfolded is defined as melting 
or transition temperature Tm [250]. For example, the Tm for IFN-α was denoted at 
around 60 °C when the protein was dissolved in acetate buffer (pH>4.0) [202] .  
In addition to physical instability, the rate constant of chemical reactions increases 
exponentially with temperature. Consequently, high temperatures also accelerate 
chemical degradation [38, 250]. 
In contrast to the rather low thermal stability of proteins in aqueous solution, proteins 
suspended as dry powder in non-aqueous media maintained their biological activity 
even at high temperatures. The melting temperature for bovine pancreatic 
ribonuclease, for instance, increased from 61 °C in aqueous solution up to 124°C 
when the protein was suspended in anhydrous nonane [242]. Generally, solid 
proteins transferred to anhydrous organic solvent systems retain their correct 
conformation. Furthermore, the minimal layer of water necessary to solvate folded 
proteins remains associated with the protein. Since an unfolding would require a 
greater number of water molecules, unfolding becomes unlikely in hydrophobic 
systems. Moreover, water is a pivotal participant for deleterious reactions such as 
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deamidation and hydrolysis. Thus, in addition to increased stability against unfolding, 
proteins can be expected to be more stable against chemical degradation pathways 
when they are suspended in organic solvents [66, 123].  
Assuming parallelism between non-hydrous protein suspensions and the dispersion 
of dry protein powder within a hydrophobic molten carrier material an increased 
resistance of proteins against heat can be expected during implant manufacturing.  
Indeed, a few authors reported such a scenario. Rothen-Weinhold investigated the 
thermal stability of the somatostatin analogue vapreotide within a PLGA matrix during 
ram extrusion. It was shown that a short exposure (10 min) to temperatures up to 
120 °C did not lead to impurities, whereas a significant destruction of vapreotide was 
observed when the extrusion times exceeded 10 minutes. At lower temperatures (80-
90 °C) no degradation of the peptide occurred even for a period of 1 h [186]. More 
recently, Maschke et al. developed a micronisation process for pharmaceutical 
peptides and proteins based on the high pressure homogenisation within oils or 
molten fats. After micronisation of insulin crystals in molten tripalmitin at a 
temperature of 75 °C and a pressure of 1000 bar HPLC-MS revealed no chemical 
degradation [146]. 
Beside these studies which comprised only peptides, IFN-α dispersed in molten 
polyglycerol esters of fatty acids (60 °C) maintained 95 % of its antiviral activity after 
incubation at 60 °C for 6 hours [255]. Furthermore, the biological activity of lysozyme 
dispersed in molten glyceryl palmitostearate (65 °C) was not affected [174]. In 
contrast, the addition of Gelucire 50/13 to the formulation led to an activity loss, 
indicating that not only the applied temperatures but also the characteristics of the 
formulation are of importance for the preservation of the protein stability [174].  
4.4.2. ELEVATED PRESSURES 
The effects of high pressure on the protein stability are quite complex. Pressure has 
long been recognized as potential source for protein denaturation and aggregation 
[21, 250]. On the other hand, high pressures are also applied for protein folding and 
aggregate dissociation [81]. 
Moreover, during implant manufacturing a stabilisation against pressure induced 
denaturation can be expected when the protein is dispersed as solid in the matrix 
material, since it is reported that pressure induced unfolding of proteins decreases 
with the water content of the system [161]. In accordance with this, Maschke et al. 
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showed that insulin crystals suspended in oily medium insulin maintained their 
biological activity even after  exposure to high pressures (1500 bar) [146]. 
 
Compared to the high melting points of PLA/PLGA, triglycerides that will be 
employed within this thesis offer the benefit of rather low melting points (35-80 °C). 
Considering the aforementioned studies dealing with the effects of elevated 
temperatures on protein stability, the utilisation of the extrusion techniques is not 
generally prohibitive. This motivates to explore the possibilities of extrusion 
techniques to prepare lipid-based implantable delivery systems within the course of 
this project. 
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5. GENERAL MECHANISM OF PROTEIN RELEASE AND MATHEMATICAL MODELLING 
For the development and the optimisation of controlled release systems it is crucial to 
understand how drug release is controlled. One tool to get an insight into the 
underlying release mechanisms is the description of the release data with a 
mathematical model. Beside the so obtained knowledge, the correct choice of an 
existing mathematical model or the creation of a new one offers the practical benefit 
that the effects of various design parameters (e.g. the device geometry or the matrix 
composition) on the release can be predicted. As a result, the number of experiments 
required to achieve a certain desired drug release profile is minimised [8, 114, 207].  
Therefore, the following chapter will first outline the fundamentals of protein release 
from matrix like systems. Then an introduction into the most important mathematical 
models will follow. Though the release systems described in the present thesis are 
non-degradable, a short overview on the drug release mechanism and the 
mathematical models for degradable matrices will also be given. This is enclosed not 
only for matters of comparison but also to illustrate potential improvements for 
mathematical models, since the models for non-degradable systems are usually 
more sophisticated.  
5.1. PROTEIN RELEASE FROM NON-DEGRADABLE MATRICES 
During in-vitro incubation implants based on various triglycerides revealed no erosion 
or swelling [153, 240]. Consequently, an analogy to protein release from non-
degradable polymeric matrices can be assumed.  
Until the seventies it was commonly accepted that the development of effective 
controlled release systems for macromolecules is not realisable, since these 
molecules were simply considered being too large to penetrate through polymer 
chains [132, 205]. However, in 1974 Davis reported the sustained release of various 
proteins and peptides from cross-linked poly(acrylamide) and poly(vinylpyrrolidone) 
gels [53]. Two years later Langer and Folkman also published that proteins and other 
large molecules can be liberated from poly-(2-hydroxyethylmethacrylate) (Hydron®) 
and ethylene-vinyl-acetate copolymer (EVA) devices [133].  
Detailed mechanistic studies on these systems revealed that protein release occurs 
via diffusion through a complex porous pathway within the inert matrix [132]. First of 
all water penetrates into the system and dissolves the incorporated polypeptide as 
well as hydrophilic excipients leading to the creation of the porous microstructure. 
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The subsequent leaching out of the protein and water soluble excipients further alters 
the matrix morphology. Pores and channels randomly distributed through the matrix 
are formed, enabling diffusion of the protein into the bulk fluid.  
Due to the randomness of the particle position, the created pores are not straight but 
very sinuous. How twisted and turned the pores are, is described with the tortuosity 
factor [13, 150, 205]. The tortuosity directly relates to the effective distance the 
protein needs to transfer for diffusing out of the matrix. An increasing tortuosity is 
associated with an increase in the diffusion pathways and thus in a stronger 
retardation of the release. Therefore, the effective diffusivity De – that characterises 
the drug mobility within the matrix – is of magnitudes smaller than in aqueous media.  
Typically, for matrices comprising spherical particles rather low tortuosities between 
1.5 and 3 are assumed [196]. Obviously, these values cannot completely explain why 
protein release is often sustained over months. Thus, Siegel and Langer suggested 
that beside the tortuosity the connection of the pores through narrow channels 
contributes to the retardation of the protein release. Since the protein is executing a 
random walk, it will need a certain time until the molecule finds its way from one pore 
to another (Figure 5) [205].  
 
Figure 5: Retardation of the protein release due to the narrowness of connecting channels.  
Due to the fact that the channel radius is much smaller than the pore radius, the passage from one 
pore to another is restricted [205].  
Apart from the applied manufacturing procedure for a certain controlled release 
device, the pore morphology and thus the in-vitro release kinetics are influenced by 
two other important parameters: the initial drug loading and the particle size of the 
drug powder. As the protein is dispersed randomly within the matrix, the chance for 
two polypeptide particles to touch each other is very rare, when protein loadings are 
low. A certain amount of drug particles is then surrounded entirely by the matrix 
material and as this is impermeable for macromolecules the protein cannot be 
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released. Only at higher drug loadings the particles get in touch and upon dissolution 
a fully interconnected pore network is created, which ensures a complete protein 
liberation (Figure 6) [184].  
Generally, protein release is reported to occur faster when larger drug particles are 
incorporated. The larger the drug particle size the more likely they will touch the 
implant surface. Moreover, the diameter of the created pores as well as the overall 
porosity increases with increasing particle size [13, 205].  
 
Figure 6: Effect of drug loading on the creation of an interconnected network [205]. 
For compressed fatty acid matrices Kaewvichit and Tucker confirmed that the release 
of BSA occurs similarly to non-erodible polymeric systems through an interconnected 
pore-network. Furthermore, the effects of particle size and drug loading on the rate of 
macromolecule release were comparable to that described above [112].  
5.2. DRUG RELEASE FROM DEGRADABLE MATRICES 
Based on the physical and chemical characteristics of a matrix polymer protein 
release from degradable matrices is governed by several mechanisms: (1) diffusion 
through a water-filled pore network, (2) degradation of the polymer, and/or (3) 
swelling of the system. The real conditions are often very complex and a combination 
of all three processes is mostly noted [80, 132, 172].  
For example, protein release from PLGA-based micropheres is initially controlled by 
desorption of the protein from the surface. This phase is followed by the diffusion of 
protein through water filled pores, which in turn might be influenced by swelling. 
Finally, the polymer starts to degrade and a combination of diffusion and erosion 
phenomena governs drug release [41, 80, 212]. As a result, a pulsatile liberation 
profile is often observed: after a burst release of surface located and poorly 
encapsulated protein, a phase of lower release rates controlled by diffusion follows. 
Ultimately, increased diffusion rates corresponding to the polymer cleavage mark the 
third release period [58, 80, 100].  
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In addition to these rather complex, overlapping processes the physical state of the 
polymer can change during in-vitro release. For instance, Park et al. reported that 
hydration of PLGA matrices during in-vitro release lowered the glass transition 
temperature. Hence, the polymer changed from the glassy to the rubbery state, 
which accelerated polymer degradation and release rates [163]. Furthermore, 
osmotic effects as well as ionic interactions e.g. between polymer terminal carboxylic 
acid groups and basic polypeptides may be important for a full understanding of the 
protein release properties from polymeric depot systems [20, 162]. 
Finally, the impact of protein stability on the in-vitro release kinetics from both, 
degradable and non-degradable delivery devices, seems to be of importance. 
Several authors attributed a high burst followed by a non-release phase to protein 
aggregation within the device. As described above, protein aggregation may be 
induced during both, manufacture and release (see Chapter I.2). Because of their 
large size higher-order aggregates cannot diffuse through the restricted diameter of 
the pore network and hence are trapped within the matrix. In this context, Park and 
co-workers demonstrated that the addition of sodium dodecyl sulphate (SDS) or 
guanidine hydrochloride (GdnHCl) to the release media, increased the fraction of 
released protein, because both excipients enabled the dissociation of non-covalent 
aggregates formed within PLGA microspheres [52, 119]  
5.3. INTRODUCTION TO MATHEMATICAL MODELLING 
The mathematical models described in literature can roughly be divided into 
mechanistic models and empirical models. Whereas mechanistic models take 
specific chemical and physical phenomena occurring during release into account, 
empirical models only describe the apparent release rates. Empirical models inhere 
the advantage that they are easier to handle. However, information about the 
underlying mass transport processes are obtained only with mechanistic models 
[207].  
The practical benefit of such models is that they might facilitate the optimisation of 
the developed controlled release device. Due to the prediction of the effects of 
various design parameters (e.g. the device geometry or the matrix composition) on 
the release, the number of experiments required to achieve a desired drug release 
profile can be minimised [8, 114, 207].  
Especially in the case of erodible matrices, the underlying drug liberation processes 
are very complex. Therefore, it is not reasonable to develop a mathematical model 
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that accounts for all processes, since such a model would be very complicated. It is 
rather crucial to identify and consider the dominant physical and chemical 
phenomena. Generally, for parallel processes the fastest and for sequential 
processes the slowest step is of prime interest [207]. Depending on the rate-
controlling step release mechanisms can be classified into:  
(1) diffusion controlled, 
(2) swelling controlled, and  
(3) erosion controlled release [114].  
This classification should just help to categorise and to understand the plethora of 
controlled drug delivery systems developed so far. Of course, the real processes are 
more sophisticated and, for instance, diffusion will be involved in all three cases.  
5.3.1. DIFFUSION CONTROLLED SYSTEMS  
5.3.1.1. FUNDAMENTALS 
Diffusion controlled systems can be categorised into reservoir and matrix systems 
depending on the region where the diffusion primarily takes place [8]. In reservoir 
systems the drug has to diffuse through a surrounding membrane with a constant 
thickness. After the saturation of the membrane the concentrations at both sites of 
the membrane are constant (provided that the initial drug load within the core is 
above the drug’s solubility). At this time point steady state conditions are achieved 
and the concentration of the diffusing substance does not depend on time. In this 
special case the rate of release is governed by Fick’s first law. In analogy to the 
transfer of heat by conduction, Fick recognised in 1855 that the transfer rate of a 
diffusing substance through a unit area is proportional to the concentration gradient: 
x
CDJ ∂
∂⋅−=   {1}   Steady state conditions: 0=dt
dC
 
where J is the flux of drug being transferred per unit area, D is the diffusion 
coefficient and dc/dx is the concentration gradient [51, 107, 114]. 
 
In matrix systems non-steady state conditions have to be considered. This means, 
that the concentration of the diffusing substance within the matrix depends on 
position and time. The one-dimensional diffusion is described by the differential 
solution of {1}, generally referred as Fick’s second law of diffusion [51]: 
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5.3.1.2. EMPIRICAL MODELS 
The Higuchi equation, postulated 1961 [97] for the release of drugs from an ointment 
base, is probably the most frequently used model to describe the drug release from 
matrix systems [114, 207, 209]:  
tCCCDQ SS )2( 0 −=    for SCC >>0    {4} 
Where Q is the amount of drug released at time t per unit area, D is the diffusion 
coefficient and C0 and CS are the initial drug concentration and the solubility of the 
drug, respectively.  
For application to porous matrices the Higuchi model must be modified and extended 
for the effective volume and path where diffusion occurs: 
tCCCDQ SSB )2( 0 ε−=    for SCC >>0   {5} 
As explained above, the diffusion of the drug from an inert, porous matrix is affected 
by the pore structure. Thus Higuchi related the bulk diffusion (DB) with the tortuosity 
(τ), the matrix porosity (ε) and the diffusion coefficient in water (Daq) as following [96]: 
τ
εaq
B
D
D =       {6} 
According to the Higuchi model the amount of drug released from the matrix is 
proportional to the square root of time. The proportionality constant depends on the 
drug load, the solubility, the diffusion coefficient, and the porosity. 
The Higuchi model relies on the following assumptions: (1) diffusion is only one-
dimensional (edge end effects must be negligible), (2) the diffusion coefficient 
remains constant during the entire release period, (3) perfect sink conditions are 
maintained, and (4) pseudo-steady state conditions are provided. The last point is the 
most important limitation of the Higuchi model, since pseudo-steady state 
circumstances are only achieved when the initial drug load is much higher than the 
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solubility of the drug (C0>>CS, monolithic dispersion). In Figure 7 the theoretical 
concentration profile under pseudo-steady-state conditions is illustrated. The solid 
line represents the concentration gradient after time t and the broken line the same 
after an additional time interval ∆t. It is apparent, that the assumed situation is similar 
to the reservoir type systems: the core with the undissolved drug Co is surrounded by 
a diffusing region. However, in contrast to the reservoir type system, the core 
incorporates not only the drug but also the matrix. Furthermore, as result of the 
ongoing release, the core region shrinks and the thickness of the diffusing region 
increases with time [8, 209].  
perfect sink
direction of depletion
direction of release
h
CS
C
 
Figure 7: Pseudo-steady state conditions considered in the Higuchi equation.  
Theoretical concentration profile assumed in an ointment containing suspended drug in contact with 
perfect sink conditions [97]. 
Due to its simplicity, the Higuchi equation is often fitted to experimental release data. 
For instance, it was used to describe the liberation of low molecular weight drugs 
from matrices comprising hydrogenated castor oil and polyethylene glycol 
monostearate. The calculated tortuosity values were orders of magnitude higher than 
expected. This effect was ascribed to the plastic behaviour of most lipids that allows 
these materials to flow around the drug particles [196, 197]. This unique behaviour of 
lipids will be utilised later for the preparation of sustained release matrices by simple 
compression.  
The derivation of the exact analytical solution for the diffusion from a sphere under 
perfect sink conditions revealed that the approximate solution of Higuchi is valid, 
when the initial drug loading highly exceeds the drug solubility. In contrast, when C0 
converges CS and C0/CS becomes 1, the deviation to the exact solution increases [2, 
8]. 
Furthermore, the original Higuchi model does not consider a boundary layer 
resistance of adjacent liquid layers. But even in-well agitated systems next to the 
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surface unstirred liquid boundary layers exist, that might lead to an additional mass 
transfer resistance [99]. Improvement was provided, for instance, by Wu and Zhou 
1999 [8]. They developed an alternative numerical solution for slabs, cylinders, and 
spheres that includes an additional diffusion boundary layer at the surface of the 
matrix. Due to the introduction of the additional diffusion boundary layer, two diffusing 
zones are assumed. The thickness of the first zone changes over time, whereas the 
second zone, the diffusion boundary layer, revealed a constant thickness. 
Importantly, the obtained mathematical model describes the entire diffusional release 
process irrespective whether the dispersed drug has been dissolved or not. 
Moreover, the solution can be applied to predict the release kinetics under sink and 
under non-sink conditions. This is a fact of practical importance, since after 
administration the available liquid content and the absorption rates can be very low, 
so that under real conditions non-sink must be assumed [8]. 
 
It is clear from both Fick´s law and the Higuchi model that the release rates decrease 
as the diffusion pathways increase with time. However, Langer and co-workers 
conducted a theoretical analysis for a hemisphere device, that allowed release only 
through a cavity in the flat surface (Figure 8) [102]. This study can be considered as 
a good example to illustrate how the understanding of the drug release mechanism 
and the subsequent mathematic analysis can facilitate the development of advanced 
controlled release systems. 
 
Figure 8: Schematic picture of the hemisphere devices developed by [102].  
Ai and A0 are the inner and the outer radius, respectively, and R is the distance between dissolved 
region (white) and dispersed zone (diagonal lines). The impermeable EVA coating layer is illustrated in 
black.  
The developed hemisphere was produced by solvent casting a blend of drug and 
ethylene-vinyl acetate in a hemisphere mould at -80 °C. Afterwards, the obtained 
hemisphere was coated with an impermeable polymer except of a small orifice in the 
centre of the circular face. For the delivery of BSA it was confirmed experimentally 
that the release follows a zero order kinetic over 60 days [102]. In order to elucidate 
Chapter I: General introduction 39 
  
the role of the burst effect, later on an exact solution of Fick´s second law of diffusion 
was derived for describing the zero-order release kinetics [160].  
 
Especially the tortuosity factor in the Higuchi model for porous matrices is an 
empirical correction parameter that is derived from curve fittings without a physical 
meaning [88]. Alternatively, the percolation theory is postulated providing a simple 
mathematically derived model that predicts the transport properties from a porous 
matrix in dependence on the device morphology. A morphological description of the 
matrix is accomplished by subdividing the porous material into many small spaces 
(i.e. sites, clusters) [88, 137]. With respect to their location, these clusters can be 
classified either as conductive (water-filled pores within the matrix) or as non-
conductive (matrix particles) (Figure 9).  
 
Figure 9: Schematic of diffusional transport according to the percolation model (from [89]).  
In order to facilitate transport through the matrix, the conductive sites must form a 
sample spanning pathway. The critical drug load at which the sample spanning 
clusters first traverse the matrix is called critical percolation threshold (Øc). Obviously, 
a non-erodible controlled release device must contain at least a loading of drug (and 
hydrophilic excipients) above Øc to allow transport through the matrix.  
The diffusivity of the drug through the matrix is defined as [88, 89]: 
aq
E
B DD Ø=    {7} 
where DB is the diffusion coefficient within the matrix, Daq the diffusion coefficient in 
aqueous media, and ØE is the relative diffusivity or effective volume fraction. The 
value for ØE can be between 0 and 1. If no sample spanning pathways exist ØE 
becomes zero and consequently there is no diffusion. The other extreme DB=Daq 
occurs under the assumption that the matrix is completely composed of drug. 
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Eliminating the tortousity the Higuchi model can be modified in terms of the 
percolation concept to [88, 89]:  
( )( )tCCDQ SADADSB ερ +−= ØØ2     {8} 
where ØAD is the drug load, ε is the initial, inherent porosity of the matrix, CS is the 
solubility and ρ is the solid state density. Determining these parameters 
experimentally from the slope of a plot of Q versus the square root of time the bulk 
diffusion coefficient DB can be obtained. From the value of DB and the experimentally 
determined Daq the percolation parameters can be evaluated. 
Several authors applied this approach to relate the effects of formulation design 
parameters (drug load, particle sizes of the matrix material) to matrix morphology and 
to the obtained release kinetics [32, 137].  
5.3.1.3. MECHANISTIC MODELS  
Assuming that: (1) the drug dissolution is very fast compared to the drug diffusion, (2) 
no matrix swelling occurs, and (3) the diffusion coefficient is constant, the amount of 
drug release from slabs, cylinders or spheres with an initially uniform or a non-
uniform drug distribution can be determined with the solutions of {2} described by 
Crank [82]. 
For instance, Siepmann et al. applied a solution of Fick´s second law of diffusion for 
spheres to predict the release rates of diltiazem hydrochloride and theophylline from 
microspheres based on ethyl cellulose and Eudragit®RS 100. The diffusion 
coefficients of the drug within the polymers as well as the effects of various non-
water soluble plasticizers were first evaluated by studying the release from the simple 
geometry of a film. The determined parameters of diffusion were then successfully 
transferred to the sphere geometry [208]. 
Fu and co-workers deduced an analytical solution of Fick`s law for a cylindrical 
geometry considering mass transport in all three dimensions. The obtained model 
was verified for the release of hydrocortisone from polycaprolactone and ethylene-
vinyl-acetate implants prepared by injection moulding. Furthermore, the model is 
applicable to cylindrical geometries ranging from flat disks (radius>thickness) to rods 
(radius<thickness) [72].  
Another model was suggested by Vergnaud by using infinite series of exponential 
functions and considering the rotational symmetry around the z-axis as well as the 
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respective initial and boundary conditions (homogeneous drug distribution before 
exposure to the release medium and perfect sink conditions) [107]: 
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where Mt and M∞ represent the absolute cumulative amounts of protein released at 
time t and infinite time, respectively; qn are the roots of the Bessel function of the first 
kind of zero order [J0(qn)=0], and R and H denote the radius and height of the 
cylinder [107]. 
Recently this solution of Fick’s second law was applied to describe the release 
pattern of lysozyme from lipidic implants [84]. The authors showed, that Equation {9} 
was well suitable to describe the diffusion controlled release of lysozyme from 
compressed matrices based on various triglycerides. Moreover, the fact that the 
model has a mechanistic character rendered the solution derived by Vergnaud in 
particular interesting for the progress of the present thesis.  
5.3.2. SWELLING CONTROLLED RELEASE 
5.3.2.1. EMPIRICAL MODELS 
When the polymeric matrix revealed extensive swelling upon the imbedding of 
solvent molecules, the drug release cannot be described adequately by a 
concentration-dependent form of Fick´s law with constant boundary conditions. The 
observed deviations from Fickian diffusion have been associated with the 
rearrangement of the polymer structures due to swelling [51, 114]. 
Based on the relative rates of diffusion and polymer relaxation three cases are 
distinguished. If the diffusion rate is lower compared to the relaxation, diffusion 
controlled release (Fickian diffusion, Case I transport) will be observed. The other 
extreme will occur in the so-called Case II diffusion if the drug release is governed by 
swelling. The intermediate Non-Fickian or anomalous diffusion is characterised by 
comparable diffusion and relaxation rates [51, 114]. 
In order to differentiate between Case I, Case II, and anomalous transport, the so-
called power law equation developed by Korsmeyer can be applied [211]: 
nt kt
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where M∞ is the amount of drug released after an infinite time, k is a constant 
describing the geometric characteristics, and the exponent n characterises the 
underlying release mechanism. If n is 0.5, 0.45 or 0.43, this will indicate a Fickian 
diffusion from a thin film, a cylinder, or a sphere. In contrast, if n is 1, 0.89 or 0.85, 
swelling controlled release (Case II) will occur from the same geometric matrices. A 
value in-between can be regarded as an indicator for the superposition of both 
phenomena [209].  
5.3.2.2. MECHANISTIC MODELS 
Lee and Peppas mechanistically investigated polymer swelling. This process is 
accompanied not only by an increase of the device volume but also by a 
transformation of the polymer from the glassy to the rubbery state. A rubbery gel 
layer is created around the glassy core of the matrix. Consequently, two moving 
fronts – the rubbery-solvent front and the glassy-rubbery front – need to be 
considered. Initially, the rubbery-solvent front is moving outward, whereas the glassy-
rubbery front is moving in the opposite direction. As soon as the polymer dissolution 
starts, the rubbery-solvent front is moving inwards until the glassy core disappears. 
At the final stage only the rubbery region is present [8].  
Compared to the very low diffusion rates in the glassy core, the mobility in the fully 
swollen polymer layers is comparable to those in aqueous solutions [210]. 
Consequently, the mathematical modelling of the drug release from such systems 
can be realised with non-constant diffusion coefficients, that depend on the degree of 
polymer swelling [8, 209]. 
A more sophisticated solution was provided by Siepmann et al. with the development 
of the “sequential layer” model. A cylindrical device based on hydroxypropylcellulose 
was assumed to be built up on a certain amount of layers, simulated with a 
computational grid. The subsequent numerical analysis enabled to simulate non-
homogeneous swelling in which the outermost layer swelled first followed by the 
neighbouring inner layers. Both the volume change and the increase in drug 
diffusivities in the swollen layer were reproduced well with the developed model [8].  
However, since triglyceride implants revealed no swelling during in-vitro incubation 
[241] such complex processes can be neglected for the investigated pure tristearin 
matrices.  
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5.3.3. EROSION CONTROLLED RELEASE  
5.3.3.1. EMPIRICAL MODELS 
Hopfenberger supposed that the rate of drug release from an erodible polymer is 
proportional to the surface area of the device and derived the following empirical 
model: 
n
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⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−=∞ 0
011  
where k0 is a rate constant, a is the radius of a cylinder or sphere, or the half 
thickness of a slab. According to the geometry of the device the shape factor n 
becomes n = 3 for spheres, n = 2 for cylinders or n = 1 for slab geometry. Thus, 
according to the Hopfenberger model a zero-order release can be achieved with 
slab-shaped systems [114, 207]. 
5.3.3.2. MECHANISTIC MODELS 
Mechanistic models for degradable matrices either treat polymer erosion as a 
combined diffusion and chemical reaction process, or consider erosion as a random 
event by applying the Monte Carlo simulation [8, 207].  
A model belonging to the first subclass was proposed by Heller and Baker. Here, 
based on the Higuchi equation, a mathematical solution for bulk eroding polymers 
was developed by considering that the permeability of the polymer matrix increases 
due to polymer cleavage. Relating the change of permeability to a function of the 
numbers of remaining bonds and assuming first order kinetics for the polymer 
degradation the following equation was established [207]: 
t
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where P is initial permeability, A the surface area, and k the first order rate constant. 
Due to the increase in diffusion pathways the release rates first decrease with time. 
After a certain time point this is compensated by the exponential term, which 
represents the permeability of the progressively eroding polymer. Hence, the release 
rates increase when erosion takes place [207].  
Several other models were developed that apply the equations of diffusion with a 
time-dependent increase in the diffusion coefficients. The diffusion coefficients are 
thereby calculated based on the molecular weight loss of the polymer matrix [8, 114, 
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207]. However, these approaches neglect the acceleration of the drug release due to 
the evolving pore network concomitant to the erosion process [8]. 
Especially in our case of macromolecule delivery, the microporous structure of the 
matrix is of outstanding importance since the release will be restricted to the diffusion 
through water filled pores. 
In order to study the release of a model macromolecule (FITC-dextran) from porous 
PLGA microspheres Ehtezazi and Washington introduced an alternative attempt to 
obtain the effective diffusivity within the matrix. Here, based on the percolation theory 
(see Chapter I.5.3.1) the diffusivity within the polymeric matrix was assumed. This 
data allowed the subsequent calculation of the released fraction with a derivation of 
Crank´s solution for diffusion in spheres [63]. 
Langer and co-workers developed another model for the release of proteins from 
PLA and PLGA microspheres that took into account alteration of the microstructure 
[12]. The structural change of the matrix was thereby related to the mass and 
molecular weight loss of the polymer during erosion. The following assumptions were 
made to describe the release process: after microsphere preparation with the double 
emulsion technique the protein is localised in occlusions that are entirely embedded 
within the polymer matrix. Consequently, the observed initial burst release was 
ascribed only to the desorption of protein from the exterior microsphere surface or 
from the surface of pre-existing mesopores. The concomitant hydration gives rise to 
polymer erosion. As a result, micropores grow up and coalesce to mesopores. Since 
the large size of the protein restricted the release until a sufficient number of 
mesopores was created, there was an “induction phase” with low or no protein 
release, followed by a second burst. 
While the developed model predicted well the release of a glycoprotein, it failed for 
tetanus toxoid. The release of the latter did not show biphasic release behaviour. The 
authors assumed that in this case, the desorption was either very slow or the 
hydration was very fast and thus both phenomena were overlapped [12]. 
A subclass of mechanistic models simulates the polymer degradation as a random 
event using the Monte Carlo technique. This attempt was introduced in the late 
1980’s by Zygourakis to describe the drug release from surface eroding polymers. 
The complexity of simultaneous polymer and drug dissolution, which in turn changes 
continuously the morphology of the erosion front, is solved by generating a two-
dimensional grid that simulates the microstructure within the device (Figure 10). Each 
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cell/pixel represents one of the device elements: drug, solvent, polymer, or pore void, 
respectively. In order to model the drug or polymer dissolution for each cell a lifetime 
is defined. According to this lifetime expectance the cellular grid is updated after 
distinct time-intervals. For example, if a drug cell is adjacent to one or more solvent 
cells, then its lifetime will end and the cell may change to a solvent cell at the next 
time interval [264]. However, the diffusional resistance to the transport of the drug to 
the bulk fluid is neglected and the drug release rate is thought to be determined only 
by the detachment of the molecule from the matrix surface. Furthermore, the model 
does not consider other mass transport processes, such as diffusion of water or 
polymer degradation products [207].  
 
Figure 10: Zygourakis´ model for the simulation of drug release from surface eroding polymers. 
The pictures depict the configuration of the cellular array modelling the cross section of the controlled 
release device. The two-dimensional grid is shown at four different stages of release: (a) initial 
situation, (b) 25 % released, (c) 50 % released, (d) 75 % released drug. Four types of pixels are 
distinguished: polymer, drug, filler, and solvent [264].  
More sophisticated models were developed by Göpferich and co-workers by taking 
into account Monte Carlo simulation based polymer degradation and diffusional mass 
transport phenomena. These models are not limited to surface eroding polymers and 
can also be applied to bulk eroding matrices. Due to the fact that polymer 
degradation is affected by porosity, device geometry, and crystallinity these 
parameters were also taken into account [207].  
While these models were developed for cylindrical implants, Siepmann et al. 
proposed a model based on Monte Carlo simulation for the release kinetics from 
PLGA microspheres. According to the symmetry conditions of an idealised sphere 
the mathematical analysis could be reduced to one quarter of the sphere (Figure 11). 
That way the computation time for numerical analysis was minimised. Importantly, 
Chapter I: General introduction 46 
  
the proposed model covers well complex triphasic drug release kinetics with an initial 
burst, followed by zero-order release, and a second burst. Due to the continuous 
update of the grid it was possible to take into account the time dependent changes of 
the microsphere morphology. As outlined above especially in the second release 
period a superposition of drug dissolution, diffusion, and polymer erosion occurs. 
Since the matrix porosity increases, the drug diffusivity within the matrix is enhanced. 
Consequently, the time- and direction-dependent porosities within the microparticle 
were calculated for any grid point. Based on this information the time-, position-, and 
direction-dependent diffusivities were calculated. Furthermore, the schematic 
representation of the microsphere by a two dimensional pixel grid allows elucidating 
the influence of drug dissolution on the resulting release kinetics. At each time 
interval the concentration of drug and water of each grid are calculated and only the 
amount of soluble drug is considered to be available for diffusion [211].  
 
Figure 11: Monte Carlo-based attempt to simulate polymer degradation and diffusional drug 
release from PLGA microspheres. 
The schematic structure of the system is illustrated before exposure to the release medium (a) and 
during release (b). 
Recently, a Monte-Carlo scheme was developed to simulate the diffusion and the 
release of proteins from cross-linked dextran microspheres. Importantly, with the 
obtained scaling relations it was possible to predict the release curves of various 
proteins [239].  
The apparent advantage of Monte Carlo-based models is that they provide a very 
realistic comprehension of the drug release mechanism. In contrast to simple analytic 
solution, these models take into account the complexity of several overlapping 
physical and chemical phenomena which influence the drug release kinetics. 
However, no explicit mathematic model is derived, hence it is difficult to get an idea 
of the effects of certain device design parameters on the drug release [8, 209]. 
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CHAPTER II: AIM OF THE THESIS 
Controlled delivery systems for proteins based on degradable polymers, in particular 
on polyesters of lactic and/or glycolic acid, inhere several substantial sources for 
protein degradation during manufacturing, release, and storage [169, 199, 212, 233]. 
These restrictions led to the evaluation of alternative matrix materials, wherein lipids 
emerged as promising candidates [127, 144, 180].  
Recently, it was demonstrated that IFN-α can be delivered over an one-month period 
from lipidic implants comprising tristearin as matrix material [153]. In contrast to 
several other studies [40, 108, 138, 174], the admixing of poly(ethylene glycol) 6000 
(PEG) to the implant formulation resulted in a more sustained protein delivery 
compared to PEG-free delivery devices [153]. Therefore, the first major aim of the 
present work was to disclose the mechanism by which PEG affects the liberation of 
IFN-α from these tristearin-based implants.  
Importantly, incorporated IFN-α was delivered from the developed implant completely 
and it its monomeric form [151]. Moreover, an excellent storage stability regarding 
both reproducibility of protein release kinetics as well as maintenance of protein 
integrity was proven [151]. However, despite these successes the implant system 
must be considered too large for a convenient way of administration. Furthermore, to 
our knowledge the manufacturing of lipidic implant systems has so far only been 
realised by self-made tools which were operated manually and only in lab-scale. 
Consequently, the second part of this thesis was focused on the development of 
new, improved lipidic implants.  
 
In brief, the goals were:  
(1) Experimental and mathematical analysis of the in-vitro release behaviour of 
IFN-α, HP-β-CD, and PEG from tristearin implants prepared by compression.  
(2) Elucidation of the mechanism by which PEG affects protein release.  
(3) Elucidation of the effects that the lyoprotectant HP-β-CD has on protein 
release and stability. 
(4) Development of new, lipidic implant systems permitting subcutaneous injection 
in a patient-friendly way and allowing feasible up-scaling of manufacture.  
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CHAPTER III: MATERIALS AND METHODS 
1. MATERIALS 
1.1. PROTEINS 
1.1.1. RECOMBINANT INTERFERON α-2A (IFN-α) 
Three classes of interferons are distinguished: interferon-α, interferon-β, and 
interferon-γ. Each of these classes can be further subdivided. In contrast to natural 
interferon-α, rh-interferon α-2a (IFN-α) is non-glycosylated [57]. IFN-α (Mw = 
19.237 Da) was provided as a gift by Roche Diagnostics (Penzberg, Germany). The 
protein is formulated with a concentration of either 1.7 mg/mL or 4.9 mg/mL in 25 mM 
acetate buffer pH 5.0, containing 120 mM sodium chloride.  
IFN-α contains four cysteins and two disulfide linkages one from position 1 to 98 and 
one from position 29 to 138 [57]. The three-dimensional structure of IFN-α 
determined by NMR revealed that IFN-α is a an all-helical protein containing five  
α-helices [122]. 
Due to its antitumour and antiviral efficacy, recombinant IFN-α (Roferon® A) is 
approved for the treatment of hair cell leukaemia, AIDS related Kaposi’s sarcoma, 
and chronic hepatitis B and C [57]. 
1.1.2. HEN EGG WHITE LYSOZYME 
Lysozyme from hen egg white was purchased from Sigma Aldrich (Lot 114K7054, 
Steinheim, Germany). Historically, lysozyme was first described by Alexander 
Fleming in 1922 as remarkable bacteriolytic element found in tissues and secretions. 
Lysozyme hydrolyses β (1-4) linkages between N-acetylmuramic acid and N-acetyl-
D-glucosamine residues in bacterial peptidoglycan [110].  
Lysozyme is a 129 amino acid protein with a molecular weight of 14.7 kDa. The 
secondary structure of lysozyme comprises three helical regions and two regions of 
β-sheets  [178]. An overall α-helical content of 42 % was estimated by x-ray 2Å 
resolution, this means that 55 of the 129 amino acids are included into these helical 
structures [17].  
1.2. LIPIDS 
1.2.1. TRIGLYCERIDES 
1.2.1.1. MONO-ACID TRIGLYCERIDES 
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Mono-acid triglycerides (Dynasan®) in the stable β-modification were received from 
Sasol GmbH (Witten, Germany). The used triglycerides and their characteristics are 
summarised in Table 3.  
Table 3: Characterisation of used Dynasan® triglycerides. 
 Dynasan® 
D112 
Dynasan® 
D114 
Dynasan® 
D118 
Dynasan® 
D120 
Chemical structure trilaurin trimyristin tristearin triarachidin 
Acid value  
(mg KOH/g) 
max. 3 max. 3 max.3 max. 0.7 
Hydroxyl number 
(mg KOH/g) 
not indicated max.10 max.10 not indicated 
Saponification no. 
(mg KOH/g) 
256-268 229-238 186-192 180-200 
Iodine number  
(g I2/100g) 
max.1 max.1 max.1 max.3 
Melting area (°C) 43-47 55-58 70-73 67-72 
1.2.1.2. PHOSPHOLIPIDS 
Distearoyl-phosphatidyl-choline (DSPC, Lipoid PC 18:0/18:0) was kindly provided by 
Lipoid, Ludwigshafen, Germany. Lipoid PC 18:0/18:0 reveals a high chemical purity; 
the content of non-esterified fatty acids and the content of lysophosphatidylcholine 
was less than 0.5 %, respectively (certificate of analysis). 
1.2.1.3. MIXED-ACID TRIGLYCERIDES 
Solid triglycerides of various saturated fatty acids were provided by Sasol GmbH 
(Witten, Germany). The features of the mixed-acid triglycerides are given in Table 4. 
In addition, Softisan®378 and Miglyol®812 were used in the present work. 
Softisan®378 is a special blend of triglycerides based on saturated even-numbered, 
unbranched fatty acids with a chain length of C8-C18. Miglyol®812 is a mixture of 
triglycerides of caprylic (C8) and capric (C10) fatty acids obtained from coconut and 
palmkernel oil. The used Softisan® 378 and Miglyol® 812 met the requirements of the 
European Pharmacopoeia for Hard Fat and for Medium Chain Triglycerides, 
respectively.  
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Table 4: Characterisation of used mixed-acid triglycerides. 
 Triglyceride type H12 Triglyceride type E 85
C12 fatty acid,% 71.0 27.0 
C14 fatty acid, % 26.8 70.1 
C16 fatty acid;% 2.0 2.0 
Hydroxyl number (mg KOH/g) 1.4 3.1 
Saponification no. (mg KOH/g) 269.38 240.5 
unsaturated fatty acids no no 
Melting point (°C) 35.5 41.3 
   
 
1.2.2. CHEMICALS AND REAGENTS 
Acetic acid (100 %), p.a., VWR International GmbH, Darmstadt, Germany 
Acetonitril, gradient grade, VWR International GmbH, Darmstadt, Germany 
Ammonium thiocyanate, ACS reagent, Sigma-Aldrich, Steinheim, Germany 
Chloroform, CHCl3,VWR International GmbH, Darmstadt, Germany 
Dipotassium hydrogen phosphate, K2HPO4, p.A., VWR International GmbH, Darmstadt, Germany 
Disodium hydrogen phosphate dihydrate, Na2HPO4 x 2 H2O, VWR Int. GmbH, Germany 
Ferric chloride, FeCl3, VWR International GmbH, Darmstadt, Germany 
Hydroxypropyl-β-cyclodextrin (HP-β-CD), Cavasol W7 HP Pharma, Wacker specialities, 
Burghausen, Germany 
Methylene blue, VWR International GmbH, Darmstadt, Germany 
Phenolphthalein, C20H14O4, VWR International GmbH, Darmstadt, Germany 
Poly(ethylene glycol) 6000 (PEG), Clariant, Gendorf, Germany 
Potassium chloride, KCl, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium azide, NaN3, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium chloride, NaCl, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium dihydrogen phosphate monohydrate, NaH2PO4 x H2O, p.A., VWR Int. GmbH, Germany 
Sodium dodecyl sulphate, C12H25NaO4S, VWR International GmbH, Darmstadt, Germany 
Sodium hydroxide, NaOH, p.A:, VWR International GmbH, Darmstadt, Germany 
Trifluoroacetic acid, p.A:, Merck KGaA, Darmstadt, Germany 
α,α-Trehalose-dihydrate, British Sugar, Peterborough, UK 
Tween®20, Polysorbate 20, Serva, Heidelberg, Germany 
Ultra pure water, taken from Purelab Plus®, USF GmbH, Ransbach-Baumbach, Germany 
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2. METHODS 
2.1. PREPARATION OF LIPIDIC CONTROLLED RELEASE DEVICES 
2.1.1. LYOPHILISATION OF IFN-α 
Lyophilisation was performed in accordance with Mohl [151]. IFN-α was lyophilised 
either with trehalose or with HP-β-CD in a protein/excipient ratio of 1 to 3. Before 
lyophilisation the pH of the stock solution was adjusted to 4.2 with acetic acid 
(30 % vol/vol). A freeze-dryer ε12G (Christ, Osterode, Germany) was used for 
lyophilisation. 1 mL protein/lyoprotectant stock solution filled into 2R glass vials was 
frozen to -45 °C at a rate of 1.6 °C/min. This temperature was maintained for 
90 minutes. Afterwards, the temperature was increased to -20 °C in steps of 
0.1 °C/min. Simultaneously, the chamber pressure was reduced to 10-2 mbar. This 
primary drying program was maintained for 30 hours. Then, the temperature was 
increased by 0.1 °C/min up to 20 °C and concomitantly the pressure was reduced to 
10-3 mbar. Secondary drying was performed for 15 hours. Finally, the chamber was 
vented with nitrogen to a pressure of 800 mbar and the vials were closed with rubber 
stoppers.  
The average weight per lyophilisate was 64 mg, comprising 25 % IFN-α and 75 % 
excipient. 
2.1.2. MANUFACTURING OF IMPLANTS BY COMPRESSION 
IFN-α loaded, tristearin-based implants were prepared by compression as described 
previously [151]. Briefly, lyophilised IFN-α (Lot PZ 0210P017, c (IFN-α) = 1.7 mg/mL) 
was blended with different amounts of PEG and tristearin and filled into a compaction 
tool (diameter: 5 mm). The powder blends were compressed with a force of 19.6 kN 
for 30 s using a hydraulic press (Maassen, Eningen, Germany). In order to evaluate 
the impact of compression force and compression time on the in-vitro release 
behaviour, the compression was also performed at 9.8 kN or for 2 min, respectively. 
The average mass and height of the implants were 50 mg and 2.3 mm, respectively. 
The drug loading was calculated on the total implant weight (wt/wt).  
Lysozyme–loaded implants were prepared in same way, but as lysozyme was 
already purchased as solid powder, lyophilisation could be omitted. For matters of 
comparison, 7.5 % of placebo HP-β-CD lyophilisate, 2.5 % lysozyme and optionally 
PEG were admixed to the tristearin material.  
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2.1.3. MANUFACTURING OF IMPLANTS BY RAM EXTRUSION 
In accordance to Chapter III.2.1.2, the lipid powder was blended with lyophilised IFN-
α and optionally PEG in an agate mortar. This mixture was filled into the barrel of a 
purpose made extruder device shown in Figure 57 Chapter V. After inserting the 
extruder piston a force of 3.92 kN was applied for 30 s with a hydraulic press 
(Maassen, Eningen, Germany). Then, the extruder was lifted on a rack and the lipidic 
formulation was extruded with the hydraulic press.  
As the extruder die was 1.2 mm, extrudates revealed a diameter of 1.2 mm. The 
average length of the extrudates was 15 mm.  
2.1.4. MANUFACTURING OF IMPLANTS BY TWIN SCREW EXTRUSION 
The lipid powder comprising the low and the high melting point lipid was prepared by 
grinding in a mortar. Subsequently, the obtained blend was admixed with  
10 % IFN-α/HP-β-CD lyophilisate (IFN-α bulk material Lot PZ0005P025,  
c (IFN-α) = 4.8 mg/mL) and PEG, optionally 10 % or 20 %. In the case of lysozyme 
2.5 % lysozyme powder, 7.5 % HP-β-CD and 20 % PEG were compounded with the 
lipids. Extrusion was performed using a twin screw extruder (MiniLab®Micro Rheology 
Compounder, Thermo Haake GmbH Karlsruhe, Germany, see Figure 77, Chapter V). 
The extruder was heated to 40 °C (D118/H12 lipid blend) or to 47 °C (D112/D118 
lipid blend) prior to filling. The rotation speed of the screws was fixed at 40 rpm. Then 
the extruder was manually filled with the lipid blend. Extrusion was performed with 
closed bypass channel to allow a direct extrusion without circulation. In order to 
prepare extrudates of different sizes, dies with a diameter of 0.5 mm, 1.0 mm or 
1.4 mm were fixed in front of the standard extruder outlet (diameter 2.0 mm). The 
extruded strands were cut into pieces with a length of approximately 2.3 cm. 
2.2. MECHANICAL STABILITY OF THE LIPIDIC IMPLANTS 
The mechanical properties of extrudates prepared either by ram extrusion or by twin 
screw extrusion were estimated with the Texture Analyser TA XT2i (Stable Micro 
systems, UK). A 25 mm cylinder probe was used, and the extrudates were placed 
centrally under the probe. The standardised test program “Failure behaviour of 
tablets due to diametrical compression using a cylinder probe” (settings: pre-test 
speed 2mm/s, test speed 0.03 mm/s and post-test speed 10 mm/s) was applied. 
From the obtained force versus time plot the maximum force value was used as the 
longitudinal tensile strength. 
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2.3. EXTRACTION OF PROTEIN FROM THE LIPID MATRIX 
The protein was extracted with the aqueous extraction method developed by 
Mohl [151]. Briefly, the protein-loaded matrix was ground in an agate mortar. 
Subsequently, 50 mg of the sample were suspended in 1 mL pH 7.4 isotonic 0.01 M 
sodium phosphate buffer containing 0.05 % (wt/vol) sodium azide and 1 % (wt/vol) 
polysorbate 20 (PBST). After gentle agitation for 2 hours the samples were 
centrifuged at 5000 rpm for 5 minutes (4K15 laboratory centrifuge; Sigma, Osterode, 
Germany).  
2.4. IN-VITRO RELEASE STUDIES OF IFN-α 
The protein-loaded implants were placed into TopPac® vials (cycloolefin copolymer 
vials; Schott GmbH, Mainz, Germany). Depending on the mass of the studied 
implants the vials were filled with isotonic 0.01 M phosphate buffer pH 7.4 containing 
0.05 % (wt/vol) sodium azide (PBS). In the case of ram extrudates and extrudates 
prepared with the twin-screw extruder revealing a diameter of 0.5 or 1 mm 1.0 mL of 
buffer was added. For compressed implants and rods prepared by twin screw 
extrusion with a diameter of 1.4 or 2.0 mm the volume of buffer was increased to 
2.0 mL. 
The vials were placed in a horizontal shaker (40 rpm, 37 °C, Certomat®IS; B. Braun 
Biotech International, Göttingen, Germany). At predetermined time points, the 
release medium was completely exchanged and the amounts of IFN-α, PEG, and 
HP-β-CD in the phosphate buffer were determined as described below. 
In order to investigate the pH effect on in-vitro release, the pH of PBS buffer was 
adjusted to pH 4.0. In vitro release was carried out as described above. The frequent 
buffer exchange as well as the absence of acidic/basic degradation or release 
products ensured a virtually constant pH in the release media throughout the 
experiments.  
2.4.1. SIZE EXCLUSION CHROMATOGRAPHY OF IFN-α 
Protein concentration was measured by size-exclusion chromatography (SE-HPLC) 
using a TSKgel (G3000SWXL, 7.8 mm x 30.0 mm column; Tosoh Biosep, Stuttgart, 
Germany). The mobile phase consisted of 120 mM disodium hydrogen phosphate 
dihydrate, 20 mM sodium dihydrogen phosphate and 4 g/L sodium chloride (adjusted 
to pH 5.0 with hydrochloric acid), the flow rate was 0.5 mL/min, and IFN-α was 
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detected spectrophotometrically (λ = 215 nm, UV 1000; Thermo Electron 
Cooperation, Dreieich, Germany). 
2.4.2. CONCENTRATION OF HP-β-CD 
The HP-β-CD content was determined using a modification of the method proposed 
by Basappa et al. [11]. The assay is based on the formation of a colourless, stable 
inclusion complex of HP-β-CD and phenolphthalein (molar ratio 1:1): The fading of an 
alkaline phenolphthalein solution is followed spectrophotometrically. Briefly, 500 µL 
freshly prepared 0.03 mM phenolphthalein solution (in 0.6 M sodium carbonate, 
pH 11) were added to 500 µL sample solution. Immediately after mixing, the 
absorbance at 551 nm was measured (UV 1, Thermo Electron Cooperation, Dreieich, 
Germany). It was confirmed that the calibration curve (R2 > 0.99) obtained with 
protein- and PEG-free HP-β-CD solutions (concentration range: 50-1000 µg/mL) 
overlaps with that obtained in the presence of IFN-α and PEG (0.164 mg/mL and 
2.5 mg/mL, respectively).  
2.4.3. CONCENTRATION OF PEG 
500 µL ammonium ferrothiocyanate reagent (16.2 g/l anhydrous ferric chloride, 
30.4 g/L ammonium thiocyanate), 500 µL chloroform and 150 µL sample solution 
were vigorously mixed (21°C, 1400 rpm, 30 min, Eppendorf Thermomixer; 
Eppendorf, Hamburg, Germany). Subsequently, the aqueous phase was removed 
and the absorbance of the chloroform phase was measured at 510 nm (UV 1; 
Thermo Spectronic, Dreieich, Germany). A linear correlation (R2 > 0.99) between 
absorbance and PEG content was found in the range of 0.025 mg/mL - 2 mg/mL. 
Any interference by the presence of IFN-α and HP-β-CD could be excluded (samples 
spiked with 0.164 mg/mL IFN-α and 1.875 mg/mL HP-β-CD resulted in unchanged 
absorbance values). 
2.5. DETERMINATION OF POROSITY 
Compressed implants were prepared and incubated as described above. At 
predetermined points of time the implants were removed and vacuum dried (VO 200 
vacuum chamber, Memmert, Schwabach, Germany) to constant weight. Then, the 
true volume of the implants was determined with a helium pycnometer using the 
1 mL volume cell (accuPyc 1330, Micromeritics, Mönchengladbach, Germany). The 
geometric volume of the implants was determined by measuring implant height and 
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diameter with a digital calliper rule (Digimatic CD-15CD, Mitutoyo, Oberndorf, 
Germany). 
 
The porosity (ε) in % was calculated with: 
1001 ⋅⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
geom
true
V
Vε        {10} 
where Vtrue is the implant volume determined with the helium pycnometer and Vgeom is 
the calculated theoretical volume. 
2.6. WATER UPTAKE AND EROSION 
Protein-loaded implants were removed from incubation buffer, wipe dried to remove 
adhesive water, and weighed (UMX 2, max. 2.1 g, d=0.1 µg, Mettler Toledo, Giessen, 
Germany). After drying to constant weight (VO 200 vacuum chamber, Memmert, 
Schwabach, Germany) the implants were weighed again. The matrix erosion and the 
water uptake were determined with equation {11} and {12}: 
100
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100⋅⎟⎟⎠
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dr
M
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uptake Water      {12} 
where M0 is the initial implant mass, Mr and Md are the wet and the dry implant mass 
after exposure to incubation media, and Mc is the total mass of incorporated 
hydrophilic compounds (assuming complete release).  
2.7. IN-VITRO RELEASE STUDIES OF LYSOZYME 
Lysozyme release from implants prepared either by compression or by twin screw 
extrusion was studied in accordance to Chapter III.2.4. In order to determine 
lysozyme stability and concentration SE-HPLC analysis was carried out. A TSKgel 
G3000SWXL, 7.8 mm x 30.0 mm column (Tosoh Biosep, Stuttgart, Germany) was 
used with a mobile phase consisting of 200 mM disodium hydrogen phosphate 
dihydrate (adjusted to pH 6.8 with hydrochloric acid), the flow rate was 0.4 mL/min, 
and lysozyme was detected spectrophotometrically (λ = 215 nm, UV 1000; Thermo 
Electron Cooperation, Dreieich, Germany). Calibration curves were generated with 
lysozyme solutions in a concentration range of 20.3 to 324.8 mg/mL. 
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2.8. SOLUBILITY STUDIES  
Solutions of poly(ethylene glycol) 6000 (PEG unless otherwise indicated) with a 
concentration of 2-40 % (wt/vol) in PBS pH 4.0 or 7.4 were prepared. These solutions 
were mixed in a ratio of 1:1 with IFN-α bulk solutions (initial concentration of 
4.9 mg/mL pH 4.0 or 7.4). Afterwards, the samples were equilibrated for 2 h at 37°C, 
40 rpm (Certomat IS). Subsequently, precipitated protein was separated by 
centrifugation at 5000 rpm (5 °C, 5 min, 4K15 laboratory centrifuge; Sigma, 
Osterode, Germany) and the residual IFN-α concentration in the supernatant was 
determined. Thus, solubility is referred to the solute concentration of the supernatant 
in equilibrium with the precipitated phase. Protein concentration was determined by 
reversed phase chromatography (see below). The effect of pH on the precipitation of 
IFN-α was investigated at a final PEG concentration of 5 % (wt/vol) PEG. The pH of 
the PEG and protein solution was adjusted with 0.1 N NaOH or 0.1 N HCl prior 
mixing, respectively.  
Solubility studies of lysozyme were performed by mixing different concentrated PEG 
solutions with lysozyme solutions (c=4.8 mg/mL, PBS). As no protein precipitation 
occurred and the protein concentration remained constant, lysozyme solubility was 
assessed by stepwise adding of lysozyme powder to buffer media (PBS, ph 7.4) until 
a sediment occurred. After equilibration for 2 h at 37°C, 40 rpm (Certomat IS), the 
samples were centrifuged (5 °C, 5 min, 4K15 laboratory centrifuge; Sigma, Osterode, 
Germany) and the concentration of dissolved lysozyme was determined by SE-
HPLC. The same procedure was carried out with 5, 10, 15 and 20 % (wt/vol) PEG 
solutions (in PBS pH 7.4). (Remark: In contrast to IFN-α, the high solubility of 
lysozyme in the presence of PEG allowed a dilution of 1 to 2000 before SE-HPLC 
analysis. Consequently, no interference of PEG with the separation of lysozyme was 
observed.) 
2.9. REVERSE PHASE CHROMATOGRAPHY OF IFN-α 
Reverse phase chromatography (RP-HPLC) of IFN-α was performed using a Jupiter 
5u C18 300 Å 250 x 4.60 mm column (Phenomenex, Aschaffenburg, Germany). The 
mobile phase consisted of a 49:51 (vol/vol) acetonitrile/ultra pure water mixture which 
was acidified with 0.1 % (vol/vol) trifluoroacetic acid. The flow rate was adjusted to 
1 mL/min; UV detection (UV 1000; Thermo Electron Cooperation, Dreieich, 
Germany) was performed at 215 nm wavelength. 
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2.10. SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-
PAGE) 
SDS-PAGE was conducted under non-reducing conditions using an XCell II Mini cell 
system (Novex, San Diego, CA). The protein solutions were diluted in a pH 6.8 tris-
buffer, containing 2 % SDS and 2 % glycerine. Samples were denatured at 90°C for 
30 min and subsequently 20 µL were loaded into the gel wells (NUPAGE Novex 10 % 
Bis Pre-Cast Gel 1.0 mm; Invitrogen, Groningen, The Netherlands). Electrophoresis 
was performed in a constant current mode of 30 mA in a tris-glycine/SDS running 
buffer (MES running buffer; Invitrogen, Groningen, The Netherlands). Gel staining 
and drying was accomplished with a silver staining kit (SilverXpress) and a drying 
system (DryEase), both provided from Invitrogen, Groningen, Netherlands.  
2.11. FLUORESCENCE SPECTROSCOPY 
Fluorescence studies were carried out on a Varian fluorescence spectrometer Cary 
eclipse at 20 °C. IFN-α stability after precipitation with PEG and re-dissolution, was 
assessed by precipitating IFN-α with 5 to 20 % PEG and re-dissolving in excess of 
buffer to a final protein concentration of 0.05 mg/mL. The obtained spectra were 
compared to that of native IFN-α (also 0.05 mg/mL in PBS buffer). To study IFN-α 
HP-β-CD interactions the cyclodextrin was added to IFN-α bulk solution in a mass 
ratio of 1 to 3. These solutions were diluted with PBS buffer to a protein 
concentration of 0.05 mg/mL.  
In both experiments the excitation wavelength was fixed at 295 nm, and fluorescence 
emission scans were collected from 300 to 450 nm using a scan speed of 30 nm/min 
at an excitation and emission slit width of 5 nm.  
2.12. FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR) 
2.12.1. TRANSMISSION FTIR-SPECTRA OF DISSOLVED IFN-α  
In order to evaluate the effect of precipitation and re-dissolution on the secondary 
protein structure, IFN-α was precipitated in the presence of 5 to 20 % PEG as 
described above. After centrifugation the supernatant was removed and the obtained 
protein pellet was re-dissolved in PBS buffer. The obtained solutions, as well as  
IFN-α bulk solutions were filled in a calcium fluoride flow through cell (Aquaspec AS 
1110 M, Bruker Optik, Ettlingen, Germany) with 6.5 µm path length. FTIR spectra 
were recorded with the Confocheck system on a Tensor 27 (Bruker Optik, Ettlingen, 
Germany) equipped with a nitrogen-cooled photovoltaic MCT detector at a resolution 
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of 4 cm-1. At least two measurements of 120 scans were performed. The temperature 
of the cell was maintained at 25 °C via a cryostat (DC 30-K20; Thermo Haake, 
Dreieich, Germany). The obtained spectra were background subtracted and vector 
normalised from for relative comparison. Finally, the second derivative spectra were 
generated via the spectrometer software (OPUS, Bruker Optik, Ettlingen, Germany).  
The FTIR spectra of IFN-α in the presence of HP-β-CD (mass ratio 1 to 3) were 
collected in the same way.  
2.12.2. TRANSMISSION FTIR-SPECTRA OF SOLID IFN-α  
For transmission measurements 2 mg of lyophilised IFN-α, lipid/protein/PEG blend 
before or after extrusion were mixed with 150 mg KBr, respectively. After 
compression (78.4 kN for 2 minutes) the KBr pellet was fixed in the sample holder 
(Tensor 27, Bruker Optik, Ettlingen, Germany) and spectra were collected with a total 
of 256 scans at a resolution of 2 cm-1. The obtained absorbance spectra were 
automatically baseline corrected (OPUS, Bruker Optik, Ettlingen, Germany). 
Background correction was performed manually (described in detail in 
Chapter V.2.3). The obtained spectra were vector-normalised and analysed by the 
second derivatisation in the amid I band region (OPUS, Bruker Optik, Ettlingen, 
Germany). 
2.12.3. THERMAL DENATURATION OF IFN-α 
Investigations on the thermal protein stability were performed with the Bio-ATR unit. 
The spectra were collected in the wavenumber range from of 4000 to 850 cm-1. The 
temperature was ramped from 25 to 70 °C in 5 degree increments. Before recording 
the spectrum the cell was equilibrated for 120 seconds. Each spectrum was obtained 
with 240 scans at a resolution of 4 cm-1. Separately, the thermal dependence of the 
buffer was collected under the same conditions. The protein spectra were 
automatically background corrected by the buffer spectra at the respective 
temperature. The adsorption spectra were further processed by vector-normalisation. 
Afterwards, the second derivatives were calculated and again vector-normalised 
(OPUS, Bruker Optik, Ettlingen, Germany). 
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2.13. INVESTIGATIONS ON THE LIPID MODIFICATION 
2.13.1. WIDE-ANGLE X-RAY SCATTERING (WAXS) 
Lipidic controlled release systems, the pure lipids as well as lipidic blend before 
manufacturing were ground. Wide–angle X-ray scattering (WAXS) was performed by 
an X-ray Diffractometer XRD 3000 TT (Seifert, Ahrensberg, Germany), equipped with 
a copper anode (40 kV, 30 mA wavelength 0,154178 nm). Experiments were 
conducted at 0.05° (2 theta) within a 5° - 40° range.  
2.13.2. DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
Samples were ground and approximately 10 mg were analysed in a sealed Al-
crucible. Measurements were performed with DSC 204 Phoenix (Netzsch, Selb, 
Germany). Heating and cooling were conducted at a scan rate of 5 K/min within a 20-
100°C (tristearin) or a -20 to 100°C (H12) temperature range.  
2.14. MICROCALORMETRY 
Microcalorimetry was carried out with a VP-DSC (MicroCal®, Milton Keynes, UK). 
Before measurement, all solutions were degassed (ThermoVac, MicroCal®, Milton 
Keynes, UK). IFN-α bulk solution with a protein concentration of either 4.8 mg/mL or 
0.48 mg/mL was loaded into the sample cell using a tight Hamilton 2.5 mL glass 
syringe. The reference cell was loaded with bulk buffer (25 mM acetate buffer, 
120 mM sodium chloride, pH 5.0). The same procedure was performed with solutions 
containing additional 14.4 or 1.4 mg/mL HP-β-CD. Scans were performed from 20-
80 °C at a scanning rate of 90 °C/hour.  
By loading both cells with the reference a base line was recorded. This base line was 
subtracted from the protein thermal data and the excess heat capacity was 
normalised for protein concentration. Data analysis was performed with OriginMicrocal 
software. 
2.15. SCANNING ELECTRON MICROSCOPY 
Incubated implants (prepared by compression or by ram extrusion) were dried in a 
VO 200 vacuum chamber (Memmert, Schwabach, Germany) for 48 h at 37°C and 
subsequently, coated with a fine gold layer (MED 020, Bal-tec GmbH, Witten, 
Germany). Scanning electron microscopy was carried out with a 6500F, Jeol GmbH 
(Eching, Germany).  
Chapter III: Materials and methods 60 
  
2.16. DETERMINATION OF THE DIFFUSION COEFFICIENTS OF IFN-α 
The apparent diffusion coefficient of IFN-α in the release medium was measured 
using a modification of the open-end capillary technique proposed by Anderson and 
Saddington [5]. IFN–α lyophilised either with HP-β-CD or with trehalose was blended 
with PEG in a ratio of 1 to 1 or 1 to 2. The protein/PEG blend or the lyophilised 
protein was dissolved in PBS buffer to a final protein concentration of 2.4 mg/mL. 
These solutions were filled into glass capillaries (diameter: 0.8 mm, length: 2 cm, one 
end open), respectively. The capillaries were placed into glass vials filled with 10 mL 
PBS buffer. Sink conditions were provided throughout the experiments. The vials 
were shaken horizontally with 40 rpm, if not otherwise indicated, at 37°C 
(Certomat®IS). At predetermined time points the acceptor medium was removed and 
the IFN-α content within the capillary was determined by SE-HPLC as described 
above. For each time point three separate samples were prepared. The apparent 
diffusion coefficient D of IFN-α in the release medium was determined by fitting the 
following analytical solution of Fick’s second law of diffusion (considering the 
respective initial and boundary conditions) to the experimentally measured protein 
release kinetics: 
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where Mt and M∞ represent the absolute cumulative amounts of IFN-α released at 
time t, and infinite time, respectively; L denotes the length of the capillary. [Remark: 
To be sure that convectional mass transfer was negligible for IFN-α release out of the 
thin capillaries, the agitation rate was increased from 40 to 80 rpm. Importantly, the 
determined protein release kinetics was not affected.] 
2.17. “MACROPORE MODEL” 
The developed “macropore release model” device is schematically illustrated in 
Figure 37, Chapter IV. The device was filled with protein, HP-β-CD and PEG pellets 
prepared by compression. The pellets comprised IFN-α lyophilisate, IFN-α 
lyophilisate:PEG blends, as well as IFN-α lyophilisate:HP-β-CD blends, respectively. 
The lyophilisate:PEG ratios were the same as for the implant formulations, e.g. 1:1 
for devices containing 10 % PEG, 10 % lyophilised protein; and 1:2 for implants 
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containing 10 % lyophilised protein and 20 % PEG. The pellets were placed in a 
small volume container, connected with an open capillary of around 10 mm length 
and 2 mm diameter. Subsequently, the devices were filled with isotonic phosphate 
buffer (pH 7.4, 0.05 % (w/v) sodium azide) and fixed at the bottom of a sterile 
polypropylene tube (Greiner bio-one, Frickenhausen, Germany). Afterwards, the 
polypropylene tube was filled with 3 mL acceptor medium (isotonic phosphate buffer, 
pH 7.4, 0.05 % (w/v) sodium azide) and incubated at 37°C and 40 rpm (Certomat IS). 
At predetermined time points, the acceptor medium was completely replaced and the 
protein concentrations in the samples were determined by RP-HPLC as described 
above. 
2.18. MATHEMATICAL MODELLING 
IFN-α, PEG and HP-β-CD release from the investigated lipidic implants into the 
release media was quantitatively described using an analytical solution of Fick’s 
second law of diffusion introduced into Chapter I.5.3. The model considers 
protein/PEG diffusion in axial as well as in radial direction in cylindrical matrices: 
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where c is the concentration, t represents time; r, z denote the radial and axial 
coordinates and θ the angle perpendicular to the r-z-plane; D is the apparent 
diffusion coefficient within the lipidic implant. 
The theory takes into account that perfect sink conditions are maintained throughout 
the experiments and considers the rotational symmetry around the z-axis (no 
concentration gradients in θ direction) as well as homogeneous distributions within 
the implants at t = 0 (before exposure to the release media). Based on these initial 
and boundary conditions, Equation 14 can be solved using infinite series of 
exponential functions, leading to [107]: 
 
( )
( )
⎟⎟⎠
⎞
⎜⎜⎝
⎛ ⋅⋅⋅+⋅−⋅+⋅⋅⎟⎟⎠
⎞
⎜⎜⎝
⎛ ⋅⋅−⋅⋅−= ∑∑ ∞
=
∞
=∞
tD
H
π1p2exp
1p2
1tD
R
qexp
q
1
π
321
M
M
2
22
0p
22
2
n
1n
2
n
2
t
  
 
{Repetition of Equation 9, Chapter I.5.3} 
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where Mt and M∞ represent the absolute cumulative amounts of protein, PEG or  
HP-β-CD released at time t and infinite time, respectively; qn are the roots of the 
Bessel function of the first kind of zero order [J0(qn)=0]; R and H denote the radius 
and height of the cylinder.  
If release levelled off below 100 %, the experimentally determined plateau values 
were considered as 100 % reference values for protein/PEG diffusion. For the 
implementation of the mathematical model the programming language C++ was 
used. 
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CHAPTER IV: MECHANISMS CONTROLLING THE RELEASE 
FROM LIPID-BASED DELIVERY SYSTEMS  
Despite the steadily increasing importance of lipid-based delivery systems for 
controlled protein release [127, 144] the knowledge of the underlying drug release 
mechanisms is very limited so far. However, as illustrated in the introduction, this 
knowledge would help to optimise existing controlled release systems and to develop 
new ones.  
Therefore, it was the aim of the following work to understand the mechanisms 
controlling the release from tristearin implants. Such systems containing IFN-α  
co-lyophilised with hydroxypropyl-β-cyclodextrin (HP-β-CD) were recently shown to 
deliver the incorporated protein in a sustained manner over a period of one month. 
Importantly, an excellent protein stability was proven during implant preparation, 
release, and storage [151-153]. Furthermore, the addition of various amounts of 
poly(ethylene glycol) 6000 (PEG) to the implant formulation were shown to enable a 
modification of the protein release. Interestingly, the presence of PEG resulted in a 
more sustained protein liberation, which was so far not understood. Therefore, firstly 
the release of IFN-α from tristearin implants containing different initial PEG loadings 
was investigated. 
 
1. EFFECT OF PEG ADDITION ON RELEASE KINETICS FROM TRISTEARIN IMPLANTS 
1.1. RELEASE MECHANISMS OF IFN-α FROM TRISTEARIN IMPLANTS 
The effects of varying the relative PEG contents of the lipidic implants on the 
resulting protein release kinetics in phosphate buffer pH 7.4 are illustrated in 
Figure 12. The initial PEG content of the formulations was varied from 0 to 20 %, in 
5 % increments. As it can be seen, the resulting IFN-α release rate and the amount 
of totally released protein significantly increased with increasing PEG contents. For 
instance, protein release from PEG-free implants levelled off at 31 % after 7 d, 
whereas complete IFN-α release was observed from devices containing 10-20 % 
PEG after approximately 16 d. With 5 % PEG an intermediate release profile was 
obtained (i.e. 54 % after 13 d).  
Thus, the addition of small amounts of PEG to the lipidic implants was a very efficient 
tool to provide a complete protein recovery. The enhanced recovery yields found 
here agreed well with the effects of PEG described in literature. Usually the impact of 
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PEG on the release kinetics is ascribed to its role as a pore former [40, 108, 138, 
174]. Due to the elevated levels of the water-soluble fraction of the matrix the 
formation of an interconnected pore-network is enhanced. Hence, PEG facilitates the 
diffusion of the drug out of the matrix (see Chapter I.5.1).  
Interestingly, not only the slope of the release curves, but also their shape was 
altered. The release rates from PEG-free matrices monotonically decreased with 
time, whereas IFN-α was delivered in a constant manner over at least 7 days from all 
PEG-containing matrices. This alteration of the release kinetics indicates differences 
in the underlying mass transport mechanisms. 
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Figure 12: Effects of the addition of various amounts of PEG on the release of IFN-α from 
tristearin-based cylindrical implants. 
The implants were prepared by compression as described in Chapter III. All devices were loaded with 
10 % IFN-α co-lyophilised with HP-β-CD and the indicated PEG amount (average +/- SD; n = 3). 
In addition, another effect of PEG was obvious: PEG-containing implants exhibited a 
lower burst release than PEG-free systems (Figure 13). For example, matrices 
containing 0 % PEG released 18.3 % (± 1.7 %) of the incorporated IFN-α within the 
first 10 h, whereas implants comprising 10 % PEG liberated only 11.9 % (± 2.2 %) 
within the same time period.  
The reduced burst release was very astonishing considering the well known role of 
PEG as a pore former in controlled release systems [40, 108, 138, 174]. PEG can be 
expected to leach rapidly from the matrix. As a result the creation of pores and 
channels through which the release medium can enter the device occurs in an 
accelerated manner. Furthermore, the enlargement of the created pore-network 
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mostly accounts for a reduction of the geometric restrictions of the pore-network. 
Thus, the addition of PEG to degradable as well as to non-degradable depot 
formulations was predominantly reported to be associated with an increase of the 
initial burst effect [40, 108, 138, 174].  
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Figure 13: Effects of the addition of various amounts of PEG on the burst release of IFN-α.  
The implants were prepared by compression. All devices were loaded with 10 % IFN-α co-lyophilised 
with HP-β-CD and the indicated PEG amount (average +/- SD; n = 3). 
 
Figure 14: External (left) and internal (right) morphology of the tristearin-based implants before 
exposure to the release medium. 
Scanning electron microscopy of tristearin implants before in-vitro incubation. The implants were 
loaded with 10 % IFN-α/HP-β-CD co-lyophilisate and the indicated PEG amount. 
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To better understand the impact of PEG the internal and external morphology of the 
lipidic implants was studied before and after exposure to the release medium. 
Figure 14 shows examples of surfaces and cross-sections of tristearin-based 
implants loaded with 10 % IFN-α/HP-β-CD and 0, 5, or 15 % PEG before exposure to 
phosphate buffer pH 7.4. Clearly, the implants were very dense, showing low initial 
porosity. No significant differences in the morphology were visible between the 
devices containing different amounts of PEG.  
 
Figure 15: External (left) and internal (right) morphology of the tristearin-based implants after 
in-vitro release studies. 
Scanning electron microscopy of tristearin implants after in-vitro incubation. The implants were loaded 
with 10 % IFN-α/HP-β-CD co-lyophilisate and the indicated PEG amount. 
In contrast, clear differences were visible after 28 d of incubation in phosphate buffer 
pH 7.4 (Figure 15). With an increasing PEG content, the inner and outer porosity of 
the devices significantly increased. This can be attributed to the leaching out of the 
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water-soluble PEG (together with IFN-α and HP-β-CD) into the bulk fluid upon 
exposure to the release medium. The observed changes in the implants’ morphology 
agreed very well with the protein release patterns (Figure 12): With higher PEG 
loadings, the porosity of the lipidic matrices increased upon exposure to the release 
medium, resulting in enhanced IFN-α mobility and, thus, in increased protein release 
rates. Importantly, the created pore network was highly interconnected at more 
elevated initial PEG contents (Figure 15G). Furthermore, it became evident that at 0 
and 5 % initial PEG loadings, not all of the protein had direct access to water-filled 
pores. As the permeability through crystalline lipidic plates can be expected 
negligible, IFN-α  surrounded completely by tristearin cannot be released. This may 
explain the levelling off of protein release below 100 % from PEG-free and 5 % PEG 
containing matrices (Figure 12).  
The external and internal morphology clearly indicates that PEG acts as a pore 
forming agent which explains well the increased amount of delivered protein. 
However, the observed changes in the shape of the release curves and especially 
the decreasing burst effects are still unclear and cannot be ascribed to the effect of 
PEG as a pore former.  
In order to get a deeper insight into these phenomena a mathematical model was 
fitted to the release data. The used tristearin implant systems revealed no swelling or 
erosion during in-vitro and during in-vivo release [151]. In Chapter I.5 it was 
explained that the release from such inert matrices can be expected to be governed 
by pure diffusion through a water-filled pore-network penetrating the matrix. Thus, an 
adequate solution of Fick´s second law of diffusion was fitted to the experimental 
release data (see Equation 9, Chapter I.5.3 as well as Chapter III.2.18). 
In Figure 16 the theoretical release curves and the experimental data are illustrated. 
Good agreement between theory and experiment was obtained in the case of IFN-α-
loaded implants which did not contain any PEG (R² = 0.99). This indicated that 
diffusion through the interconnected pore network dominated the overall control of 
IFN-α liberation. Based on this fitting, the apparent diffusion coefficient of the protein 
in the lipidic matrix was determined to be 5.8 (+/- 1.2) x 10-8 cm²/s.  
In contrast, systematic deviations between the applied theory and the experimentally 
determined IFN-α release kinetics were observed with all PEG containing implants. In 
Figure 16 B the theoretical and experimental data for implants containing 10 % PEG 
are shown exemplarily. At early time points, protein release was overestimated, 
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whereas at late time points IFN-α release was underestimated. The observed 
differences between the theoretical and the experimental release profiles suggest 
that in PEG-containing implants, not only pure protein diffusion (with constant 
diffusivities) through the water-filled pores is of importance. 
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Figure 16: Effect of the addition of PEG on the underlying drug release mechanisms of IFN-α 
from tristearin implants. 
Experiments (symbols) and theory (curves): fittings of Equation 9 Chapter I.5.3 to the experimentally 
determined IFN-α release kinetics from tristearin-based implants containing: (A) 0 % PEG, and 
(B) 10 % PEG in phosphate buffer pH 7.4. On the right hand-sight the protein release within the first 
24 h is shown, respectively (for experimental results: average +/- SD; n = 3). 
Recently, Guse et al. also used Equation {9} Chapter I.5.3 to quantify drug release 
from compressed lipidic implants. It was found that the release of lysozyme from 
implants prepared with the emulsion-compression method (see Chapter I.3.2.3) was 
purely diffusion-controlled, irrespective of the type of triglyceride used. In contrast, 
the dominating release mechanism was depended on the type of lipid in the case of 
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pyranine-loaded implants prepared by compression of a lyophilised lipid-drug 
solution: trilaurin- and tristearin-based systems were found to be purely diffusion 
controlled, whereas also other mass transport phenomena were of importance in 
trimyristin- and tripalmitin-based devices. However, when reducing the applied 
compression force also diffusion controlled release was reported for the latter 
systems, indicating that the underlying drug release mechanism was affected by the 
preparation method [107].  
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Figure 17: Effects of compression time (A) and compression force (B) on IFN-α release. 
All tristearin implants were loaded with 10 % IFN-α co-lyophilised with HP-β-CD and 10 % PEG 
(average +/- SD; n = 3). 
In order to investigate potential effects of the manufacturing procedure on the protein 
release mechanisms IFN-α loaded tristearin implants containing 10 % PEG were 
prepared with different compression forces and compression times, respectively. In 
Figure 17 A the impact of the compression time can be seen. The compression time 
was prolonged from 30 seconds to 2 minutes while maintaining a constant 
compression force of 19.6 kN. Obviously, extended compression times resulted in 
lower and more sustained protein liberation. Implants compressed for 30 seconds 
delivered 89.2 % of the incorporated IFN-α within 13 days, whereas exerting a 
compression over 2 minutes resulted in an ongoing release of 68 % of the initially 
incorporated protein over 27 days.  
By increasing the compression forces (Figure 17 B) also decreasing liberation rates 
were found. Matrices yielded after applying a force of 9.8 kN revealed significantly 
faster protein release than matrices prepared with the doubled force.  
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The impact of compression force and time on the protein release kinetics can 
presumably be ascribed to alterations in the packing arrangement of drug, excipient, 
and matrix particles, which in turn influences the pore characteristics and 
consequently the drug release [112]. Tristearin, protein/HP-β-CD, and PEG particles 
can be expected to be packed more closely with increasing compression time and 
force. Thus, the implant porosity decreases, resulting in decreased drug release 
rates.  
However, the fitting of Equation {9} based on Fick’s second law of diffusion to the 
experimental release data clearly showed that the underlying drug release 
mechanisms were not affected by the alteration in the manufacturing procedure 
(Figure 17). Irrespective of the applied compression force or time, systematic 
deviations between the theoretical data considering pure diffusion and the 
experimentally determined release values were observed. This means, that 
independent of the applied implant compression method the release of IFN-α from 
PEG-containing tristearin matrices was not purely governed by diffusion. 
1.2. DETERMINATION OF THE DIFFUSION COEFFICIENT OF IFN-α 
The simultaneous dissolution and leaching out of HP-β-CD, PEG, and IFN-α 
continuously alters the composition of the medium generated within the implant pores 
during the release period. According to the Stoke-Einstein equation the diffusion 
coefficient is a function of the viscosity. Due to the dissolution of PEG a concentrated 
PEG solution of a high viscosity within the implant pores can be initially expected. As 
PEG leaches out the viscosity of the pore liquid decreases, which may impair the 
mobility of the protein diffusing within the liquid-filled pores. Consequently, it may be 
possible that the change of the liquid conditions within the implant pores affects the 
protein diffusivity. This assumption is backed by the reports on bovine serum albumin 
and lysozyme for which the diffusion coefficients in aqueous media decrease with an 
increasing concentration of poly(ethylene glycol) [170, 238].  
Thus, the presence or absence of PEG within the water-filled pores of the implants 
may affect the mobility of IFN-α. This situation would provide an explanation of the 
aforementioned deviations between the theoretical release kinetics considering pure 
diffusion with constant diffusion coefficients and the experimental release data 
observed with PEG-containing lipidic implants. 
Therefore, it was necessary to evaluate the diffusion coefficients of IFN-α in the 
release medium in the presence and absence of PEG. For the study of the protein 
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diffusion in gels or liquids several methods have been described in literature [252]. 
Dynamic Light Scattering was applied to investigate the diffusional behaviour of 
lysozyme [238] and bovine serum albumin [170] in the presence of various 
poly(ethylene glycols). Furthermore, Fluorescence Recovery after Photobleaching 
(FRAP) or the more elaborated Holographic Relaxation Spectroscopy (HRS) were 
used to evaluate the diffusion coefficient of macromolecules [173, 183].  
Apart from the obvious need for advanced equipment and skills these methods 
impose some further restrictions. In HRS and FRAP the diffusant is tagged to a 
photochromic or photobleachable label, which in turn might affect the mobility [252].  
Alternatively, the open-end capillary technique proposed by Anderson and 
Saddington provides a less laborious approach to determine the diffusion coefficient. 
Here, the rate at which the solute diffuses out of the open end of a capillary into the 
acceptor medium is monitored under perfect sink conditions [5]. In addition to its 
simplicity the open-end capillary technique would provide the benefit that the 
conditions within the pores of the controlled release system can be simulated. As the 
liquid generated within the implant pores would presumably compromise IFN-α, HP-
β-CD, and optionally PEG the capillaries were filled with these compounds dissolved 
in buffer medium. In contrast to the original experimental protocol, the acceptor 
medium did only contain phosphate buffer. This means that IFN-α, HP-β-CD, and 
PEG would diffuse out of the capillary simultaneously, which should provide 
additional information on the interdependency of excipient and protein liberation.  
The experimental setup applied is illustrated in Figure 18. The capillaries with a 
diameter of 0.9 mm and a length of 3 cm were filled with IFN-α/HP-β-CD:PEG blends 
dissolved in isotonic phosphate buffer pH 7.4 to a final protein concentration of 
2.5 mg/mL. The ratios of IFN-α/ HP-β-CD to PEG were chosen in analogy to the 
implant formulations. An IFN-α/HP-β-CD:PEG ratio of 1 to 1 dissolved within the 
capillary corresponds to an implant formulation with a preload of 10 % IFN-α/HP-β-
CD co-lyophilisate and 10 % PEG. After filling, the capillaries were uprightly fixed in a 
beaker filled with the acceptor medium and tempered at 37 °C. The acceptor was 
stirred at 300 rpm.  
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Figure 18: Schematic presentation of the experimental setup used to determine the diffusion 
coefficient of IFN-α. 
After predetermined points of time a capillary was removed and the remaining protein 
content within the capillary was determined. Figure 19 represents the declining 
protein concentrations within the capillary over time.  
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Figure 19: Decrease of IFN-α concentration within the capillary.  
The diffusion out of a capillary was measured according to the experimental setup shown in Figure 18. 
Open symbols represent decay of IFN-α concentration in the absence and closed symbols in the 
presence of PEG (IFN-α/HP-β-CD:PEG blends 1:1) (average +/- SD; n = 3).  
Clearly, no important differences between PEG-containing and PEG-free samples 
were found. However, the standard deviations were high and thus, the calculation of 
accurate diffusion coefficients was not possible. Presumably, the large deviations 
between the samples are due to the manual withdrawal of the capillaries, which 
might cause an uncontrollable convectional mass transfer out of the remaining 
capillaries.  
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Figure 20: Schematic presentation of the modified experimental setup used to determine the 
diffusion coefficient of IFN-α. 
In order to improve accuracy an alternative experimental setup was established 
(Figure 20). Each capillary was now fixed at the bottom of a separate vial. After filling 
the capillary the vial was carefully charged with the acceptor medium. The prepared 
vials were incubated at 37 °C and 40 rpm. At predetermined time points the acceptor 
medium was removed with a pipette. Then the content of the thin glass capillary was 
transferred to determine the remaining protein concentration. 
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Figure 21: Decrease of IFN-α concentration within the capillary.  
The diffusion out of a capillary was measured according to the experimental setup shown in Figure 20. 
Open symbols represent decay of IFN-α concentration in the absence and closed symbols in the 
presence of PEG (IFN-α/HP-β-CD:PEG blends 1:1 ?, IFN-α/HP-β-CD:PEG blends 1:2 ?) (average 
+/- SD; n = 3).  
In Figure 21 the obtained concentration profiles are presented. In accordance with 
the first experimental setup no significant differences between PEG-containing and 
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PEG-free samples were observed. Furthermore, the deviations between three 
independent vials were lower than those found with the first approach (compare 
Figure 19 and 21).  
Based on the experimental determined protein liberation data the diffusion 
coefficients of IFN-α in the presence and in the absence of PEG were evaluated by 
fitting an analytical solution of Fick´s second law (see Chapter III.2.16). 
As the protein release could only occur via the capillaries´ openings, the 
mathematical analysis could be restricted to one dimension with the following 
equation [5]:  
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where Mt and M∞ represent the absolute cumulative amounts of IFN-α released at 
time t, and infinite time, respectively; L denotes the length of the capillary. 
Table 5 summarises the calculated protein diffusivities of IFN-α. It should be 
mentioned that the modification of the original capillary technique might account for 
an apparent increase in the diffusion coefficients. As only the liquid within the 
capillaries contains HP-β-CD and optionally PEG there might be an osmotic driven 
water influx. This effect would contribute the diffusion release of IFN-α resulting in 
diffusion coefficients higher than those which would be obtained with the original 
method proposed by Anderson and Saddington [5]. However, the obtained values 
are in good agreement with literature data reported for proteins with a comparable 
molecular weight. For instance, for lysozyme, a 14.4 kDa protein, diffusion 
coefficients between 0.8-1.3 x 10-6cm2/s were reported [83]. Furthermore, comparing 
the diffusion coefficients obtained in PEG-free and in PEG-containing medium it can 
be concluded that the presence of different amounts of PEG did not substantially 
alter the mobility of IFN-α in the release medium.  
Therefore, it can be summarised that the presence of PEG within the water-filled 
pores of the implants did not affect the mobility of dissolved IFN-α during the release 
from tristearin implants. As explained above, a time-dependent alteration of protein 
diffusivity in such a context would mainly arise from the effects of PEG on the 
viscosity of the buffer media.  
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Table 5: Diffusion coefficients of IFN-α within phosphate-buffer filled capillaries comprising 
various amounts of PEG.  
The diffusion coefficients were determined by fitting Equation {13} to the release data shown in 
Figure 21. 
IFN-α/HP-β-CD:PEG ratio D, x 10-6 cm2/s 
1:0 1.8 
1:1 1.8 
1:2 1.7 
 
However, the drug diffusivity within a controlled release device is not only a function 
of the composition of the liquid within the pores. In addition, the characteristics of the 
generated pores might be even more important for the diffusivity of the drug (see 
Chapter I.5).  
It has to be taken into account that the continuously leaching out of the protein itself 
and of the incorporated hydrophilic excipients (HP-β-CD and PEG) progressively 
increases the porosity of the implants. Such a time-dependent increase in porosity 
might enhance the diffusivities during release. However, the mathematical solution of 
Fick´s second law of diffusion used to analyse the release data assumed constant 
diffusion coefficients over the entire release period. This means, a possible 
explanation for the observed deviations between the calculated release curves and 
the experimental obtained protein liberation might be a time-dependent increase in 
the protein mobility due to an increase in matrix porosity.  
In order to evaluate if such a scenario is of relevance, the release of PEG and  
HP-β-CD was monitored simultaneously to the protein delivery. If a time-dependent 
increase in diffusivity by changes of the pore structure is of importance, systematic 
deviations between the mathematical predicted release data and the experimentally 
obtained data should be observed also for HP-β-CD and PEG. 
1.3. RELEASE MECHANISMS OF THE INCORPORATED EXCIPIENTS – HP-β-CD AND PEG 
The PEG concentration was determined using a modification of the ammonium 
ferrothiocyanate assay described by Nag et al. [159]. The method is based on the 
partitioning of the ammonium ferrothiocyanate chromophore from the aqueous phase 
to the chloroform phase in the presence of PEG. The original assay was modified to 
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allow also the quantification of PEG in the concentration range from 0.025 mg/mL to 
2 mg/mL (see Chapter III).  
Concentrations of HP-β-CD were determined by following the fading of an alkaline 
phenolphthalein solution spectrophotometrically [11]. The original assay needed to 
be adapted to allow the determination of small quantities of released cyclodextrin 
(see Chapter III).  
Since the hydrophobic side chains of proteins [105] as well as of PEG [87] are able to 
interact with the cyclodextrin cavity the released protein or the liberated PEG might 
interfere with the developed assay. However, it could be shown that the calibration 
curve obtained with protein- and PEG-free HP-β-CD solutions overlapped with that 
obtained in the presence of IFN-α and PEG (data not shown). Thus, any interference 
of released IFN-α or PEG with the formation of the phenolphthalein/HP-β-CD 
inclusion complex was negligible in the present study. 
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Figure 22: Release of HP-β-CD, PEG, and IFN-α from the tristearin-based implants. 
The implants were loaded with 10 % IFN-α / HP-β-CD co-lyophilisate and 10 % (average +/- SD; n = 
3). 
Figure 22 compares the in-vitro release kinetics of IFN-α, PEG, and HP-β-CD from 
tristearin implants containing 10 % PEG. Clearly, PEG leaching was fastest, followed 
by HP-β-CD and IFN-α liberation. Importantly, the shape of the release curves of 
PEG and HP-β-CD was different from that of IFN-α: the slope monotonically 
decreased with time for the two excipients, whereas it remained almost constant 
during at least 7 d for the protein. This already indicated differences in the underlying 
mass transport mechanisms. In order to judge the importance of diffusional mass 
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transport of the release of the excipients, the above described mathematical model 
(Equation 9, Chapter I.5.3) was fitted to the experimentally determined release rates 
considering PEG and HP-β-CD as the diffusing species. 
In Figure 23 the obtained releases profiles of PEG from implants with initial PEG 
contents of 5 - 20 % as well as the respective fittings are illustrated. Clearly, good 
agreement between the applied theory and experiments was obtained in all cases 
(R² > 0.99), indicating that pure diffusion (in axial and radial direction) with constant 
diffusion coefficients governed the transport of this excipient. As it can be seen, the 
release rate significantly increased with higher initial PEG loading.  
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Figure 23: Effects of the initial PEG loading on the release of PEG.  
Experimental data are shown as symbols and theoretical data based on Equation 9, Chapter I.5.3 as 
solid lines. All tristearin-based implants were loaded with 10 % IFN-α/HP-β-CD co-lyophilisate and the 
indicated amount of PEG (for experimental results: average +/- SD; n = 3). 
Since the used mathematical model described well the experimental release kinetics 
it was possible to determine the apparent diffusion coefficients of PEG within the 
lipidic matrices based on theoretical fittings shown in Figure 23. This approach 
allowed to quantify the impact of the initial PEG loading on the diffusivity of PEG. The 
dependence of the calculated apparent diffusion coefficients on the PEG content of 
the matrix is shown in Figure 24. Obviously, the diffusivity significantly increased with 
higher initial PEG loading and an exponential relationship between the diffusion 
coefficient D, and the initial PEG content could be established (R² = 0.99, equation 
indicated in Figure 24).  
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Figure 24: Effects of the initial PEG loading on the apparent diffusion coefficient of PEG within 
the tristearin matrix. 
The release patterns of HP-β-CD as well as the respective fittings based on 
Equation {9} (Chapter I.5.3) are illustrated in Figure 25 for various initial PEG 
contents. Like PEG release (and in contrast to IFN-α release), pure diffusion with 
constant diffusivities was the dominating mass transport mechanism of HP- β-CD. 
This was indicated by the good agreement between theory and experiments 
(R² >0.98). In accordance with the liberation of PEG from matrices with various PEG 
loadings, the release rates increased with rising PEG contents. 
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Figure 25: Effects of the initial PEG loading on the release of HP-β-CD.  
Experimental data are shown as symbols and theoretical data based on Equation 9, Chapter I.5.3 as 
solid lines. All tristearin-based implants were loaded with 10 % IFN-α/HP-β-CD lyophilisate and the 
indicated amount of PEG (for experimental results: average +/- SD; n = 3). 
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Based on the theoretical fittings shown in Figure 25, the apparent diffusion coefficient 
of HP-β-CD in the lipidic matrices was calculated. The obtained D values are plotted 
versus the initial PEG loading of the matrix in Figure 26. Clearly, a higher PEG 
content of the matrix accounted for an increase in the diffusivity of HP-β-CD, which is 
in well accordance with the results obtained for PEG itself (Figure 24). Furthermore, 
similar to the diffusion coefficient of PEG an exponential relationship between the 
diffusivity of HP-β-CD and the initial PEG content could be established (R² = 0.98). 
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Figure 26: Effects of the initial PEG loading on the apparent diffusion coefficient of HP-β-CD 
within the tristearin matrix. 
The observation that the diffusivities of both excipients increased with rising initial 
PEG loading is consistent with the SEM pictures of tristearin implants after in-vitro 
incubation (Figure 15). Enhanced levels of initial PEG amounts clearly resulted in a 
more pronounced pore formation. So, less restricted pore dimensions accounted for 
increased mobility of the excipients within the lipidic matrix. As a result the delivery 
rates of both excipients from matrices comprising higher initial PEG loadings were 
significantly accelerated.  
Since release kinetics of PEG as well as of HP-β-CD were described well by a 
solution of Fick’s second law of diffusion assuming constant diffusivities during 
release, time-dependent variations of the diffusivity during the release period were 
not of importance for the tristearin implants studied here. This result clearly 
contradicts the assumption that the observed deviations of IFN-α release from purely 
diffusion-controlled mass transport from matrices containing PEG can be attributed to 
the time-dependent increase in the porosity of the matrices.  
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1.4. SUMMARY AND CONCLUSION 
The admixing of PEG to tristearin implants was shown as an efficient tool to modify 
the protein release kinetics. In addition to an increase of the totally released protein 
the shape of the release curves was altered. The release rates monotonically 
decreased with time for PEG-free implants, whereas PEG-comprising implants 
revealed nearly constant liberation rates over prolonged periods of time. Interestingly, 
compared to PEG-free matrices the admixing of PEG to the matrix formulation 
resulted in reduced initial burst effects.  
In order to understand the underlying drug release mechanisms an adequate 
mathematical solution of Fick´s second law of diffusion was fitted to the release data. 
The protein release from PEG-free matrices was found to be purely diffusion 
controlled. In contrast, the addition of 5 to 20 % PEG to the formulations significantly 
altered the underlying mass transport mechanisms. Already the addition of only 5 % 
PEG resulted in systematic deviations between the experimental results and the 
purely diffusion-based mathematical model. 
Both effects of PEG - the reduced burst release as well as the significant deviations 
from purely diffusion controlled protein release – are very astonishing considering the 
well – known role of PEG as pore forming agent. The addition of porogens generally 
facilitates the creation of interconnected pore networks and, thus, leads to increased 
total amounts of drug released (see Chapter I.5). However, the amplified pore 
creation reduces the geometrical hindrance of the pore networks, what accounts for 
high burst effects and elevated release rates [40, 108, 113, 138, 174].  
One possible reason for the observed systematic deviations between the applied 
mathematical model and the experimentally measured IFN-α release kinetics may be 
that the simultaneous dissolution and diffusion of PEG within the water-filled pores of 
the implants affects the mobility of the protein. In order to evaluate the relevance of 
this hypothesis, the diffusion coefficients of IFN-α in the release medium in the 
presence and the absence of PEG were determined using a modification of the open 
capillary method described by Anderson and Saddington [5]. However, the presence 
of different amounts of PEG did not substantially alter the diffusivity of IFN-α in the 
release medium.  
Furthermore, the liberation rates of PEG and the co-lyophilisation agent HP-β-CD 
were determined. Unlike protein release, the release of PEG and HP-β-CD from the 
implants remained purely diffusion controlled, irrespective of the amount of added 
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PEG. Thus, different mass transport mechanisms govern the release of the drug and 
the excipients out of the lipidic implants.  
The fact that the release of both PEG and HP-β-CD was purely diffusion-controlled 
(with constant diffusivities), irrespective of the initial PEG content of the implants, is 
an important information: it renders the hypothesis very unlikely that the deviations of 
IFN-α release from purely diffusion-controlled mass transport can be attributed to the 
time-dependent increase in the porosity of the matrices. Such a time-dependent 
increase in matrix porosity could result in a significant time-dependent increase in 
protein mobility. However, in this case a similar effect should have been observed 
also with PEG and HP-β-CD. 
Screening the literature aside from the studies describing the impact of PEG as 
porogen, a few alternative features of PEG used within controlled release systems 
are outlined. For PLGA-based matrices, for instance, the accelerated pore formation 
enhanced the diffusion of acid species generated during polymer degradation. 
Consequently, the acidification within the devices became less pronounced and the 
tendency of protein aggregation is minimised [108]. Further positive effects of 
PEG 400 addition have been shown, when preparing PLGA microparticles by solvent 
extraction/evaporation methods. The major cause of protein denaturation occurring 
during this type of preparation techniques was the exposure of the macromolecules 
to the aqueous-organic interfaces. As PEG 400 adsorbed to these interfaces too, it 
competed with the proteins and, thus, protects them from degradation [34, 167].  
It was also suggested that the amphiphilic character of PEG 6000 reduced the 
solubility of PLGA in methylene chloride. During the preparation of microspheres, 
therefore, an accelerated solidification of PLGA was observed, which in turn 
decreased the porosity and the initial burst release from the obtained microspheres 
[260].  
The group of Morita employed phase separation during the lyophilisation of an 
aqueous protein-PEG mixture to generate spherical fine protein microparticles [155]. 
The obtained BSA particles were incorporated in PLGA microspheres using the 
“polymer-allow” technique. This methodology was based on the selective localization 
of solid BSA particles in a phase separated-structure between PLGA and PLA in 
methylene chloride. Due to the resulting reservoir type system with a outer drug-free 
PLA-shell the produced microspheres revealed a low burst effect (<10 %) despite the 
presence of PEG [154]. 
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Although the latter two studies disclosed a low burst effect for PEG-comprising 
controlled release systems the provided explanations can obviously not be adapted 
to the lipidic implant systems studied here.  
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2. SOLUBILITY STUDIES AND INVESTIGATIONS ON THE PROTEIN STABILITY 
In biotechnology the ability of PEG to reversibly precipitate/crystallise proteins has 
been widely used for protein separation and purification [149, 165]. However, these 
effects have so far not been considered in the context of controlled release.  
Therefore, the solubility of IFN-α was experimentally determined in differently 
concentrated aqueous PEG solutions. Solutions of IFN-α with an initial protein 
concentration of 4.8 mg/mL were diluted in a one to one ratio with highly 
concentrated PEG solutions (2-40 % (wt/vol)). Immediately after mixing both 
solutions, a macroscopic visible precipitation of IFN-α occurred when the final PEG 
concentration exceeded 3 %. After equilibrating the samples for 2 hours at 37 °C and 
40 rpm the protein concentration in the supernatant was determined. As illustrated in 
Figure 27, the soluble fraction of IFN-α decreases non-linearly with increasing PEG 
concentration. Interestingly, already 10 % PEG resulted in an almost negligible 
protein solubility (0.02 mg/mL).  
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Figure 27: Effects of the PEG concentration on the apparent solubility of IFN-α at 37 °C in 
phosphate buffer pH 7.4 (average +/- SD; n = 3). 
The tremendous impact of PEG on protein solubility might offer an explanation for the 
effects of PEG on the protein release from lipidic matrix systems. Due to the small 
pore volume within the lipid matrices the dissolution of the incorporated PEG should 
first result in a highly concentrated PEG solution. Therefore, protein solubility within 
the device might be reduced, resulting in a more sustained protein delivery from PEG 
containing implants compared to PEG-free systems. 
Chapter IV: Mechanisms controlling the release from lipid-based delivery systems 84 
  
 
 
Figure 28: Morphology of the precipitated protein observed by light microscopy.  
The final PEG concentration of the solution is indicated in the figure.  
Figure 28 visualises the appearance of the obtained solid material upon precipitation 
of IFN-α by the addition of PEG. The ordered, needle-like structures indicated a 
crystallisation of IFN-α in the presence of PEG. This was an important information 
considering protein stability, since the crystalline form may be more stable than the 
corresponding soluble or amorphous material [203]. It was further apparent from 
Figure 28 that increasing PEG concentrations led to smaller needles. This was in 
good agreement with theory: with increasing the nucleation rate due to enhanced 
precipitant concentrations the amount of protein available per crystal nucleus is 
reduced, leading to smaller crystals [67]. 
2.1. PROTEIN STABILITY AFTER PRECIPITATION AND REDISSOLUTION 
Generally, the precipitation of proteins by PEG has been explained on the basis of 
volume exclusion effects. Mainly due to sterical hindrance, proteins are excluded 
from the solvent space that is occupied by the linear PEG chains. Hence, the protein 
is locally concentrated until the solubility is exceeded and precipitation and/or 
crystallization occurs [149].  
From a thermodynamic point of view the preferential exclusion of PEG from the 
protein surface (preferential hydration) leads to an increase in the chemical potential 
of the protein. This thermodynamically unfavourable situation can be relieved by 
protein precipitation (salting-out), which reduces the total protein-solvent interface [7, 
9, 204].  
The potential effects of PEG on protein stability are more complicated. Therefore, in 
brief the general mechanism of protein stabilisation by preferential exclusion will be 
outlined. According to Timasheff co-solvents that are preferentially excluded from the 
protein surface can be classified into two distinct categories: (1) those that are totally 
independent of the chemical nature of the protein surface and (2) those for which the 
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particular chemical features of the protein surface play a role. Co-solvents of the first 
category are either excluded due to sterical hindrance or, due to an increase in 
surface tension of water by the co-solvent. The predominant driving forces of the 
second class are the solvophobic effect (e.g. polyols, glycerol) and electrostatic 
repulsions between the charged protein surface and the co-solvent (2-methyl-2,4-
pentanediol, MPD) [226, 227].  
Irrespective of its category a preferentially excluded co-solvent will reduce protein 
solubility due to an increase in the chemical potential of a protein. However, the 
effects on protein stability of preferentially excluded co-solvents can be very different. 
Whereas co-solvents of the first class are always stabilising, compounds of the 
second category may also be destabilising. Importantly, such destabilising effects 
have been reported for PEG too [14, 226, 227].  
PEGs are hydrophobic in nature and have an affinity for non-polar residues on 
proteins. In the native state most of these non-polar residues are hidden inside the 
folded protein structure inaccessible to PEG. As a result the interactions of PEG with 
native proteins are determined predominately by the sterical exclusion. However, as 
the protein unfolds, hydrophobic regions of the protein become exposed. 
Consequently, PEG will favourably interact with these newly exposed non-polar 
residues, thereby stabilising the unfolded structures. This explains why PEG has 
been found to promote protein unfolding, especially at high temperatures [68, 136].  
The extent of thermal destabilisation strongly depends on the molecular weight. For 
PEG 10000 sterical exclusion being the major factor, determining the interaction to 
human serum albumin (HSA) even during thermal denaturation. Thus, thermal 
stability increases. In contrast, the low molecular weight PEGs 1000 and 4000 were 
found to interact favourably with hydrophobic side chains exposed during thermal 
unfolding. This was manifested in lowering the thermal transition temperature (Tm) 
[68].  
The opposite was reported by Remmele. Tm of interleukin-1 receptor (IL-1R) was 
shifted to lower values when increasing the molecular weight of PEG (TmPEG 300> 
TmPEG 1000 > TmPEG 3350) [181]. Presumably, in the latter case the increased 
hydrophobicity of the higher molecular weight PEGs overcompensates the impact of 
sterical exclusion.  
On the other hand, Cleland et al. revealed that the presence of PEGs significantly 
enhanced the recovery of active protein during refolding after chemical denaturation. 
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It was suggested that PEG acted like chaperons - i.e. the binding to specific 
segments of the protein during refolding prevented intermolecular interactions (i.e. 
aggregation) [42, 44].  
Generally, the precipitation of proteins by PEG is considered to inhere only little 
tendency for denaturation [104]. Thus, crystals grown from PEG-solutions are widely 
used to solve protein structures [149]. However, recently Sharma and Kalonia 
revealed irreversible alterations of the protein structure for IFN-α upon precipitation 
by high molecular weight PEGs. Attenuated total reflectance Fourier transform 
infrared spectroscopy (ATR-FTIR) of precipitated IFN-α featured slight changes in the 
secondary structure of the protein. After re-dissolution these changes were observed 
to be reversible, when IFN-α was precipitated by PEG 1450. However, when PEG 
8000 was used, also after re-dissolution far and near UV circular dichroism (CD) 
indicated alterations in the secondary and tertiary structure [201].  
75
80
85
90
95
100
105
0 3 4 5 8 10 15 20
PEG, %
 IF
N
- α 
re
co
ve
ry
, %
0.00
0.50
1.00
1.50
2.00
ox
id
is
ed
 IF
N
- α
, %
IFN-α recovery,% oxidised IFN-α,%
 
Figure 29: Recovery and chemical protein integrity after precipitation and re-dissolution. 
After precipitation of IFN-α with the indicated PEG concentration the samples were diluted and 
analysed by RP-HPLC (average +/- SD; n = 3). 
In order to investigate the stability of IFN-α after precipitation with PEG 6000, 
dispersions of protein precipitates (in the presence of 3 to 20 % (wt/vol) PEG) were 
diluted with buffer to PEG concentrations below 0.2 %. The protein precipitates 
instantaneously dissolved in an excess of buffer and the re-dissolved protein 
concentration was determined by RP-HPLC. As illustrated in Figure 29, a virtually 
complete protein recovery could be proven, irrespective of the PEG concentration 
used for precipitation (4-20 %). The fraction of oxidised IFN-α was comparable to that 
present in protein bulk solution and thus could not be ascribed to the precipitation 
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and re-dissolution process. Importantly, apart from this marginal amount of oxidised 
IFN-α no further degradation products were detected.  
In addition, the reconstituted precipitates were analysed by SDS-PAGE to exclude 
the formation of protein aggregates and fragments associated to a precipitation. 
Obviously, irrespective of the applied PEG amount, only monomeric protein was 
determined after silver staining (Figure 30). 
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Figure 30: SDS-PAGE of precipitated and re-constituted IFN-α.  
Lane 1: Molecular weight standard, lane 2: IFN-α standard, lanes 3-8: re-constituted IFN-α precipitates 
(precipitated in phosphate buffer pH 7.4 containing 4, 5, 7.5, 10, 15 and 20 % PEG). 
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Figure 31: Recovery and protein integrity after precipitation and re-dissolution investigated by 
SE-HPLC. 
After precipitation of IFN-α with the indicated PEG concentration, the supernatant was removed and 
the obtained precipitates were dissolved in phosphate buffer pH 7.4 (average +/- SD; n = 3). 
However, the presence of SDS may dissolve non-covalent aggregates during sample 
preparation [251]. To overcome this limitation size-exclusion chromatography was 
carried out. Unfortunately, even low amounts of PEG interfere with the separation of 
dimeric IFN-α (data not shown). In order to remove PEG as far as possible, the 
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dispersion of protein precipitates was centrifuged. After removing the supernatant, 
the obtained protein precipitates were diluted with buffer. Since the removal of the 
supernatant inheres the risk of losing a certain amount of protein this procedure 
cannot provide precise protein recoveries as the simple dilution of the precipitated 
samples used for RP-HPLC. Nevertheless, the results mirrored that at least 95 % of 
the protein were recovered (Figure 31). Importantly, the recovered protein comprised 
only monomeric IFN-α. Irrespective of the PEG concentration used for precipitation 
no formation of soluble aggregates was detectable by SE-HPLC analysis. The 
marginal amount of approximately 0.1 % dimer fraction was already present in the 
protein bulk material prior to precipitation. 
For the investigation of the effects of precipitation and re-dissolution on the 
secondary structure of IFN-α, the FTIR spectra in the amid I region of reconstituted 
precipitates were compared to that of native IFN-α. As it can be seen in Figure 32, 
the spectra of native IFN-α revealed an intense peak at 1654 cm-1, the typical feature 
of an alpha helical protein [60]. Importantly, the vector-normalised FTIR spectra as 
well as the corresponding second derivatives of reconstituted protein precipitates 
were almost congruent with that of native IFN-α, irrespective of the PEG 
concentration used for precipitation. Therefore, the secondary structure of IFN-α 
remained unaffected upon precipitation and re-dissolution.  
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Figure 32: Effects of precipitation and re-dissolution of IFN-α in phosphate buffer pH 7.4 on the 
secondary protein structure. 
(A) Background corrected and vector-normalised amid I FTIR-spectra; (B) Second-derivative amid I 
FTIR-spectra. The PEG concentrations at which IFN-α precipitation was performed are indicated. 
Finally, the potential impact of precipitation and re-dissolution on the tertiary structure 
was probed with the intrinsic protein fluorescence spectroscopy. IFN-α contains two 
tryptophan (Trp) residues [202]. Trp residues of a protein can be selectively excitated 
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at 295 nm. Depending on the microenvironment of Trp the emission spectra revealed 
a maximum between 302 nm and 350 nm. Emission at lower wavelengths is 
characteristic for Trp buried entirely in the hydrophobic environment, whereas an 
emission maximum at longer wavelengths indicates Trp residues on the protein 
surface. Due to protein unfolding hydrophobic amino residues would become more 
solvent exposed and, therefore, unfolding often results in a decrease of the 
fluorescence quantum yield and in a red shift [182, 250]. 
Figure 33 shows the Trp fluorescence emission scans of IFN-α in PBS buffer at a pH 
of 7.4. The observed λmax of Trp emission at 336 nm indicated that the two Trps of 
IFN-α were partially buried in the hydrophobic core of the protein [202]. Importantly, 
λmax of IFN-α after precipitation and re-dissolution was determined at 336 nm and the 
obtained fluorescence scans were almost identical with those of native IFN-α.  
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Figure 33: Trp fluorescence emission spectra of native IFN-α and after precipitation and re-
dissolution with various amounts of PEG (as indicated in the figure). 
2.2. SUMMARY AND CONCLUSION 
The presence of PEG was shown to have a tremendous effect on IFN-α solubility: a 
concentration of 3 % PEG was already sufficient to cause protein precipitation. 
Importantly, precipitation was completely reversible. After re-dissolution of IFN-α the 
protein was completely recovered in its monomeric form without structural alterations 
detectable by SE- and RP-HPLC. Furthermore, FTIR- and fluorescence spectroscopy 
indicated a preservation of the native secondary and tertiary structure after 
precipitation and re-dissolution.  
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As the release of PEG occurred delayed from tristearin implants, it was hypothesised 
that within the water-filled pores of the tristearin implant a highly concentrated PEG 
solution might be generated in the first period of the release process. Taking into 
account the dramatic effect of PEG on the solubility of IFN-α, reduced protein 
solubility or even a reversible precipitation of IFN-α within PEG-containing matrices is 
highly likely. Not until PEG is completely leached out of the matrix, only a minor, non-
precipitated fraction of the incorporated protein is available for diffusion. Thus, at an 
early stage of release the protein liberation from PEG-comprising implants is 
hindered. Furthermore, the creation of water-filled pores might be reduced due to the 
un-dissolved protein. Both effects could explain the reduced burst of protein release 
from PEG-containing implants in comparison to PEG-free implants. 
In the case of purely diffusion controlled drug release, the time-dependent 
prolongation of the diffusion ways results in monotonically decreasing release rates. 
This was shown to be true for PEG-free implants. In contrast, in PEG-containing 
devices the solubility of IFN-α within the water-filled pores increases continuously 
due to the leaching out of PEG of the system. Thus, the amount of protein available 
for diffusion increases with time. Consequently, the increasing length of the diffusion 
pathways is partly compensated, resulting in about constant IFN-α release rates over 
prolonged periods of time. Such considerations would explain the systematic 
deviations between the presented mathematical model (assuming unlimited protein 
solubility and constant diffusion coefficients) and the experimentally determined  
IFN-α release kinetics from PEG-containing implants.  
Although in-situ precipitation would explain well the effects of PEG on the release 
behaviour of IFN-α, such release controlling mechanisms by PEG are not described 
in literature. Protein precipitation/crystallisation in general has so far only been used 
to provide beneficial protein stabilisation during the fabrication process of controlled 
release devices. For example, the formation of an insoluble complex of rhGH and 
zinc enables the encapsulation and slow release of unaltered rhGH from PLGA 
microspheres [10, 109]. Furthermore, van de Wetering used the precipitation of rhGH 
by zinc or by PEG to protect the protein from reaction with gel precursors during the 
preparation of chemically cross-linked hydrogels [232]. In addition, the reversible 
precipitation of α-chymotrypsin and lactate dehydrogenase in the presence of 
poloxamer 407 has been used to increase the protein loading of in-situ forming 
poloxamer gels [217].  
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However, in the present project IFN-α, PEG, and the lipid were simply mixed as solid 
powders and subsequently compressed to implants. Thus, in contrast to the studies 
mentioned above, precipitation will only occur in-situ during release.  
In order to evaluate if in-situ reduced protein solubility or a protein precipitation within 
PEG-containing matrices is relevant, the following chapter reports on various model 
experiments carried out to prove the presented hypothesis. 
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3. POLY(ETHYLENE GLYCOL) ACTING AS IN-SITU PRECIPITATION AGENT – PROOF OF 
CONCEPT 
Together with the release data of PEG the time-dependent increase in matrix 
porosity should provide information on the PEG concentrations generated within the 
implant pores. In order to determine the kinetics of pore formation three independent 
implants loaded with 20 % PEG and 10 % IFN-α/HP-β-CD co-lyophilisate were 
removed from the incubation buffer at predetermined points of time. The implants 
were wipe-dried with an adsorbent paper to remove adhesive water and were then 
weighed. Subsequently, the implants were vacuum dried to constant weight. Finally, 
the density of the devices was determined by means of helium pycnometry. Based 
on these values the porosity and the absolute pore volume were calculated. Together 
with the release rates of PEG, presented in Chapter IV.1, the theoretical PEG 
concentrations within the implant pores could be determined.  
After manufacturing the lipidic implants revealed a low porosity of approximately 2 %. 
As illustrated in Figure 34, immediately after immersion into the release media the 
porosity increased until the fourth day of incubation, which was followed by a plateau 
of approximately 25 %. 
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Figure 34: Time-dependent increase in matrix porosity. 
After incubation in the release medium the implants were dried and the porosity was determined by 
means of a helium pycnometer. The implants were loaded with 20 % PEG and 10 % IFN-α/HP-β-CD 
co-lyophilisate (average +/- SD; n = 3).  
Assuming that the pores were completely filled with release medium, the actual PEG 
concentrations within the implant pores can be calculated at each time point using 
the determined pore volume and the amount of PEG remaining in the implant 
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(Table 6). The small pore volume combined with the sustained release of PEG 
resulted in quite high PEG concentrations within the implant pores.  
Table 6: Calculated PEG concentrations within the implant pores.  
time, d  porosity, % conc. dissolved PEG, % (wt/vol)
0 1.91 0.00
0.08 4.21 377.61
0.17 5.81 230.69
0.25 7.83 148.07
0.5 11.27 86.89
1 17.09 53.67
4 23.55 22.94
7 23.65 0.53
10 24.61 0.00
30 25.20 0.00  
 
However, the presented calculation of the PEG concentrations is somewhat 
speculative, as it is based on the assumption that the total amount of incorporated 
PEG immediately dissolves after incubation in the release buffer. The real conditions 
may differ as it is likely that not the entire hydrophobic matrix is wetted immediately 
after the incubation start. In fact water will first dissolve PEG located in the outermost 
implant region. Then, at a later stage of release the entire matrix is percolated by the 
release medium and the overall amount of PEG is dissolved (Figure 35). This 
scenario was confirmed by the experimentally determined water uptake during  
in-vitro incubation (Figure 36). 
 
before incubation during incubation I
PEG disolved in water-filled pores
PEG dispersed as solid in the lipid matrix
during incubation II
 
Figure 35: Migration of the dissolution front during release. 
Before incubation PEG is dispersed as solid in the lipidic matrix (left). At an early stage (middle) of 
release water penetrates in the outermost areas of the implant and dissolves PEG. Finally, the lipidic 
matrix is completely wetted and the entire PEG is dissolved within the water-filled pores (right).  
As the matrix took up water until the fourth day of incubation (Figure 36), the 
concentrations of PEG calculated before are overestimating the real PEG 
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concentrations within the water-filled pores. However, it is highly conceivable that at 
the fourth day of incubation the matrix is completely wetted. Therefore, it becomes 
realistic that a PEG solution with concentrations of approximately 20 % PEG is 
generated within the implant pores (Table 6). Taking into account the effect of PEG 
on the solubility of IFN-α (Figure 27), reduced protein solubility or even a reversible 
precipitation of IFN-α within these PEG-containing matrices can be assumed until 
day four of incubation. 
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Figure 36: Time-dependent water-uptake of tristearin implants prepared by compression. 
The implants were loaded with 20 % PEG and 10 % IFN-α/HP-β-CD co-lyophilisate. The water uptake 
was determined by weighing wet and dry implants (see Chapter III) (average +/- SD; n = 3).  
In order to cope with the remaining uncertainties of the aforementioned method, and 
to prove the postulated hypothesis of a reversible precipitation and reduced solubility 
of IFN-α within PEG-containing matrices, further model experiments were carried out. 
3.1. “MACROPORE MODEL” 
In order to determine whether the reduced protein solubility or even a reversible 
precipitation within the lipidic matrix could play a role for the IFN-α release, a model 
device simulating the conditions in the water-filled pores within the implant was 
developed. The idea was to elucidate the relevance of protein dissolution versus 
protein diffusion in the presence of PEG by mimicking the inner content of a pore 
filled with IFN-α and the water-soluble excipients. For that purpose a small volume 
container connected with a capillary was intended to imitate a drug reservoir with an 
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associated pore within the controlled release system. The device (schematically 
illustrated in Figure 37) was named “macropore model”. The container was filled with 
compressed lyophilised protein pellets or with compressed lyophilised protein/PEG 
pellets. In the latter case, lyophilisate/PEG ratios of 1:1 or 1:2 (corresponding to 
implants containing 10 % PEG or 20 % PEG, respectively) were studied. In addition, 
pellets containing HP-β-CD instead of PEG were placed in the cylindrical chamber of 
the “macropore model” (in contrast to PEG, HP-β-CD does not cause protein 
precipitation). 
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Figure 37: Schematical presentation of the experimental setup of the “macropore model”.  
Protein, protein/PEG, or protein/HP-β-CD pellets were placed into a cylindrical chamber with only one 
opening into a cylindrical capillary. This device was placed into a plastic flask filled with phosphate 
buffer pH 7.4. The flask was agitated at 40 rpm and kept at 37 °C. 
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Figure 38: IFN-α release from pellets consisting of IFN-α lyophilisates, IFN-α lyophilisates:PEG 
blends, and IFN-α lyophilisates:HP-β-CD blends into phosphate buffer pH 7.4 measured using 
the “macropore model” (schematically illustrated in Figure 37) (average +/- SD; n = 3). 
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Figure 38 demonstrates that the release of IFN-α from PEG-free devices was almost 
ten times faster than protein delivery from systems containing pellets with a 
lyophilisate/PEG ratio of 1:2. Interestingly, when PEG was present the pellets did not 
disintegrate and remained visible during the entire release period. This indicated that 
within the “macropores” highly concentrated PEG solutions were created and, hence, 
the dissolution of the protein/excipient pellets was hindered. Therefore, the 
dissolution step can be considered as one of the major rate limiting factors for protein 
release in the presence of PEG. 
3.2. PH-DEPENDENCE OF SOLUBILITY AND RELEASE 
Further insight into the significance of reduced protein solubility and reversible 
precipitation within PEG-containing tristearin implants was obtained by studying the 
pH-dependence of protein solubility and release.  
As it can be seen in Figure 39 A, the solubility of IFN-α in phosphate buffer 
containing 5 % PEG was strongly affected by the pH: a minimum was observed in 
the pH range 6-9. At lower or higher pH values, no protein precipitation was notified 
under the given experimental conditions.  
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Figure 39: Effects of the pH of the phosphate buffer solution on the apparent solubility of IFN-α 
at 37 °C  
(A) Solubility in the presence of 5 % PEG (B) Solubility at pH 7.4 and at pH 4.0 in the presence of 
different concentrated PEG solutions (average +/- SD; n = 3). 
Therefore, a pH change of the release buffer offers the possibility to “switch off” the 
in-situ precipitation. Since several authors reported good IFN-α stability at low pH 
values [62, 142], pH 4.0 was chosen to investigate the effects of higher PEG 
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concentrations on protein solubility. Importantly, even PEG concentration up to 20 % 
did not induce protein precipitation under this experimental setup (Figure 39 B).  
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Figure 40: Effects of the pH of the phosphate buffer solution on IFN-α release from tristearin-
based implants.  
Matrices were loaded with 10 % IFN-α/HP-β-CD lyophilisate and 0 % PEG (A), 10 % PEG (B), 
15 % PEG (C) and 20 % PEG (D). The release was studied either in phosphate buffer pH 7.4 [open 
symbols: experimental values (average +/- SD; n = 3), dashed curves: theory (Equation 9)] or in 
phosphate buffer pH 4.0 [closed symbols: experimental values (average +/- SD; n = 3), solid curves: 
theory (Equation 9)]. 
Figure 40 compares the release kinetics of IFN-α from tristearin-based implants in 
phosphate buffer pH 7.4 and pH 4.0. In the case of PEG-free implants, the pH had no 
effect on the resulting in-vitro release kinetics (Figure 40 A). Protein release levelled 
off at approximately 30 % after 4 d, irrespective of the pH of the medium. In contrast, 
the pH was found to affect fundamentally IFN-α release patterns from lipidic implants 
containing PEG.  
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As shown in Figure 40 B-D, the lack of protein precipitation at pH 4.0 resulted in 
significantly accelerated protein release rates with a high burst effect. For example at 
pH 4.0, implants loaded with 20 % PEG exhibited a high initial release of 78.3 % (± 
0.43) after 24 h and the release was already complete after only 4 d. In contrast, 
sustained IFN-α release was observed from the same type of implant in phosphate 
buffer pH 7.4. Not only the slope of the release curves, but also their shapes were 
affected by the pH of the release medium. All release rates monotonically decreased 
at pH 4.0, whereas at pH 7.4 they remained about constant for 7 d.  
This observation indicated differences in the underlying protein release mechanisms. 
To get deeper insight into the involved mass transport phenomena, an analytical 
solution of Fick’s second law of diffusion considering radial as well as axial mass 
transfer in cylinders with constant diffusion coefficients (Equation 9, Chapter I.5.3) 
was fitted to the experimentally determined release rates. As it can be seen in 
Figure 40, good agreement between theory and experiment was obtained in all cases 
at pH 4.0, irrespective of the initial PEG loadings of the implants (R2>0.99). Thus, 
protein release at pH 4.0 was predominantly controlled by pure diffusion with 
constant diffusivities. In contrast, at pH 7.4 the presence of PEG within the lipidic 
systems resulted in systematic deviations between the applied mathematical theory 
and the measured protein release kinetics. 
Furthermore, the total amounts of IFN-α released from PEG-containing implant 
systems strongly depended on the pH of the release medium. This effect will be 
investigated in Chapter IV.3.4.  
Chapter IV: Mechanisms controlling the release from lipid-based delivery systems 99 
  
3.3. ALTERNATIVE POROGEN AND ALTERNATIVE PROTEIN 
Finally, either the pore forming agent or the protein of the implant formulation was 
substituted to prove the postulated hypothesis of an in-situ precipitation prior protein 
release.  
3.3.1. RELEASE OF IFN-α FROM TRISTEARIN IMPLANTS LOADED WITH AN ALTERNATIVE 
POROGEN 
Following the postulated release mechanism an alternative porogen, that does not 
cause protein precipitation, should lead to an accelerated release of IFN-α from 
tristearin matrices.  
HP-β-CD was chosen as alternative porogen for three main reasons:  
(1) HP-β-CD is already present in the original implant formulation. Thus, potential 
unforeseeable effects (on the protein stability, matrix compressibility etc.) of the 
“new” porogen are improbable.  
(2) Cylodextrins are reported to form inclusion complexes with peptides and proteins 
[105]. Such interactions may affect protein solubility as well as diffusivity which in turn 
would account for various effects on the protein release kinetics. However, in 
Chapter IV.4 it will be shown that the formation of inclusion complexes between IFN-
α and HP-β-CD is unlikely.  
(3) The release of HP-β-CD from tristearin implants is slower than the release of PEG 
(Figure 22). Consequently, an accelerated liberation of IFN-α due to a faster leaching 
out of HP-β-CD can be excluded.  
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Figure 41: Effect of porogen character on the in-vitro release of IFN-α. 
Matrices were loaded with 10 % IFN-α/HP-β-CD lyophilisate and with 10 % lyophilised HP-β-CD or 
with 10 % PEG (average +/- SD; n = 3). 
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The replacement of PEG by HP-β-CD tremendously altered the release behaviour of 
IFN-α from tristearin implants (Figure 41). As expected, accelerated protein delivery 
from implants comprising 10 % HP-β-CD as porogen was observed. IFN-α was 
completely liberated within the first 24 hours. This result demonstrated the 
importance of the protein precipitation for a sustained protein release. 
3.3.2. RELEASE OF LYSOZYME FROM TRISTEARIN IMPLANTS  
In a second attempt the effect of PEG on the in-vitro release behaviour of an 
alternative protein was investigated. Due to volume exclusion effects it is highly 
expectable that the addition of polyethylenglycols reduces protein solubility in general 
[204, 226]. However, the extent of “salting out” depends on the protein.  
Thus, in the following experiment the impact of different PEG loadings on the release 
kinetics of a protein with a less strong precipitation in the presence of PEG was 
studied. Based on the postulated release mechanism PEG should mainly act as a 
porogen resulting in accelerated protein release with enhances burst effects [40, 108, 
138, 174].  
Atha et al. (1981) investigated the effect of PEG 4000 on the solubility of various 
proteins. It was shown that proteins with a molecular weight between 150 to 670 kDa 
tend to precipitate at lower PEG concentrations than proteins with a molecular weight 
between 14 and 66 kDa [9]. Since a massive variation of the protein’s molecular 
weight would affect diffusivity and in consequence the release behaviour, an 
alternative protein with a molecular weight comparable to IFN-α, but with a less 
distinct precipitation in the presence of PEG 6000 was chosen.  
In the study of Atha [9], lysozyme revealed the highest solubility in the presence of 
PEG 4000. Since the molecular weight of lysozyme (14.4 kDa) is comparable to that 
of IFN-α (19.2 kDa) lysozyme was used in these studies.  
First, the solubility of lysozyme in the presence of PEG 6000 was investigated. As 
shown in Figure 42, the influence of PEG on protein solubility was significantly lower 
than that observed for IFN-α. Even at a PEG concentration of 20 % (wt/vol) a high 
lysozyme solubility of 63.9 mg/mL (SD 4.0 mg/mL, n=3) was determined. In 
comparison, PEG concentrations of 10 % resulted in an almost negligible IFN-α 
solubility (soluble fraction of IFN-α 0.02 mg/mL).  
Thus, it could be expected that in-situ precipitation is of minor importance for the 
release of lysozyme from PEG containing matrices compared to IFN-α.  
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Figure 42: Effects of the PEG concentration on the apparent solubility of IFN-α and lysozyme at 
37 °C in phosphate buffer pH 7.4 (average +/- SD; n = 3). 
 
The release patterns of lysozyme from tristearin implants containing various amounts 
of PEG are illustrated in Figure 43. In analogy to the release of IFN-α, the addition of 
PEG enhanced the total amount of liberated lysozyme. However, an important 
distinction between IFN-α and lysozyme liberation is evident from Figure 43 B: the 
burst release of lysozyme increased with increasing the PEG loading. For instance, 
implants loaded with 20 % PEG delivered approximately 61 % of the incorporated 
lysozyme within the first 24 h. In contrast, the burst release of IFN-α from tristearin 
implants was substantially lowered by the addition of PEG (compare to Figure 13). 
Even with an initial PEG loading of 20 % no more than 23 % of IFN-α was released 
within 24 hours. The accelerated release of lysozyme from PEG-containing tristearin 
implants was also reflected in the overall release kinetics. As it can be seen in 
Figure 44 lysozyme liberation was less sustained. Moreover, the liberation curve of 
lysozyme revealed a parabolic shape, whereas a linear phase up to 7 days was 
observed in the case of IFN-α. Actually, the mathematical analysis of the release 
profiles of lysozyme with the aforementioned solution of Fick´s second law of 
diffusion (Equation 9, Chapter I.5.3) revealed good agreement between the 
theoretical and the experimental data (data not shown, [206]). Consequently, the 
release of lysozyme was predominantly governed by pure diffusion irrespective of the 
PEG content of the matrix. In contrast, in the case of IFN-α delivery from PEG-
containing matrices pure diffusion controlled release could be excluded since 
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systematic deviations between the applied mathematical model and the experimental 
release data were found.  
0
20
40
60
80
100
0 5 10 15 20 25 30 35 40
time, d
cu
m
ul
at
iv
e 
ly
so
zy
m
e 
re
le
as
e,
 %
A
 
0
20
40
60
80
100
0 5 10 15 20
time, h
cu
m
ul
at
iv
e 
ly
so
zy
m
e 
re
le
as
e,
 %
B
 
Figure 43: Effects of various PEG loadings on release of lysozyme from tristearin-based 
cylindrical implants. 
In (A) the release over 40 days is illustrated. (B) Represents a zoom of the lysozyme release within 
24 hours. All devices were loaded with 2.5 % lysozyme and 7.5 % HP-β-CD. The admixed PEG 
amount was: (?) 0 %, (?) 5 %, (?) 10 %, (?) 15 % and (?) 20 %, respectively (average +/- SD; 
n = 3). 
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Figure 44: Comparison of IFN-α and lysozyme release from tristearin-based implants.  
Matrices were loaded with 20 % PEG. The release was studied in phosphate buffer pH 7.4 (average 
+/- SD; n = 3). 
The release kinetics of lysozyme from PEG-containing matrices led to the conclusion 
that the impact of PEG can be fully explained in this case by its role as a pore 
forming agent. Due to the leaching out of PEG the creation of water-filled pores is 
facilitated. As a result the amount of totally delivered protein increases compared to 
PEG-free matrices. On the other hand, the accelerated creation of pores and the 
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concomitant reduction of geometrical hindrances by the pore network account for 
less sustained protein liberation and enhanced burst effects.  
3.4. IMPORTANCE OF THE PRECIPITATION MECHANSISM FOR PROTEIN STABILITY 
In the case of release studies at pH 7.4 the addition of 10 % PEG (or more) to a 
lipidic matrix allowed a complete recovery of IFN-α (totally 93.6 % SD=6.8 % of the 
incorporated protein were delivered). In contrast IFN-α release levelled off at 47.8 % 
(SD=4.91) after 4 days when incubation of the same implants took place at pH 4.0 
(Figure 45). Possible reasons for the different IFN-α recovery rates will be discussed 
in the following section.  
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Figure 45: Effects of the pH of the phosphate buffer solution on IFN-α release from tristearin-
based implants.  
Matrices were loaded with 10 % IFN-α/HP-β-CD lyophilisate and 10 % PEG. The release was studied 
either in phosphate buffer pH 7.4 or in phosphate buffer pH 4.0 (average +/- SD; n = 3). 
As described in Chapter I.5.1 the creation of an interconnected pore-network is 
essential for the diffusion of proteins from inert matrices. Thus, one explanation for 
different protein recoveries might be a pH-dependence of the kinetics of pore 
creation. Since the formation of water-filled pores occurs upon the dissolution and 
leaching out of the incorporated hydrophilic excipients PEG and HP-β-CD, the 
release rates of both were determined simultaneously with protein release at pH 4.0 
and at pH 7.4.  
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Figure 46: (A) PEG release from tristearin-implants at pH 4.0 and at pH 7.5 (B) The apparent 
diffusion coefficients of PEG in lipidic implants at different PEG loadings and different pH 
values. 
(A) The release of PEG from implants loaded with 10 % IFN-α/HP-β-CD lyophilisate and 10 % PEG 
was studied at pH 7.4 or 4.0 [symbols: experimental results (average +/- SD; n = 3), curves: theory 
(Equation 9, Chapter I.5.3)].                
(B) Based on the fittings the apparent diffusion coefficients of PEG were determined. The indicated 
PEG content represents the initial PEG loading of the investigated implant formulation, respectively 
(average +/- SD; n = 3).  
However, as shown in Figure 46 A the pH of the release medium did not affect the 
release of PEG from tristearin-based implants. Exemplarily, the results obtained with 
devices (initially) containing 10 % PEG are shown. The tendencies with 15 and 20 % 
PEG-loaded implants were similar. Fitting an adequate solution of Fick’s law of 
diffusion (Equation 9, Chapter I.5.3) to the experimentally determined PEG release 
kinetics, good agreement between theory and experiment was obtained in all 
cases (two examples are illustrated in Figure 46 A). This clearly indicated that PEG 
release was primarily controlled by pure diffusion with constant diffusivities, 
irrespective of the pH of the release medium. 
Based on the obtained fittings, the apparent diffusion coefficients of PEG within the 
lipidic implants were determined. For all investigated PEG loadings the pH of the 
phosphate buffer (pH 7.4 or 4.0) was only of minor importance for the mobility of 
PEG within the tristearin-based implants (Figure 46 B).  
The results obtained when studying the pH-dependence of the release of the co-
lyophilisation agent HP-β-CD are given in Figure 47. The diffusivity of HP-β-CD 
increased at pH 4.0 for higher PEG-loadings, but obviously this effect was not helpful 
to explain the levelling off of the protein release at pH 4.0 due to reduced pore 
formation as it leads into the opposite direction. 
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Figure 47: (A) HP-β-CD release from tristearin-implants at pH 4.0 and pH 7.4 (B) The apparent 
diffusion coefficient of HP-β-CD in the lipidic implants. 
(A) The release of HP-β-CD from implants loaded with 10 % IFN-α/HP-β-CD lyophilisate and 
10 % PEG was studied at pH 7.4 or 4.0 [symbols: experimental results (average +/- SD; n = 3), 
curves: theory (Equation 9, Chapter I.5.3)].             
(B) Based on the fittings the apparent diffusion coefficients of HP-β-CD were determined. The 
indicated PEG content represents the initial PEG loading of the investigated implant formulation, 
respectively (average +/- SD; n = 3).  
The release kinetics of PEG and HP-β-CD suggest that potential differences in the 
creation of water-filled pores at different pH values of the bulk fluid can be excluded 
as reason for the observed significant effects of the pH on protein release.  
At pH 7.4 the solubility of IFN-α is reduced in the presence of PEG. As a 
consequence only low protein concentrations within the implant pores are generated. 
In contrast, at pH 4.0 the water-uptake and the subsequent dissolution of IFN-α will 
result in highly concentrated protein solutions, which may favour intermolecular 
interactions and, thus, leading to increased aggregation [250]. 
In order to investigate the possibility of IFN-α aggregation during release at pH 4.0 
within the matrix, the protein drug remaining within the lipidic implants after in-vitro 
incubation was extracted and analysed by SDS-PAGE. As visualised in Figure 48, 
irrespective of the initial PEG loading the formation of dimers as well as the presence 
of higher-order aggregates within the implants was evident at pH 4.0. In contrast, it 
has been shown early that the stability of IFN-α within the same implants was not 
compromised at pH 7.4 [151, 153]. Mohl and Winter extracted IFN-α from tristearin 
implants after in-vitro incubation at pH 7.4. SDS-PAGE of the samples revealed only 
marginal dimer formation [151, 153].  
It was shown for PLGA matrices that the creation of higher-order aggregates within 
the controlled release devices is one of the major causes for incomplete release. Due 
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to their large sizes such specimens are not able to diffuse through the restrictive 
pore-network [52, 119].  
Thus, it can be concluded that the precipitation of IFN-α by PEG at pH 7.4 ensures 
low protein concentration within the water-filled pores, which in turn contributes to the 
stabilisation of the protein during release. In contrast, the lack of protein precipitation 
at pH 4.0 resulted in high protein concentrations within the implant pores favouring 
protein aggregation. 
In addition, a further contribution to lower protein stability at pH 4.0 might be provided 
by the fact that the diffusivity of HP-β-CD is increased at pH 4.0. Consequently, low 
concentrations of HP-β-CD might be available within the implant pores. Considering 
that HP-β-CD presumably stabilises IFN-α during the release period (see Chapter 
IV.4), this stabilisation of IFN-α by HP-β-CD might be less effective at pH 4.0. 
36.5 kDa
14.4 kDa
1 2 3 4 5 6
 
Figure 48: SDS-PAGE of IFN-α extracted from tristearin implants at pH 4.0.  
Lane 1: Molecular weight standard, lane 2: IFN-α standard, lane 3-6: IFN-α extracted from tristearin 
implants after in-vitro incubation at ph 4.0. The implants were loaded wit 0 %, 10 %, 15 % and 20 % 
PEG, respectively. 
3.5. SUMMARY AND CONCLUSION 
This chapter clearly pointed out that the role of PEG as protein precipitant is crucial 
for the full understanding of IFN-α release from PEG-containing lipidic matrices. The 
hypothesis of reduced protein solubility within the PEG-loaded lipidic implants 
presented in Chapter IV.2 was confirmed by several additional and independent 
experiments. 
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The developed “macropore model”, which enabled to evaluate simultaneously the 
relative importance of dissolution and diffusion of IFN-α, HP-β-CD, and PEG revealed 
that within the “macropores” a highly concentrated PEG solution was created. Thus, 
the dissolution of the protein was restricted and, compared to PEG-free 
“macropores”, only a minor fraction of IFN-α was available for diffusion. As a result, 
the release of IFN-α from PEG-containing “macropores” was drastically reduced, 
suggesting that the dissolution step is one of the major rate limiting factors for protein 
release in the presence of PEG.  
Further insight into the significance of reduced protein solubility and reversible 
precipitation within PEG-containing tristearin implants was obtained by studying the 
pH-dependence of protein solubility and release. At pH 7.4 already low PEG 
concentrations of about 3 % resulted in the precipitation of IFN-α. In contrast, at 
pH 4.0 PEG concentrations of up to 20 % did not cause protein precipitation under 
the investigated conditions. This means that the selection of different pH values for 
in-vitro release studies offers the possibility to “switch on/off” the “limited protein 
solubility” release mechanism. Lacking protein precipitation at pH 4.0 the release 
patterns of IFN-α from PEG-containing implants showed a significantly accelerated 
protein release with a high burst effect. In this case, protein release was purely 
diffusion controlled with constant diffusion coefficients and monotonically decreasing 
release rates, irrespective of the initial PEG loading.  
Whereas the addition of 10 % PEG (or more) to a lipidic matrix allowed complete 
protein recovery at pH 7.4, at pH 4.0 IFN-α release levelled off at 48 % after 4 d. In 
contrast to protein liberation, the release of both hydrophilic excipients – PEG and 
HP-β-CD – revealed only marginal pH-dependence. Therefore, pH dependent 
differences in the creation of water-filled pores can be neglected and very similar 
pore volumes at pH 7.4 and pH 4.0 can be assumed.  
As mentioned before (Chapter I) incomplete protein release is often ascribed to 
protein aggregation/denaturation within the matrix [156, 199, 233]. Since the solubility 
of IFN-α is reduced in the presence of PEG, only low protein concentrations within 
the implant pores were generated at pH 7.4. In contrast at pH 4.0, the water 
imbedding and the subsequent dissolution of IFN-α resulted in highly concentrated 
protein solutions. Therefore, intermolecular interactions are favoured and thus 
increased aggregation within the matrix can be expected [250]. 
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Consequently, the presented sustained release mechanism offers two major benefits 
for its practical application. Firstly, the reversible precipitation of IFN-α facilitates the 
sustained protein delivery with nearly constant release rates and a low burst effect. 
Secondly, the precipitation also ensures low protein concentrations within the implant 
pores, which in turn reduces the tendency towards protein aggregation. 
Furthermore, the hypothesis of a reversible precipitation was confirmed by the 
replacement of PEG by an alternative porogen. Compared to the implant formulation 
containing PEG, the use of HP-β-CD as porogen resulted in a markedly accelerated 
IFN-α liberation from tristearin matrices.  
In an alternative experimental setup, IFN-α was replaced by lysozyme, which inhered 
a minor tendency to precipitate. Comparing the release kinetics of lysozyme from 
PEG-free and PEG-loaded tristearin implants the typical features described in 
literature for the addition of PEG to controlled release devices were evident: the total 
amount of delivered protein increased due to the formation of an interconnected 
pore-network. Concomitantly, the burst release significantly increased with rising up 
the PEG content.  
The latter experiment can be regarded as further proof for the postulated in-situ 
precipitation of IFN-α within PEG-containing tristearin implants. On the other hand, 
the results obtained with lysozyme pointed out the fragile balance between PEG 
acting as porogen and PEG acting as protein precipitant. Aiming at a prolongation of 
the delivery period powerful precipitation is crucial. In the case of lysozyme high 
protein solubility persisted in the presence of high PEG concentrations. Hence, the 
PEG content within the implant pores was not sufficient to limit the release of 
lysozyme from such implants. The liberation of lysozyme was therefore less 
sustained compared to the delivery of IFN-α.  
It is highly conceivable that the described in-situ precipitation mechanism might be 
transferable to other protein precipitants than PEG. In order to achieve benefits 
similar to the case of the IFN-α-PEG system the precipitant should fulfil the following 
features: (1) high efficiency to precipitate even in low concentrations, (2) reversible 
precipitation without affecting protein stability, and (3) water-solubility. The first point 
is evident with respect to the comparison of the release data for lysozyme and IFN-α. 
The second request arises from the scientific knowledge that protein denaturation 
and aggregation can be claimed as one of the major causes for incomplete recovery 
[169, 199, 233]. Furthermore, the release of proteins which are not properly folded 
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and in particular the delivery of aggregates from controlled release devices inheres 
the risk of inducing an immune response [93, 194]. Thus, reversibility of precipitation 
needs to be carefully evaluated. Third, the water-solubility of the precipitation agent 
will allow a concomitant leaching out of precipitant and drug. As the diffusion 
pathways increase with advanced release times the release rates monotonically 
decrease. Such effects can be compensated by increasing the drug solubility within 
the matrix, which can be accomplished by decreasing the concentration of the 
available precipitant due to permanent leaching out of the same.  
Analysing the literature plenty of solvent conditions are available for reducing protein 
solubility. According to McPherson precipitants of macromolecules can be 
categorised into four classes: (1) organic solvents, (2) salts, (3) long-chain polymers, 
and (4) low molecular weight polymers [149].  
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4. POTENTIAL EFFECT OF HP-β-CD ON IFN-α RELEASE AND STABILITY 
Before implant manufacturing IFN-α has to be lyophilised in order to obtain a solid 
protein powder. As freezing and dehydration can induce protein denaturation, the 
presence of lyoprotectants during lyophilisation is crucial for maintaining protein 
stability [249]. It has been shown that trehalose and HP-β-CD are suitable for 
conserving the stability of IFN-α during lyophilisation [151].  
By comparing tristearin implants loaded either with IFN-α/trehalose or with IFN-α/HP-
β-CD lyophilisates, the use of HP-β-CD co-lyophilisates resulted in a faster and more 
complete protein liberation [153]. Furthermore, co-lyophilisation with HP-β-CD 
increased protein stability during the release period in comparison to co-lyophilisates 
containing trehalose [153]. This superiority of HP-β-CD was also reflected during 
long-term storage: lyophilisation with HP-β-CD ensured an excellent protein integrity 
and highly reproducible release kinetics. In contrast, the delivered amount of dimer 
and trimer species, as well as of oxidised protein increased during storage when 
trehalose was used as lyoprotectant. Moreover, the release profiles changed and 
IFN-α delivery became incomplete after six-months storage [152].  
From these studies it can be concluded that HP-β-CD compared to trehalose has two 
main effects: (1) accelerating the protein release and (2) increasing protein stability 
during release and storage. Therefore, it was aimed in the following section to 
provide additional experiments that should help to understand the effects of HP-β-CD 
on IFN-α release and stability. 
4.1. POTENTIAL EFFECTS OF HP-β-CD ON THE RELEASE OF IFN-α FROM TRISTEARIN 
IMPLANTS 
Cyclodextrins are a group of cyclic oligosaccharides that have a hydrophilic exterior 
and a hydrophobic internal cavity. This hydrophobic interior enables cyclodextrins to 
form inclusion complexes with the hydrophobic side chains accessible at the protein 
surface. In particular, aromatic amino acids are considered to be inserted into the 
hydrophobic cavity and these interactions are reported to stabilise and to solubilise 
various peptides and proteins [105]. For instance, the aqueous solubility of ovine 
growth hormone (O-GH) at pH 7.4 was increased by the use of HP-β-CD [26].  
For low molecular weight drugs it was shown that such effects on the solubility 
increased the drug release rates from various polymeric controlled release systems 
[15]. Furthermore, cyclodextrins are able to complex PEG [87].  
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Therefore, the interactions of HP-β-CD with IFN-α and/or with PEG 6000 may affect 
the ability of PEG to precipitate IFN-α. In order to determine such effects the protein 
solubility in the presence of both excipients was investigated. However, the 
presence/absence of this co-lyophilisation agent did not alter the impact of PEG on 
the protein solubility (Figure 49).  
This suggested that in-situ precipitation of IFN-α within PEG-containing tristearin 
implants occurs to the same extent regardless whether HP-β-CD is present or not. 
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Figure 49: Effects of HP-β-CD on the precipitation of IFN-α in the presence of PEG (average +/- 
SD; n = 3). 
Apart from the effect of cyclodextrins on solubility, the formation of inclusion 
complexes may modify the drug diffusivity and consequently the drug release from 
delivery systems [15]. De Rosa et al. applied Attenuated Total Reflection (ATR)-FTIR 
spectroscopy to investigate the influence of HP-β-CD incorporation on the properties 
of insulin-loaded PLGA microspheres prepared by spray drying. Upon addition of  
HP-β-CD, insulin embedded within microspheres revealed an extended content of  
β-sheet structures, which was ascribed to the formation of an insulin/CD complex 
within the microspheres. Since the mobility of this complex within the polymeric 
matrix was considered to be lower than the mobility of free protein, the overall 
release rate was slowed down by the addition of HP-β-CD [54].  
In the case of tristearin implants the solubility of IFN-α was primarily affected by PEG 
(Figure 49). However, interactions between IFN-α and HP-β-CD might affect the 
diffusivity of IFN-α as well. Various techniques such as competitive spectroscopy 
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[101], isothermal titration calorimetry, and nuclear magnetic resonance [56] are 
proposed to gain insight into the interactions of cyclodextrins with peptides and 
proteins after dissolution. Furthermore, spectroscopic techniques like FTIR, circular 
dichroism, and fluorescence spectroscopy were shown to be suitable for 
characterising protein cyclodextrin interactions.  
For instance, Chen et al. revealed that the interactions of HP-β-CD with the 40 kDa 
protein horseradish peroxidase were sufficient to increase the amount of α-helical 
structure detectable by FTIR spectroscopy [37]. 
The potential of steady state fluorescence for monitoring cyclodextrin-peptide 
interactions was outlined by Khajehpour et al. for melittin interacting with HP-β-CD. In 
the presence of HP-β-CD a blue shift of the fluorescence maxima and a slight 
increase in the intrinsic fluorescence emission maxima of melittin were observed. 
The blue shift was ascribed to the reduction of the polarity around Trp. This might be 
a result of interactions with the cyclodextrin cavity or of an overall change of the 
peptide structure upon cyclodextrin addition [116].  
In the course of this thesis fluorescence and FTIR spectroscopy were used to 
evaluate potential cyclodextrin-protein interactions. The protein to cyclodextrin mass 
ratio applied for lyophilisation and subsequent implant loading was 1 part protein to 3 
parts cyclodextrin. This can be regarded as the highest protein to cyclodextrin ratio 
achievable within the implants, as HP-β-CD was found to leach out faster from the 
lipidic implant than IFN-α (see Figure 22). The following experiments were, therefore, 
consistently carried out with a protein to cyclodextrin mass ratio of 1 to 3. 
Figure 50 A illustrates the vector-normalised spectra as well as the vector-normalised 
second derivative spectra of IFN-α in the presence and in the absence of HP-β-CD. 
As it can be seen, no differences were detectable in the amid I region between both 
samples. Furthermore, the addition of HP-β-CD had no effect on the Trp 
fluorescence emission spectrum of IFN-α (Figure 50 B). In both spectra the emission 
maxima were detected at 336 nm with an identical intensity.  
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Figure 50: (A) Vector-normalised and second derivative transmission FTIR-spectra; (B) Trp 
fluorescence emission scans of IFN-α in the presence and in the absence of HP-β-CD (n=2).  
FTIR and Fluorescence spectroscopy provided information on the secondary and on 
the tertiary protein structure, respectively. Since both, FTIR and fluorescence spectra 
of IFN-α were not affected by the presence of HP-β-CD it could be assumed that 
potential interactions with the cyclodextrin had no influence on the overall protein 
structure. Since such an alteration of the three-dimensional protein structure as well 
as the formation of stable complexes would affect the protein diffusivity, it can be 
supposed that the mobility of IFN-α within the water-filled pores of tristearin implants 
was not affected by the presence of HP-β-CD. 
In order to prove this experimentally the diffusion coefficients of IFN-α in the 
presence and in the absence of HP-β-CD were determined by the open-end capillary 
technique introduced in Chapter IV.1.2. The improved experimental setup illustrated 
in Figure 20 was applied. For matters of comparison HP-β-CD was replaced by 
trehalose as alternative stabilising agent.  
This experiment was supposed to provide information on the diffusivity of IFN-α 
within the water-filled implant pores. In addition to IFN-α and HP-β-CD some implants 
were loaded with PEG as porogen and precipitant. Thus, after water penetration, 
IFN-α, HP-β-CD, and PEG will be dissolved within the implants pores. Hence, the 
effects of HP-β-CD on the diffusion coefficient of IFN-α were determined additionally 
with and without PEG. In agreement to implant formulation comprising 10 % IFN-
α/HP-β-CD co-lyophilisate and 10 % or 20 % PEG, the IFN-α/HP-β-CD co-
lyophilisate to PEG ratio was 1 to 1 or 1 to 2, respectively.  
In Figure 51 the protein concentrations determined within the capillary over time are 
depicted. Obviously, the release of IFN-α out of capillaries containing HP-β-CD or 
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trehalose was comparable (Figure 51 A). The same tendency was observed when 
PEG was present (Figure 51 B and C). 
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Figure 51: Determination of the diffusion coefficient of IFN-α: decrease of IFN-α concentration 
within the capillary.  
Open symbols represent the IFN-α concentration in the presence of trehalose and closed symbols 
represent the IFN-α concentration in the presence of HP-β-CD. Protein concentration within capillaries 
containing no PEG (A), lyophilisate:PEG blend in the ratio 1:1 (B), and lyophilisate:PEG ratio of 1:2 (C) 
(average +/- SD; n = 3, experimental setup according to Figure 20).  
The diffusion coefficients of IFN-α were calculated based on the liberation rates (as 
described in Chapter IV.1.2). The determined diffusivities of IFN-α are listed in 
Table 7. As the diffusivities of IFN-α in samples containing HP-β-CD and in samples 
containing trehalose were in the same order of magnitude, it could be concluded that 
HP-β-CD neither affected the release of IFN-α from tristearin implants by a 
modulation of the protein solubility nor by an alteration of the protein diffusivity.  
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However, as a water-soluble excipient HP-β-CD will promote the creation of water-
filled pores and in this regard HP-β-CD will surely contribute to the formation of 
water-filled pores allowing protein release from lipidic implants.  
Moreover, unlike natural cyclodextrins, HP-β-CD is surface active [106]. Recently, 
Koennings et al. revealed that the incorporation of surface active compounds 
accounted for increased water imbedding and consequently for increased release 
rates from lipidic implants [124].  
Table 7: Diffusion coefficients of IFN-α within phosphate-buffer filled capillaries comprising 
various amounts of PEG. IFN-α was lyophilised either with HP-β-CD or with trehalose. 
The diffusion coefficients were determined by fitting Equation {13} to the release data shown in 
Figure 51. 
 lyophilisate:PEG ratio D, x 10-6 cm2/s
HP-β-CD 
1:0 
1:1 
1:2 
1.80 
1.77 
1.71 
trehalose 
1:0 
1:1 
1:2 
1.48 
1.29 
1.72 
 
4.2. POTENTIAL EFFECTS OF HP-β-CD ON THE STABILITY OF IFN-α 
The effects of cyclodextrins on protein stability are often investigated under stress 
conditions such as during thermally or chemically induced unfolding. Since in vitro 
release studies are carried out at 37 °C, a thermal stabilisation of IFN-α by HP-β-CD 
may be important to inhibit unfolding and aggregation during the release period.  
Differential scanning calorimetry (DSC) is commonly used to characterise the thermal 
stability of a protein and to obtain information on the thermodynamics of protein 
unfolding. In Figure 52 the heat capacity curves of IFN-α in the presence and in the 
absence of HP-β-CD are shown. Protein unfolding due to the increasing temperature 
was reflected by a single endothermic transition. The midpoint of this denaturation 
peak is generally referred to the melting temperature Tm, and the integrated area 
under the peak corresponds to the overall enthalpy change ∆H, associated with the 
unfolding of IFN-α. It is obvious from Figure 52 that the addition of HP-β-CD had no 
effect on both Tm and ∆H. Furthermore, a steep decrease in the DSC signal was 
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observed after reaching Tm irrespective of the cyclodextrin. This is typically ascribed 
to protein aggregation suggesting irreversibility of IFN-α unfolding during heating.  
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Figure 52: DSC scans of IFN-α in the presence and in the absence of HP-β-CD.  
The protein concentration was 4.8 mg/mL corresponding to a cyclodextrin concentration of 14.4 
mg/mL. 
Apart from DSC measurements the thermal stability of proteins can be evaluated 
spectroscopically. The temperature-induced changes in the secondary structure of 
IFN-α were monitored by attenuated total reflection (ATR)-FTIR.  
In Figure 53 the original background corrected spectra of IFN-α as well as the 
corresponding second derivatives recorded during heating are shown. The overall 
intensity of the adsorption spectra rose when the temperature was ramped up 
(Figure 53 A). Generally, such an intensity increase during heating can be ascribed 
to protein precipitation [27]. The normalised second derivative spectra (Figure 53 B) 
revealed drastic perturbations of the structural components underlying the amid I and 
the amid II bands. At 25 °C IFN-α exhibited an amid I band maximum at 1653 cm-1 
which is characteristic for proteins containing predominantly α-helical structures [60]. 
Elevating the temperature to 50 °C resulted in a decrease of the amid I band at 
1653 cm-1 which was accompanied by an intensity increase at 1622 cm-1. Bands in 
the range of 1620 cm-1 were interpreted as intermolecular β-sheets [35, 147, 230], 
indicating protein denaturation and the beginning of aggregation. Furthermore, at 
higher temperatures a smaller peak around 1692 cm-1 became evident. This peak 
Chapter IV: Mechanisms controlling the release from lipid-based delivery systems 117 
  
has also been associated with the formation of intermolecular β-sheets during protein 
denaturation [35, 147, 230].  
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Figure 53: Background corrected ATR-FTIR absorbance spectra (A) and vector-normalised 
second derivatives (B) during heating of IFN-α from 25 to 70 °C.  
 
Interestingly, the presence of HP-β-CD seemed to increase the thermal stability of 
IFN-α. Exemplarily, in Figure 54 the spectra at 25 °C, 50 °C, 60 °C, and 70 °C are 
illustrated. At the starting temperature the spectra of IFN-α in the presence and in the 
absence of HP-β-CD were nearly identical. In contrast, at elevated temperatures 
during heating clear differences were visible: samples without HP-β-CD revealed 
significant unfolding and aggregation, whereas in the presence of HP-β-CD only 
slight spectral changes occurred (Figure 54 B). Until a temperature of 70 °C was 
reached the addition of HP-β-CD resulted in a lower decrease of helical elements 
and in a reduced formation of intermolecular β-sheets compared to IFN-α without  
HP-β-CD. Finally, when the temperature ramp reached 70 °C no differences between 
HP-β-CD-free and HP-β-CD-containing samples were detectable and both spectra 
showed the same extend of protein denaturation.  
This suggested that the presence of HP-β-CD protects the native protein up to a 
critical value. Nevertheless, exceeding this temperature will also result in irreversible 
protein aggregation and precipitation as shown for samples without HP-β-CD. 
Protein stability is generally depending on protein concentration [250]. In order to 
evaluate whether the observed effects can also be expected for other protein 
concentrations the concentration of IFN-α was reduced from 4.8 to 1.6 mg/mL. This 
corresponds to a reduction of the cyclodextrin concentration from 14.4 mg/mL to 
4.8 mg/mL. Here, a similar stabilisation of IFN-α against thermal induced 
denaturation was observed (data shown in Figure 55).  
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Figure 54: Vector-normalised second derivative ATR-FTIR spectra at 25 °C (A), 50 °C (B), 60 °C 
(C), and 70 °C (D).  
The spectra of IFN-α (c=4.8 mg/mL) were recorded in the absence (solid lines) and in the presence 
(broken line) of HP-β-CD (c=14.4mg/mL). 
The effects of cyclodextrin addition on the thermal stability of IFN-α can be quantified 
by calculating the melting temperature based on the ATR-FTIR spectra. Different 
interpretation methods are available in the literature to extract Tm from the spectral 
changes [147]. One possibility is plotting the intensities of the decreasing or 
increasing bands over the changing temperature. The decreasing α-helical bands at 
1653 cm-1 and the increasing intermolecular β-sheet bands at 1622 cm-1 and their 
temperature dependency is shown in Figure 55.  
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Figure 55: Intensity change of the α-helical band at 1653 cm-1 (left) and intensity change of the 
β-sheet band at 1622 cm-1(right) during heating.  
Figure A and B represent the thermal transition curves obtained with a protein concentration of 
4.8 mg/mL. Figure C and D the thermal transition curves received with a protein concentration of 
1.6 mg/mL (average +/- SD; n = 3). 
Obviously, the presence of HP-β-CD during thermal denaturation shifted the loss of 
the α-helical structure and the increase of the β-sheet to higher temperatures, 
respectively. This observation was consistent at a protein concentration of 4.8 mg/mL 
as well as at a protein concentration of 1.6 mg/mL. Based on the plots shown in 
Figure 55 the midpoint of thermal denaturation was obtained by performing a sigmoid 
fit. 
Alternatively, it has been suggested to use the cross section point between the 
increasing and the decreasing denaturation curve as Tm [147]. In accordance with the 
aforementioned methods this data evaluation also indicated a shift of Tm to higher 
values (Figure 56).  
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Figure 56: Intensity of band at 1653 cm-1 (?/?) and at 1622 cm-1(?/?) in the temperature range 
from 25 to 70 °C.  
The protein concentration was either 4.8 mg/mL (A) or 1.6 mg/mL (B) (average +/- SD; n = 3). 
Table 8: Melting temperature Tm of IFN-α in the presence and in the absence of HP-β-CD.  
The melting temperatures based on ATR-FTIR experiments were obtained from the inflection point of 
thermal denaturation curves of the band at 1653 cm-1(method I) or the band at 1622 cm-1 (method II). 
Alternatively, the cross section point of both intensity-temperature curves was referred as denaturation 
temperature (method III) (average +/- SD; n = 3 for FTIR measurements, average +/- SD; n = 2 for 
µDSC measurements). 
conc. IFN-α formulation FTIR µDSC 
  method I method II method III*1  
0.48 mg/mL 
without HP-β-CD 
with HP-β-CD 
n.d. n.d. n.d. 
67.67°C*2 
67.99°C*2 
1.6 mg/mL 
without HP-β-CD 
with HP-β-CD 
57.99±2.02°C 
61.67±0.46°C
48.60°C 
57.99±2.02°C
55.16°C 
61.81°C  
65.34°C*2 
65.46°C*2 
4.8 mg/mL 
without HP-β-CD 
with HP-β-CD 
54.1±0.96°C 
60.74±1.18°C
50.98±0.62°C 
59.21±0.63°C
53.80°C 
61.04°C 
64.30±0.30°C 
64.52±0.23°C
*1 data represent the cross section of the average curves shown in Figure 56 
*2 only one experiment performed 
 
The different melting temperatures of IFN-α determined with ATR-FTIR and with 
µDSC measurements are given in Table 8. From the comparison of the results 
obtained with FTIR and µDSC two observations are evident: first, the Tm determined 
by means of ATR-FTIR strongly differed from that obtained with the µDSC technique. 
Tm values detected by the FTIR spectra were up to 10 degrees lower than that 
measured with µDSC. Second, the addition of HP-β-CD had a drastic impact on the 
melting temperature of IFN-α determined with FTIR measurements, whereas no 
differences between HP-β-CD-containing and HP-β-CD-free samples were 
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detectable by µDSC experiments. Irrespective of the method applied for interpreting 
the FTIR spectra a significant increase in the melting temperature was observed. 
Variations of Tm dependent on the applied method to evaluate the thermal stability 
were also reported by other authors. For instance, Matheus et al. recently 
demonstrated differences between the Tm values of lysozyme determined by  
ATR-FTIR spectroscopy and by µDSC experiments [147]. One explanation for the 
observed deviations might be the differences in the applied heating rates. FTIR 
spectroscopy requires an interruption of the heating at each temperature point to 
collect the spectral information and to average the signal. In contrast, normally a 
completely linear temperature profile is applied with µDSC measurements [147]. 
On the other hand, the presented data suggested that subtle changes in the protein 
structure occurring at moderate temperatures were detectable by FTIR but not by the 
DSC technique. Without the addition of HP-β-CD IFN-α revealed the first perturbation 
of the secondary structure at 50 °C. In contrast, no change in the heat capacity was 
detectable by µDSC up to a temperature of 57 °C. Likewise results have been 
mentioned by Sharma and Kolonia for IFN-α [202]. It was shown that near- and far-
UV CD were capable to identify slight changes in secondary and in tertiary protein 
structure at moderate temperatures. However, at these temperatures no changes in 
the baseline of DSC thermograms were detectable indicating that subtle 
conformational changes may not induce changes in the heat capacity sensitive 
enough to be picked up by µDSC [201].  
These inherent differences between FTIR spectroscopy and µDSC may also explain 
the observed differences between FTIR and µDSC experiments regarding the 
thermal stability of IFN-α in the presence of HP-β-CD.  
The interactions between cyclodextrins and proteins depend on the type of 
cyclodextrin used as well as on the characteristics of the protein; therefore, the 
impact of cyclodextrins on the thermally or chemically induced unfolding is described 
heterogeneously in literature.  
For instance, humane growth hormone revealed a reduced tendency to undergo 
thermally induced aggregation in the presence of hydrophilic cylodextrins, which was 
manifested by an increase in the melting temperature (Tm) of rhGH measured by 
means of differential scanning calorimetry [223]. In accordance with this observation 
Charman et al. [36] reported that HP-β-CD was very effective in preventing 
precipitation of porcine growth hormone during heating. On the other hand, most 
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other studies described another scenario: due to interactions between cyclodextrins 
and hydrophobic side chains exposed during heating, cylodextrins stabilised the 
unfolded state. Consequently, the equilibrium between folded and unfolded state was 
shifted to the unfolded state, which was associated with a lowering of Tm values [47] . 
After chemically induced denaturation cylodextrins often act as artificial chaperons. 
For instance, Tavornvipas et al. investigated the influence of various cyclodextrins on 
the refolding of lysozyme, of basic fibroblast growth factor (bFGF) [222], and of 
human growth hormone [223]. First, the proteins were denaturated with guanidinium 
hydrochloride. Afterwards the denaturated protein solution was diluted and it was 
shown that the addition of branched β-cyclodextrins significantly reduced the 
tendency towards aggregation for all proteins, whereas HP-β-CD, α-CD-derivatives, 
and γ-CD-derivatives were less or not effective in preventing aggregation. As protein 
unfolding induced by GdnHCl is associated with solvent exposure of hydrophobic 
side chains, it has been suggested by the authors that the interactions of cylodextrins 
to these exposed hydrophobic residues result in an inhibition of aggregation.  
4.3. SUMMARY AND CONCLUSION 
Due to the lack of any detectable interactions between IFN-α and HP-β-CD in the 
mass ratio used for implant formulation, it is highly conceivable that the release of 
IFN-α is not affected by the formation of inclusion complexes. Such complexation 
would affect the protein solubility as well as the diffusivity of IFN-α. However, it was 
shown experimentally that the protein solubility is mainly affected by PEG rather than 
by the presence of the cyclodextrin. Furthermore, the diffusion coefficient determined 
by using the open-end capillary technique remained unaffected upon HP-β-CD 
addition. Thus, these results suggested that HP-β-CD will predominantly influence 
the protein release by increasing the matrix porosity and/or promoting the hydration 
of the controlled release system. 
On the other hand, thermal protein denaturation monitored with ATR-FTIR 
spectroscopy indicated a stabilisation of IFN-α at elevated temperature. In 
comparison to HP-β-CD-free samples thermally induced unfolding occurred at higher 
temperatures in the presence of HP-β-CD. This stabilisation of IFN-α due to the 
addition of HP-β-CD is in good agreement to the observation that HP-β-CD ensured 
the preservation of the protein stability during release as well as during long-term 
storage [152, 153].  
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CHAPTER V: DEVELOPMENT OF IMPROVED LIPID BASED 
DELIVERY SYSTEMS FOR PHARMACEUTICAL PROTEINS 
1. MANUFACTURING OF EXTRUDATES BY RAM EXTRUSION 
Tristearin implants were deemed as promising platform for the continuous delivery of 
IFN-α over a period of 1 month [153]. However, the geometry of these implants 
(average diameter and height of 5 mm and 2.4 mm, respectively) necessitates a 
surgical intervention for application. To overcome this limitation the manufacturing of 
small cylindrical rods that can be deposited subcutaneously via a trochar is highly 
desirable. As explained in the introduction section extrusion is applied most 
commonly to produce injectable implant systems. Since ram extrusion can be 
conducted in lab-scale with comparable low material costs (see Chapter I.4.3) the 
potential of implant preparation by means of a ram extruder was evaluated first.  
1.1. EXPERIMENTAL SETUP 
Based on the general assembly of ram extruders (see Chapter I, Figure 2) a 
purpose-built extruder device was designed (Figure 57). To allow the softening of the 
lipid mixture prior to or during extrusion the extruder could optionally be equipped 
with a heatable coat. In a pilot study different heating temperatures were applied. It 
was found that a temperature of around 60 °C allowed the manual extrusion of 
tristearin material. However, temperature exposure may induce a polymorphic 
transition of the lipidic matrix material or a destabilisation of the protein drug (see 
Chapter I.3.3 and I.4.4, respectively). Therefore, an extrusion at room temperature 
was favoured and an alternative procedure was developed.  
Since tristearin is very brittle, high pressures were needed to allow the flow through 
the extruder die. In consequence, extrusion was only possible by the employment of 
a hydraulic press to force tristearin through the extruder die. The obtained extrudates 
revealed high surface roughness and a low mechanical stability. In order to improve 
the extrudate quality a separate compression step before extrusion was introduced. 
After filling the extruder barrel with the lipophilic material a force of 3.92 kN was 
applied for 30 seconds. Afterwards, the extruder device was lifted on a rack and the 
extrusion was performed with a hydraulic press.  
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Figure 57: Ram extruder device. 
 
After this manufacturing procedure the surface appeared smooth, with only low 
ruggedness (Figure 58). Furthermore, the mechanical stability of the extrudates was 
increased; to quantify this effect the forces needed for breaking the extrudates 
perpendicularly to the longitudinal axis were measured. Without a compression step 
the extrudates revealed a breaking strength of 26.5 N (n=3, SD=5.9 N), whereas 
after compression the extrudates resisted a force of 42.9 N (n=3, SD=1.0 N).  
With the developed extrusion method not only tristearin could be processed, but also 
the manufacturing of extrudates based on various lipidic matrix materials 
(triglycerides of C12-C20, phospholipids etc.) with different amounts of hydrophilic 
excipients (0-30 %) was realised. Thus, the possibility to extrude various matrix 
compositions in a standardised way was given.  
The prepared extrudates had an average length of 1.5 cm and a diameter of 1.2 mm 
according to the used extruder die. Importantly, the achieved geometry enables to fill 
the obtained extrudates in an injection device approved as suitable method for 
application of peptide containing extrudates, like Zoladex®. 
 
Figure 58: Improved extrudates (A) macroscopic appearance (B) SEM zoom of the extrudate 
surface.  
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1.2. INFLUENCE OF THE MANUFACTURING PROCESS ON THE LIPID MODIFICATION  
When lipids are used as matrix material the preparation of sustained release devices 
may induce a polymorphic transformation from the stable β- to the α-modification, 
which in turn may influence the quality of the end product during storage or may 
affect the release behaviour (see Chapter I.3.3).  
In order to determine the effect of the extrusion process on the lipid modification, the 
thermal behaviour of lipidic extrudates was investigated by differential scanning 
calorimetry. The heating and cooling curves of tristearin bulk material are shown in 
Figure 59. During the first heating step an endothermic peak at 70.8 °C (n=3, 
SD=1.15 °C) was observed that corresponds to the melting of the stable β-
modification [77]. On cooling, crystallisation of the α-polymorph occurred at 43.0 °C 
(n=3, SD=0.9 °C). Reheating of the solidified melt revealed an endotherm at 52.5 °C 
(n=3, SD=0.75°C), indicating the melting of the unstable α-modification. This peak 
was followed by an exotherm, attributed to the rearrangement of the α-form to the 
crystalline β-form. By further heating a second endothermic peak was obtained, 
which displays the melting of the β-polymorph [77].  
Importantly, the thermograms recorded from freshly prepared extrudates revealed 
only one melting peak at 70.8 °C (n=3, SD=0.21°C). Hence, freshly prepared 
extrudates comprised the lipid in the stable β-modification.  
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Figure 59: Influence of the extrusion procedure on the lipid modification.  
DSC analyses of tristearin bulk material (1), melted and solidified tristearin (2), and tristearin 
extrudates directly after preparation at room temperature (3). 
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To confirm these results the crystalline states of tristearin bulk material, melted 
tristearin and extrudates were investigated by wide angle X-ray diffraction. As 
illustrated in Figure 60 tristearin bulk material showed three diffraction peaks at 
2θ=19.5°, 23.3°, 24.3°, respectively. The corresponding short spacings at 0.46 nm, 
0.38 nm and 0.37 nm are typical for the β-modification [77]. In contrast, the solidified 
melt featured one single short spacing at about 0.415 nm that can be ascribed to the 
chain packing of the α-modification [77].  
Obviously, the extrudates possessed the specific short spacings of the stable β-
polymorph. Therefore, both - WAXS and DSC experiments - confirmed that the 
extrusion process did not induce a polymorphic transformation of the lipidic matrix 
material.  
0
2000
4000
6000
8000
10000
0 10 20 30 40
2 theta, °
in
te
ns
ity
, c
ps
2
3
1
0.46 nm 0.38 nm
0.37 nm
0.415 nm
0.46 nm 0.38 nm
0.37 nm
 
Figure 60: Influence of the extrusion procedure on the lipid modification.  
WAXS analyses of tristearin bulk material (1), melted and solidified tristearin (2), and tristearin 
extrudates directly after preparation (3). 
1.3. INFLUENCE OF THE MANUFACTURING PROCESS ON PROTEIN STABILITY 
The preservation of the native protein structure is one of the major challenging tasks 
during the manufacturing of controlled release devices. As pointed out in 
Chapter I.2.1 the harsh environmental conditions proteins are often exposed to 
during the preparation of controlled release devices trigger chemical and/or physical 
degradation pathways. However, since proteins that are not properly folded show 
less or no bioactivity, this will imperil the therapeutical efficiency of the product. 
Furthermore, the delivery of non-native protein specimen inheres the risk of inducing 
an immune response [71, 250].  
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Recombinant proteins that are structural identical or nearly identical to endogenous 
proteins might induce an immune reaction based on a break down of the immune 
tolerance to self-antigens. Thereby, impurities and protein aggregates are considered 
as main elucidators [194]. The participation of aggregates in the immunogenicity of 
recombinant proteins was shown, for example, for IFN α-2a [24]. Therefore, specific 
attention should be paid to the stability of the formulation in regard to the prevention 
of protein aggregation.  
In order to survey that the extrusion procedure did not induce a protein 
destabilisation IFN-α was extracted from the extrudates. The obtained samples were 
analysed by gel electrophoreses with subsequent silver staining (Figure 61). As 
shown in lane 3 and lane 6 only the band of monomeric IFN-α was detectable 
irrespective of the extrudate formulation. 
 
Figure 61: Proof of protein integrity after extrusion.  
Lane 1: molecular weight marker, lane 2: IFN-α standard material, lane 3 to lane 6: IFN-α extracted 
from extrudates containing 0 %, 5 %, 10 % or 20 % PEG. 
Consequently, it can be stated that the manufacturing process neither induced 
protein aggregation or fragmentation nor a polymorphic transformation of the lipid 
matrix. These encouraging results suggested further investigation of the in-vitro 
release kinetics. 
1.4. IN-VITRO RELEASE STUDIES 
The addition of PEG to the lipidic matrix was an efficient tool to adjust the desired 
release kinetics of disc shaped lipid implants prepared by compression (see 
Chapter IV.1). Therefore, the in-vitro release behaviour of tristearin extrudates 
comprising various amounts of PEG was initially investigated.  
It is obvious from Figure 62 that the addition of PEG to the lipidic formulation 
significantly affects the in-vitro release kinetics of IFN-α. Extrudates containing no 
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PEG liberated just 32.71 % (n=3, SD= 1.17 %) of the incorporated protein within 
16 days. The protein was delivered mainly in the first seven days.  
Admixing of 5 % PEG prolonged the liberation period to 16 days. Furthermore, the 
amount of totally delivered protein was raised to 66.43 % (n=3, SD=1.54 %). 
Complete protein recovery was achieved after 16 days when using a formulation with 
10 % PEG or more.  
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Figure 62: Effects of the addition of various amounts of PEG on the release of IFN-α from 
extrudates (average, +/- SD; n = 3). 
The extrudates were prepared by ram extrusion. All devices were loaded with 10 % IFN-α co-
lyophilised with HP-β-CD and the indicated PEG amount (average +/- SD; n = 3). 
In contrast to the results obtained with lipid implants prepared by compression, the 
addition of PEG enhanced the burst effects. For instance, PEG-free extrudates 
liberate 21.62 % (n=3, SD=1.97 %) within the first 24 hours, whereas admixing of 
10 % PEG enhanced the burst effect to 32.36 % (n=3, SD=0.77 %).  
 
It has to be noted that the released protein almost exclusively existed in its 
monomeric form. The amount of dimer fraction detected with size exclusion 
chromatography was less than 1.5 % during the entire in-vitro release study and 
irrespective of the PEG amount. To confirm this excellent protein integrity, liberated 
IFN-α was analysed by means of gel electrophoreses followed by silver staining. As 
visualised in Figure 63, gel electrophoresis featured that the protein was delivered in 
its monomeric form. 
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Figure 63: Protein stability during in-vitro release. 
SDS-PAGE of IFN-α liberated from tristearin implants comprising 10 % PEG. Lane 1: molecular weight 
marker, lane 2: IFN-α standard material, lane 3: IFN-α released after 24 hours, lane 4: IFN-α released 
after 4 days, lane 5: IFN-α released after 7 days, lane 6: IFN-α released after 10 days, lane 7: IFN-α 
released after 13 days, lane 8: IFN-α released after 16 days. 
The elevated amounts of liberated drug as well as the accelerated burst release 
observed with increasing PEG loadings are often ascribed to the ability of PEG to act 
as a porogen. When water soluble hydrophilic excipients, such as PEG, are added to 
an inert sustained release matrix these substances facilitate the creation of an 
interconnected pore network (see Chapter I.5). As a result, a larger portion of the 
incorporated protein has access to water-filled pores and can diffuse out of the 
matrix, which accounts for increased recovery rates. On the other hand, the amplified 
pore formation reduces the geometric hindrance of the pore network, consequently 
the release is accelerated and the burst effect is often elevated [40, 40, 138, 174]. 
To investigate whether such effects occur due to the addition of PEG, the external 
morphology of the lipidic extrudates was studied by scanning electron microscopy 
before and after exposure to the release medium.  
Before in-vitro release studies no significant differences in the morphology were 
visible between extrudates containing different amounts of PEG (data not shown). 
During incubation water-soluble substances (IFN-α, together with HP-β-CD and PEG) 
were leaching out of the matrix into the bulk fluid. Accordingly, the SEM pictures of 
incubated extrudates revealed the formation of pores. A few small pores with a size 
between 2 to 5 µm were formed at the surface of extrudates comprising no PEG 
(Figure 64 A). By increasing the PEG content the pore number per area and the pore 
size increased (Figure 64 B, C, D).  
Interestingly, the shape of the pores changed: on the surface of PEG-free matrices 
circular pores were found, whereas the surface of PEG-comprising extrudates 
revealed more slit-like pores. This geometry might be generated in the course of 
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extrusion. The mechanical properties of PEG range from soft and plastic material for 
low molecular weights to hard and brittle for high molecular weights. For PEGs with 
an intermediate molecular weight, such as the here used PEG 6000, it was shown 
that the particles were easy to deform at low compaction speed and pressures [135]. 
Thus, it can be assumed that the stretched pores were formed due to the 
deformation of PEG particles during extrusion. By forcing the lipid/PEG blend through 
the small extruder die the PEG particles are racked along the extrudate axis. This 
hypothesis is further backed by the comparison to the pore structure of PEG-loaded 
compressed implants. In contrast to the morphology observed for extrudates, 
compressed samples revealed large, irregular formed pores at the implant surface 
(see Chapter IV, Figure 15). 
 
Figure 64: External morphology of extrudates containing no PEG (A), 5 %PEG (B), 15 % PEG 
(C) and 20 % PEG (D) after in-vitro release studies. 
As the extrudates featured a low coherence after in-vitro incubation, it was not 
possible to obtain cross-sections of incubated extrudates to study the internal implant 
morphology. On the other hand, the samples were too small to determine reliable 
implant porosities with a helium pycnometer or with mercury porosimetry (data not 
shown). Nevertheless, to get an idea about the relative ability of the pores to 
percolate the inert lipid matrix the water uptake of PEG-free and PEG-loaded 
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extrudates was investigated (Figure 65). This attempt was based on the report of 
Rabelo and Coutinho, that showed that the water uptake was in good agreement with 
the pore volume determined by means of mercury porosimetry measurements [177]. 
The water uptake was obtained from the weight difference between dry and wetted 
samples [177]. Recently, Pongjanyakul et al. used this simple technique to estimate 
the water uptake of lysozyme loaded glyceryl palmitostearate implants after in-vitro 
release studies [174]. Accordingly, at predetermined point of time the implants were 
removed from the incubation buffer, blotted dry, and weighed. Afterwards the 
extrudates were dried to constant mass and weighed again (see Chapter III.2.6). 
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Figure 65: Effect of PEG loading on the water uptake of tristearin extrudates.  
The extrudates were loaded with 10 % IFN-α/HP-β-CD lyophilisate and the indicated amount of PEG.  
(average +/- SD; n = 3), 
PEG-free extrudates incorporated not more than 7 % water (relative to the implant 
weight). In generally, it was suggested that at least 30-35 % water-soluble drug (and 
excipient) are necessary to create percolating diffusion pathways within inert 
matrices (see Chapter I.5). As the extrudates were only loaded with 10 % IFN-α/HP-
β-CD co-lyophilisate, an incomplete pore network through the matrix seemed 
probable. This assumption was backed by the restricted entry of water which 
indicated that the observed pores of PEG-free extrudates (Figure 64 A) were only 
located at the implant surface and were not penetrating the matrix. As a result, not all 
of the incorporated IFN-α had access to water-filled pores connected to the implant 
surface. Since tristearin matrices themselves did not erode [85, 240] and the 
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permeability of IFN-α through crystalline lipid can be considered as negligible, IFN-α 
was trapped within in the matrix. As a result, only 32.71 % (n=3, SD= 1.17 %) of the 
totally incorporated IFN-α were delivered from PEG-free extrudates (Figure 62).  
In contrast, extrudates loaded with 20 % PEG revealed a water uptake of up to 36 % 
(Figure 65). Therefore, inside the implant an increased space for the imbedding of 
water was provided which indicated the formation of pores penetrating the matrix. 
It can be concluded that the observed implant morphology as well as the water 
uptake agreed well with the protein release patterns shown in Figure 62. With a 
higher PEG content, the porosity of the lipidic matrices increased upon exposure to 
the release medium, resulting in enhanced IFN-α mobility and, hence, in increased 
protein release rates.  
1.5. MECHANISMS OF PROTEIN RELEASE FROM EXTRUDED IMPLANTS  
In Figure 66 the in-vitro release kinetics of IFN-α from extruded and compressed 
implants are compared. Irrespective of the manufacturing method, implants 
comprising no PEG revealed nearly the same protein liberation characteristics. 
Bearing in mind that the initial protein/excipients load of these formulations was not 
sufficient to create an interconnected pore network through the device, only the 
fraction of protein located on the surface and/or in cavities adjacent to the surface 
was released upon immersion in aqueous buffer. As the relative amount of surface 
touched protein is a function of the matrix composition the protein liberation from 
extrudates and implants should be comparable.  
A completely different scenario was found with PEG-loaded devices. Here, the 
protein release was significantly more extended when using compression as 
manufacturing method. Especially the burst release, which is shown exemplarily for a 
PEG loading of 20 % in Figure 66 F, was more accelerated from extruded implants. 
Furthermore, it was obvious that the total amount of recovered IFN-α at intermediate 
PEG loadings (5 and 10 %) was higher for extrudates.  
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Figure 66: Effect of the manufacturing procedure on the protein release. 
Cumulative in-vitro release rates from extruded (open symbols) and compressed (closed symbols) 
implants comprising 0 %(A), 5 %(B), 10 %(C), 15 % PEG (D) or 20 % PEG (E,F). Each matrix was 
loaded with 10 % IFN α-2a/HP-β-CD lyophilisate (average, +/- SD; n = 3). 
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The general acceleration of the protein release kinetics from extrudates can be 
ascribed to the modification of the cylinder geometry. The transfer of the 
manufacturing process to extrusion involved an extension of the implant height and a 
reduction of the implant diameter. The device shape changed from flat disks to slim 
rods (Figure 67). 
2.4 mm
5 mm 1.2 mm
15 mm
compressed implant
disk
extruded implant
rod
 
Figure 67: Geometry of compressed and extruded implants. 
When decreasing the radius while keeping constant the height accelerated drug 
liberation can be expected. The same is observed when decreasing the height and 
maintaining the implant radius. When modifying the implant shape from disks to rods 
in order to enable adequate application, both parameters radius and length were 
varied simultaneously. Thus, the prediction of the impact on the release kinetics is 
difficult.  
The available surface area is one of the crucial factors for the drug release. Thus, 
reduced or increased surface to volume ratios are often used to explain differences in 
the drug liberation rates. The accomplished change of the manufacturing procedure 
from compression to extrusion implied an increase in the surface to volume of the 
implants from 1.2 to 1.8. However, compared to literature such a slight increase in 
the surface to volume ratio cannot completely explain the tremendous alteration of 
the release profiles. For instance, a quite similar alteration of the surface to volume 
ratio - achieved by decreasing the height - did not affect the release kinetics of 
pyranine from lipidic implants based on tripalmitin [86].  
This distinction can presumably be ascribed to the fact that the surface to volume 
ratios does not depict the actual geometric situation and the resulting diffusion 
pathways. To illustrate these effects the extrudate was schematically divided into 
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implants with the height of the disked shaped devices (Figure 67). Obviously, the 
axial diffusion ways were increased for five systems, whereas the radial diffusion 
pathways decreased for all seven subunits. Furthermore, due to the symmetry 
conditions the latter aspect is important for the diffusion along two dimensions, the x- 
and the z-plane. It can, therefore, be considered as being the more influential 
parameter. 
Apart from the distinctions in the device geometry, the preparation procedures for rod 
and disk-shaped implants were quite different. Prior extrusion a force of 3.92 kN was 
applied for 30 s to compress the lipidic formulation within the extruder barrel. In 
comparison the standard method for the preparation of disked shaped implants 
included a compression at 19.6 kN for 30 s. In Chapter IV.1.1 the impact of various 
compression forces on the protein delivery rates was outlined. Although disk-shaped 
implants were investigated, it is highly conceivable that the reduced compression 
forces applied during extrusion will result in a less dense particle packaging. In fact, 
the calculated apparent densities of extrudates declined by 13 % compared to disk-
shaped implants. 
In summary, the presented considerations suggested that the accelerated protein 
release from extruded implants compared to compressed implants can be explained 
by both the alteration of the implant geometry and the reduction of the matrix 
compactness. 
 
It is furthermore evident from Figure 66 that not only the release rates were affected 
by the manufacturing method, but also the shape of the release curves. PEG-
containing disks revealed a nearly constant IFN-α release rate over at least seven 
days. In contrast, this linear phase was completely missed in the case of extrudates. 
Irrespective of the added PEG amount the release rates monotonically decreased 
with time, which led to a parabolic release profile.  
In addition, the impact of PEG on the early protein liberation was found to be different 
for extruded and compressed implants. As described in Chapter IV.1.1, for the 
compressed implants the admixing of PEG resulted in a decrease of the burst effect. 
However, the opposite was observed with extruded implants.  
To get a deeper insight into the involved mass transport phenomena, an analytical 
solution of Fick’s second law of diffusion considering radial as well as axial mass 
transfer in cylinders with constant diffusion coefficients (see Equation 9, 
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Chapter I.5.3) was fitted to the experimentally determined release rates. This model 
takes into account the homogeneous distribution of the protein within the implants 
before exposure to the release media (at t = 0), as well as sink conditions maintained 
throughout the experiments.  
For the extruded implants good agreement between the theoretical and the 
experimental data was obtained in all cases, irrespective of the initial PEG loading of 
the implant (R2>0.98) (Figure 68 A). The release kinetics of IFN-α from compressed 
implants, however, showed systematic deviations between the applied mathematical 
theory and the experimentally measured protein release kinetics when PEG was 
added (Figure 68 B). This means, that the preparation method affected the drug 
release mechanism of PEG-loaded lipidic matrices. The protein release from a PEG-
containing matrix was predominantly controlled by pure diffusion with constant 
diffusivities when the matrix was prepared by extrusion. Contrarily, for compressed 
matrices it was found that also other mass transport mechanisms were of importance 
for the protein liberation.  
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Figure 68: Experiments (symbols) and theory (solid lines).  
Fittings of Equation 9, Chapter I.5.3 to the experimentally determined IFN-α release kinetics from 
implants prepared by ram extrusion (A) or by compression (B) containing various amounts of PEG: 
(?) 0 %, (?) 5 %, (?) 10  %, (?) 15 % (average +/- SD; n = 3). 
In Chapter IV the lower burst effect, the initial constant release rates, as well as the 
resulting deviations from pure diffusion controlled protein release from PEG-
comprising disk-shaped implants were explained. It was shown that these 
phenomena can be ascribed to a reversible in-situ precipitation of IFN-α within the 
lipidic matrix. Therefore, the protein release from compressed devices was governed 
by both, the limited solubility of the protein and the diffusion through tortuous liquid-
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filled pores. However, the reduced protein solubility in the presence of PEG seemed 
to be unimportant when using extruded matrices, since the release from these 
systems was primarily dominated by diffusion.  
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Figure 69: Effect of the manufacturing procedure on the in-vitro release of PEG (A) and HP-β-
CD (B). 
The release of PEG and of HP-β-CD was studied from implants prepared by compression (closed 
symbols) or by ram extrusion (open symbols) loaded with 10 % IFN-α/HP-β-CD lyophilisate and 10 % 
PEG (average +/- SD; n = 3).  
In order to understand these distinctions the in-vitro release kinetics of the 
incorporated excipients (PEG and HP-β-CD) were studied. In accordance with the 
protein release, the delivery of PEG and HP-β-CD from compressed implants was 
more sustained than the liberation from extrudates (in Figure 69 the release kinetics 
of matrices comprising 10 % PEG are shown, similar results were obtained with other 
PEG loadings). 
Therefore, the accelerated leaching out of IFN-α, PEG, and HP-β-CD from extruded 
rods would lead to a faster creation of water-filled pores compared to compressed 
implants. Simultaneously, the amounts of PEG and IFN-α available within the implant 
pores were reduced. For instance, after 4 days PEG was already completely washed 
out from extrudates, whereas compressed disks still contained PEG. Summing up 
both effects – the accelerated increase of the available pore volume and the reduced 
amounts of PEG and IFN-α within the pores – it is highly conceivable that the actual 
concentrations of PEG generated within the extruded matrices were not high enough 
to cause precipitation of IFN-α. As a result, the protein liberation was purely governed 
by diffusion through water-filled pores. Therefore, in contrast to the “precipitation 
controlled release” from compressed implants, monotonically decreasing release 
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rates as well as increased burst effects were observed in the case of extruded 
implants.  
1.6. FORMULATION FACTORS INFLUENCING PROTEIN RELEASE  
1.6.1. INFLUENCE OF THE USED TRIGLYCERIDE 
The matrix material itself is one of the crucial parameters for the design of controlled 
release devices. However, the impact of different triglycerides on the in-vitro release 
behaviour was sparsely investigated and from the few reports available no consistent 
conclusion can be drawn.  
Guse et al. reported that the release of lysozyme from lipidic implants was 
accelerated when reducing the chain length of the esterified fatty acid. An exception 
from this rule was the protein liberation from tristearin matrices, which was found to 
be faster than the release from tripalmitin matrices (C12>C14>C18>C16) [84]. 
Recently, it was suggested that the decreasing velocities of lysozyme release with 
extension of the esterified fatty acid chain length can be explained with reduced 
wettability of of the lipid [124]. However, the opposite was found for the release of the 
low molecular weight model compound pyranine. The triglyceride with the shortest 
fatty acids revealed the slowest release (C14>C18>C16>C12) [84].  
Considering the work of Vogelhuber et al. [240], who also investigated the release of 
pyranine from different triglyceride matrices, the impact of the manufacturing process 
on the ranking order becomes apparent. In contrast to Guse, the drug loading was 
not performed by dissolving but by emulsifying the drug within the lipid solution. After 
vacuum drying the obtained drug-loaded lipid powder was compressed. Interestingly, 
the ranking order observed by Vogelhuber [240] was completely different from that 
reported by Guse [84]: the shorter the carbohydrate chain the faster the release. 
More recently, Koennings et al. showed that lysozyme was liberated with decreasing 
velocity from mini-cylinders composed of trilaurin, trimyristin, tripalmitin or tristearin 
[124]. 
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Figure 70: Effect of different triglyceride matrices on the in-vitro release of IFN-α.  
All extrudates were loaded with 10 % IFN/HP-β-CD lyophilisate and 10 % PEG (average +/- SD; n=3).  
Figure 70 illustrates the release profiles of IFN-α from ram extruded tristearin 
matrices in comparison to matrices based on other triglycerides. A total of approx. 
32-35 % of IFN-α was released within the first 24 hours from matrices comprising 
tristearin and triarachidin, respectively. The initial burst was amplified to 44-58 % 
when the carbohydrate chain was shortened. After the burst, matrices of trimyristin 
and trilaurin delivered the remaining protein within 4 days. Contrarily, the usage of 
the longer chained triglycerides facilitates a more delayed protein liberation, enduring 
over 13 days.  
Apart from the release rate the amount of totally delivered protein was also affected 
by the utilised triglyceride. Protein release was found to be complete in the case of 
tristearin, trilaurin and trimyristin extrudates. Matrices comprising triarachidin 
liberated around 80 % of the incorporated drug within 20 days.  
It was observed that extrudates based on triglycerides of the short-chained fatty 
acids revealed a reduced mechanical stability. To investigate this effect the crushing 
strength of freshly prepared extrudates was determined (Chapter III.2.2). As it can be 
seen in Figure 71, the mechanical strength of triglyceride extrudates increased in the 
same order as the fatty chain length of the used triglyceride increased. Since the 
crushing strength is determined by the interparticular bonding forces and the density 
of the matrix, it can be assumed that the more sustained release from extrudates 
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based on triglycerides with longer carbohydrate chains might be a result of the more 
consolidated particle arrangement. 
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Figure 71: Effect of triglyceride type on the crushing strength of freshly prepared extrudates 
(average +/- SD; n=3).  
1.6.2. INFLUENCE OF PARTICLE SIZE 
Particle size and shape are important parameters for the arrangement of drug and 
matrix particles during compression [112]. Since the particle arrangement determines 
the pore characteristics, the in-vitro release kinetics may depend on the particle size. 
Generally, an increase in particle size of the drug material causes increased release 
rates because the direct contact to the matrix surface is more likely [112, 205]. In 
addition, the particle size of the matrix substance is crucial, when the release occurs 
from an interconnected pore network. The use of larger particles usually extends the 
interparticular voids within compressed matrices. Accordingly, accelerated release 
rates were found [84, 112]. 
To investigate whether such relations between particle size and release kinetics are 
also relevant for extruded matrices the particle size of the lipid material was varied. 
Particle size measurement of tristearin bulk material by laser light scattering revealed 
that 90 % of the particles of tristearin bulk material already have a size smaller than 
96.74 µm (d (0.9)). Aiming for a prolongation of the IFN-α release, the large particles 
were eliminated by sieving the lipid bulk material.  
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Figure 72: Effects of different particle size of the lipid powder on the in-vitro release kinetics of 
IFN-α.  
All extrudates were loaded with 10 % PEG and 10 % IFN-α co-lyophilised with HP-β-CD (average +/- 
SD; n = 3). 
Applying the additional sieving step the width of the particle size distribution (span) 
was reduced from 3.0 to 2.2 and the d(0.9) value was shifted to 48.69 µm. However, 
as shown in Figure 72, the reduction of the particle size did not lead to a more 
extended in-vitro release. The release kinetics of IFN-α from extrudates containing 
the sieved tristearin material are almost superimposed with that obtained from 
extrudates containing unsieved bulk material.  
Therefore, it can be concluded that the pore characteristics of extruded implants 
were not importantly affected by the modification of the particle size distribution of the 
matrix material. To back up this observation the mesh-plus was also utilised for 
extrudate preparation. Obviously, extrudates prepared from this sieve fraction 
liberated IFN-α in the same manner as extrudates prepared with smaller lipid 
particles.  
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Figure 73: Effects of different particle size of the porogen on the in-vitro release kinetics of  
IFN-α. 
All extrudates were loaded with 10 % PEG and 10°% IFN-α co-lyophilised with HP-β-CD  
(average +/-SD; n = 3) 
In a second experiment the particle size distribution of the pore-forming agent PEG 
was modified. In analogy to the lipid powder, PEG was sieved and the fraction below 
63 µm and between 63 and 125 µm were collected for implant preparation. In 
Figure 73 the impact of the particle size of PEG on the in-vitro release behaviour of 
IFN-α is illustrated. Faster protein release was observed with larger particles.  
The impact of the size of porogen particles on the drug release kinetics from inert 
matrices is non-consistently discussed in literature. Accelerated as well as more 
delayed drug delivery profiles are reported. For instance, when sucrose acts as 
porogen in tripalmitin implants, the use of smaller particles resulted in a faster 
release of the model drug pyranine [86]. On the other hand, it is conceivable that the 
porogen particle sizes act on the release kinetics in a similar way like different 
particle sizes of the drug. In that case the loading of larger particle would provide the 
formation of larger channels and pores within inert matrices. Thus, the diffusion of 
water into and of drug out of the device is facilitated which in turn accounts for 
accelerated drug release rates. Such effects were reported for the liberation of the 
low molecular weight drugs cefadroxil as well as for the release of the polypeptide 
hirudin from polyurethane matrices with PEG 1450, mannitol, or BSA as porogen 
[118, 120]. 
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1.6.3. EXCIPIENTS TO MODIFY THE EROSION BEHAVIOUR  
During in-vitro release compressed matrices based on tristearin showed no erosion 
[151, 153]. These findings were recently verified in-vivo. After a 2 months 
subcutaneous implantation into rabbits, the tristearin matrices maintained their 
geometry and showed no signs of matrix erosion [141].  
In accordance to these results, extruded tristearin matrices featured no signs of 
erosion during in-vitro release studies. However, with regard to patient compliance 
erodible systems are preferred, since non-erodible controlled release devices need to 
be removed surgically after drug depletion.  
Recently, it was shown for cylindrical implants based on tripalmitin that the admixing 
of phospholipids to a triglyceride matrix enabled in-vivo and in-vitro erosion [85, 86].  
Therefore, it was decided to investigate the potential of phospholipid incorporation to 
facilitate erosion of the tristearin-based extrudates. Phospholipids are amphiphile 
compounds that belong to the class of water insoluble lipids, which swell in water and 
form a liquid crystalline hydrated phase [200]. Hence, the addition of distearoyl-
phosphatidyl-choline (DSPC) to the triglyceride formulation resulted in an increased 
water uptake of the matrix (Figure 74). Compared to pure tristearin extrudates, 
matrices containing 5 % DSPC already revealed a 5-fold increased water uptake. It 
can be assumed that this amplified water infiltration in combination with the swelling 
behaviour of phospholipids diminished the coherence of the tristearin particles during 
release. Consequently, the mechanical stability of the device was reduced and 
erosion of the lipidic device took place. As it can be seen in Figure 74, the water-
uptake correlated well with the erosion behaviour of the implants.  
However, if erosion and release occurred simultaneously, this would be accompanied 
with accelerated drug liberation. For lipid based drug delivery systems Khan et al. 
showed good correlation between the release rates of BSA and the erosion rates of 
matrices comprising cholesterol and lecithin [117]. 
In accordance with this study, an increase in the DSPC amount resulted in less 
sustained protein liberation (Figure 75). The protein delivery from extrudates 
comprising 20 % DSPC was already completed within one day. Contrarily, the 
liberation of IFN-α occurred in a sustained manner over 16 days when no more than 
5 % DSPC were added. The overall protein release from these matrices was 
comparable to that without DSPC. With 10 % DSPC an intermediate release profile 
was obtained.  
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Obviously, the effects of DSPC on the protein release behaviour agreed well with the 
increased water-uptake and erosion rates of DSPC-loaded matrices. For instance, 
the enormous burst release from extrudates containing 20 % DSPC was 
accompanied by a macroscopic visible erosion of the extrudate surface. Within 16 
days of incubation these extrudates strongly disintegrated. However, the protein 
delivery was not sustained and thus, the addition of such high amounts of DSPC 
should be avoided.  
Matrix erosion still occurred when 10 % or 5 % DSPC are incorporated. Since 
matrices still revealed a delayed protein delivery such formulations propose an 
appropriate balance between sustained release and degradation.  
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Figure 74: Effect of DSPC on the water uptake and the in-vitro erosion behaviour of tristearin 
extrudates.  
Besides the indicated DSPC amount, all implants were loaded with 10 % PEG and 10 % IFN-α/HP-β-
CD lyophilisate. Since samples containing 20 % DSPC disintegrated to a large extend, the 
determination of the water uptake was not possible.  
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Figure 75: Effect of distearyl-phosphatidyl-choline (DSPC) on the in-vitro release kinetics of 
IFN-α from tristearin based extrudates.  
All extrudates were loaded with 10 % PEG and 10 % IFN-α co-lyophilised with HP-β-CD (average +/- 
SD; n = 3). 
For PLGA matrices it was proven that degradation products and/or increased 
hydration of the matrix affect protein stability during release (see Chapter I.2.2). 
However, SEC-HPLC analysis of released IFN-α revealed only a minor fraction of 
dimer specimen (less than 1.5 %). This excellent protein integrity was further backed 
by gel electrophoresis. As illustrated in Figure 76 only monomeric IFN-α was 
detectable over the entire incubation period.  
 
 
Figure 76: Effect of DSPC on the protein stability. 
SDS-PAGE of IFN-α liberated from tristearin implants comprising 5 % DSPC (A) and 20 % DSPC (B), 
respectively. Lane 1: molecular weight marker, lane 2 IFN-α standard material, lane 3 IFN-α released 
after 2 hours, lane 4 IFN-α released after 4 hours, lane 5 IFN-α released after 6 hours, lane 6 IFN-α 
released after 10 hours, lane 7 IFN-α released after 24 hours, lane 8: IFN-α released after 4 days, lane 
9: IFN-α released after 7 days. 
Chapter V: Development of improved lipid based delivery systems for pharmaceutical proteins 146 
  
1.7. SUMMARY AND CONCLUSION 
This chapter shows that lipidic extrudates loaded with IFN-α can be prepared as 
controlled release systems. The developed extrusion procedure did not induce any 
polymorphic transformations. Hence, the obtained implants comprised the lipid 
material in the stable β-modification. With respect to increased storage stability and 
more sustained protein liberation the stable modification is preferable (see 
Chapter I.3.3). Furthermore, an important attainment of this study was that the 
protein integrity was not affected by the extrusion process. Moreover, no detrimental 
effects occurred during release. Thus, protein stability was maintained within the 
lipidic matrix, and IFN-α was delivered from tristearin extrudates almost exclusively in 
its monomeric form. 
The addition of PEG was shown to be an efficient tool to adjust the in-vitro release 
kinetics. Below a PEG loading of 10 % the protein recovery was incomplete but with 
increasing the PEG loading the amount of liberated IFN-α increased. The observed 
implant morphology agreed well with the protein release patterns – due to the 
addition of PEG the creation of an interconnected pore network was facilitated.  
Interestingly, the comparison to compressed tristearin implants introduced in 
Chapter IV revealed that not only the protein release kinetics, but also the underlying 
drug release mechanism was affected by the change of the manufacturing method. 
The implant shape was changed from disk-like implants to slim rods. Furthermore, 
the density of the implants decreased, as significantly lower compression forces were 
applied to prepare extrudates. Both effects accounted for less sustained protein 
delivery from extruded implants. The fitting of an adequate solution of Fick’s second 
law of diffusion to the experimental release data revealed a purely diffusion controlled 
protein release, irrespective of the initial PEG load of the matrix. In contrast, in PEG-
loaded disk-shaped implants IFN-α was precipitated within the pores and thus 
systematic deviations to a pure diffusion controlled release were found (see 
Chapter IV). This distinction between compressed and extruded implants could be 
correlated well with the release of PEG, which was much faster from extrudates. As a 
result, the actual PEG concentrations within the implant pores can be assumed to be 
insufficient to cause protein precipitation. 
Since the release of IFN-α from extrudates was only sustained over 16 days, several 
attempts to extend the release time were investigated. Within this framework the 
effect of various particle sizes of the porogen and the matrix material were 
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investigated. An increase in the particle size of PEG resulted in accelerated protein 
delivery, whereas little deviations of the particles size of tristearin had no impact on 
the release properties.  
Another important parameter was the triglyceride used. It was found that the 
liberation of IFN-α proceeded faster from matrices comprising triglycerides of shorter 
chain length fatty acids. This acceleration of the release can presumably be 
explained by a reduced consolidation of the device, as the compactness of the 
implant decreased with decreasing the chain length of the esterified fatty acids.  
However, none of the approaches led to an appropriate prolongation of the IFN-α 
release. Therefore, it was decided to investigate the potential of twin screw extrusion 
for the preparation of protein-loaded lipidic implants.  
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2. MANUFACTURING OF EXTRUDATES BY TWIN SCREW EXTRUSION  
The manufacturing of commercially available, subcutaneous implants is mostly 
accomplished by means of screw extrusion [121]. Compared to ram extrusion screw 
extrusion offers the advantage of a continuous operation mode facilitating the 
processing of large amounts of material (see Chapter I.4.3). In the previous section it 
was shown that ram extrusion is generally capable to produce small-sized implants 
for subcutaneous injection via a trochar. However, the liberation period of IFN-α was 
terminated after 16 days. The need for a prolonged release period in combination 
with the ease of up-scaling in later stages gave reason to investigate the potential of 
twin-screw extrusion for the production of lipid-based implants.  
2.1. EXPERIMENTAL SETUP 
The possibility to produce lipidic implants by twin screw extrusion was evaluated in 
lab-scale with the micro twin-screw MiniLab® Micro Rheology Compounder (Thermo 
Haake GmbH) illustrated in Figure 77. Compared to common twin screw extruders 
which usually require large amounts (>100 g) for extrusion, this extruder was 
especially designed for the handling of small amounts of material (starting at 5 g). Via 
an integrated back flow channel the filled-in sample can be circulated, allowing the 
blending of the material during extrusion. In addition, this back flow channel was 
constructed as rheological slit capillary with two pressure sensors. This enabled to 
obtain rheological information on the flow behaviour of the sample.  
 
Figure 77: Twin screw extruder MiniLab® Micro Rheology Compounder  
As explained above (Chapter I.4) the preparation of polymeric implants is mostly 
realised by hot-melt extrusion. Therefore, it was tried to prepared placebo implants 
based on the standard formulation (80 % tristearin, 10 % HP-β-CD lyophilisate and 
10 % PEG) by heating the extruder barrel. 
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The melting point of tristearin is at 71 °C. Thus, the applied temperature was varied 
from 65 to 72 °C in steps of one degree. Before loading the barrel, the extruder was 
heated for 30 minutes to ensure a uniform tempering.  
However, clogging of the extruder occurred after loading, when the applied 
temperatures were lower than 70 °C. Variations in the rotation speed of the screws 
also failed to avoid this clogging and a complete filling of the extruder was not 
achieved.  
On the other hand, tristearin was completely molten within the extruder at higher 
temperatures. Due to the associated decrease in viscosity, this attempt failed to 
create sufficient pressures for forcing the material through the extruder die.  
Tristearin exhibits a very sharp melting point, which presumably explains the failure 
of hot-melt extrusion of pure tristearin material: below the melting point filling of the 
extruder was not possible, whereas temperatures above the melting resulted in low 
viscosity melts inapplicable for extrusion. 
In order to obtain an extrudable lipidic mass the following approaches were 
evaluated:  
(1) admixing of oils or semi-softened lipids,  
(2) suspending the lipid in highly concentrated PEG solutions,  
(3) dissolving the lipid in an organic solvents, 
(4) admixing of low-melting point lipids.  
All manufacturing strategies were conducted with a formulation comprising 
10 % PEG and 10 % HP-β-CD placebo-lyophilisate. The approaches were ranked 
according to the quality of the obtained extrudates and to the extrudability of the 
obtained lipidic mass.  
2.1.1. ADMIXING OF OILS OR SEMI-SOFTENED LIPIDS 
In the first attempt various amounts of tristearin were replaced by Miglyol 812®. 
Miglyol 812® is a neutral oil based on triglycerides of caprylic and capric acid. An 
addition of 27 % Miglyol® to the standard formulation resulted in the formation of a 
rubbery mass that was convertible to extrudates without heating. 
As the rods revealed a quite low breaking strength of around 8 N the amount of 
Miglyol® was reduced. For instance, for extrudates with a Miglyol® content of 16 % a 
tensile strength of approximately 15 N was measured. However, a further decrease 
of the Miglyol® fraction did not further enhanced the mechanical stability of the 
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extrudates and on the other hand, a minimum amount of 13 % Miglyol® was 
necessary to provide extrusion. 
Alternatively to Miglyol®, the semi-soften lipid Softisan 378® was admixed to the 
blend of tristearin, PEG, and cyclodextrin. In analogy to the results obtained with 
Miglyol®, extrusion could be handled after admixing of 16 % Softisan 378®. However, 
these extrudates were less compact compared to those obtained by the addition of 
Miglyol®. 
In Figure 78 Miglyol®-containing extrudates are displayed. In order to estimate the 
homogeneity of the produced extrudates 1 % of methylene blue was added to the 
lipidic formulation. The extrudates revealed a uniform blue staining, independent 
whether the rods were received at the start or at the end of the extrusion procedure. 
As a consequence, it can be concluded that a homogeneous drug distribution can be 
achieved. 
 
Figure 78: Appearance of extrudates based on 10 % PEG, 10 % HP-β-CD, 16 % Miglyol®, 64 % 
tristearin and 1 % methylene blue. 
2.1.2. SUSPENDING THE LIPIDIC MATERIAL IN A HIGHLY CONCENTRATED PEG SOLUTION 
Here an adjustment of the viscosity of the lipidic mass for extrusion was aimed by 
wetting the lipidic blend with a highly concentrated PEG solution. The idea behind 
this experiment was to avoid the lyophilisation step of IFN-α before implant 
manufacturing. IFN-α can be quantitatively precipitated/crystallised by a highly 
concentrated PEG solution (Chapter IV.2). These protein crystals may provide a 
higher protein stability, allowing the handling at elevated pressures and shear 
stresses. 
Tristearin powder was wetted with a solution comprising either 40 % (wt/wt) PEG or 
50 % (wt/wt) PEG (5 g of lipidic mass were wetted with 2.5 mL or 2.0 mL PEG 
solution, respectively). Extrusion was possible with the obtained lipid slurry. However, 
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extrusion ground to a halt after the delivery of a strand with a length of approximately 
10 cm. Due to this low yield extrusion by wetting of the lipidic mass with an aqueous 
PEG solution was not further investigated. 
2.1.3. DISSOLVING THE LIPIDIC MATERIAL IN AN ORGANIC SOLVENT  
As illustrated in Chapter I.4.3, Zhu and Schwendeman prepared PLGA minicylinders 
by suspending the protein in a solution of PLGA. The obtained PLGA-slurry was then 
extruded through a needle [262]. In order to transfer such a manufacturing procedure 
to twin screw extrusion of lipids various quantities of hexane were added to dissolve 
a certain amount of the lipid. The dissolution of the lipid was supposed to provide a 
softening of the lipidic mass. On the other hand, a certain minimal viscosity of the 
material was needed for increasing the pressure within the extruder and thereby 
forcing the material through the extruders die. Hexane was chosen as solvent 
providing an acceptable stability of lyophilised IFN-α suspended within this solvent 
[94].  
The addition of 25 %, 30 %, and 40 % hexane to the blend of tristearin, PEG, and 
HP-β-CD, respectively, facilitated extrusion at room temperature. After evaporating 
the organic solvent the extrudates exhibited an improved mechanical stability. In 
comparison to the extrudates containing Miglyol® the tensile strength increased up to 
37.3 N (SD=8.7, n=5).  
 
 
 
Figure 79: Extrudates based on tristearin, PEG, and HP-β-CD wetted with various amounts of 
hexane. 
1.5 g hexane (A) and 2 g hexane (B) were added to 5 g of lipidic formulation comprising 10 % PEG, 
10 % HP-β-CD, 79 % tristearin, and 1 % methylene blue. Figure C is a magnification of A. 
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However, as illustrated in Figure 79 the extrudates revealed a non-uniform methylene 
blue staining – darker and brighter areas were visible within one rod (Figure 79 C) – 
indicating different methylene blue contents in these regions. In addition, some 
extrudates revealed a complete depletion of methylene blue at their edges.  
This heterogeneous methylene blue distribution as well as the general concerns 
associated with the use of organic solvents (see Chapter I) led to the decision that 
manufacturing of extrudates by suspending the material within organic solvents is 
unsuitable for the preparation of lipidic extrudates. 
2.1.4. ADMIXING OF LOW MELTING POINT LIPIDS 
Finally various amounts of tristearin were replaced by alternative lipids with a melting 
point lower than that of tristearin. Thereby, selective melting of the low-melting point 
lipid should provide a softening of the lipidic mass during the manufacturing 
procedure. On the other hand, the re-solidification of the lipid mass after extrusion 
should offer the benefit of an increased mechanical stability.  
First, tristearin was replaced by the mixed-acid triglyceride H12. H12 is a triglyceride 
based on saturated, even-numbered, unbranched, natural fatty acids. In particular 
the fatty acid composition is: 71 % lauric acid, 27 % myristic acid and 2 % palmitic 
acid. As H12 melts at 36 °C, the extruder was heated to 40 °C in order to ensure a 
complete melting of H12 during manufacture.  
In a preliminary study the amount of H12 needed for acceptable extrusion was 
explored. Initially, 40 % H12 were applied, allowing the filling of the extruder. 
However, as visualised in Figure 80 A, the obtained rods were not solidified after 
leaving the extruder outlet. By stepwise reduction of the amount of the low melting 
point fat stable extrudates could be produced. The optimum amount of H12 was 
found to be 16 % (Figure 80 C).  
 
Figure 80: Effect of H12 addition on extrusion. 
The formulations based on 10 % HP-β-CD, 10 % PEG and 40 % H 12 and 40 % tristearin (A), 24 % 
H12 and 56 % tristearin (B), 16 % H12 and 64 % tristearin (C), and 8 % H12 and 72 % tristearin (D) 
were extruded, respectively.  
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Reducing the admixed content of H12 from 40 % to 16 % led to an increase in the 
torque from ~7 Ncm to ~14 Ncm. At a constant screw rotation speed of 40 rpm this 
increase suggested an increasing viscosity of the semi-soft mass generated during 
extrusion. A further reduction of the H12 content to 8 % resulted in a torque of 100-
150 Ncm which was accompanied with a grey staining of the extrudates (Figure 
80 D), which implied material abrasion from the barrel.  
Based on these results it was concluded that an extrudable formulation should 
contain 16 % to 24 % of a compound which melts during extrusion. In order to 
evaluate if this formulation strategy was transferable to other lipid combinations the 
low-melting point lipid or high-melting point lipid were substituted.  
Instead of H12 the triglyceride E85 was used. E85 is also a mixed-acid triglyceride 
but in comparison to H12 the amount of myristic acid is increased accounting for a 
melting point of 41 °C. Thus, extrusion was performed at a temperature of 45 °C. In 
accordance with formulations containing H12 an addition of 16 % E85 facilitated a 
continuous extrusion. In order to evaluate if the developed manufacturing procedure 
is also applicable for lipidic blends based solely on mono-acid triglycerides H12 was 
replaced by trilaurin. As the melting point of trilaurin is 43 °C the extruder barrel was 
heated to 47 °C which allowed extrusion with a trilaurin content of 16 %.  
In a second attempt tristearin was substituted by tripalmitin or triarachidin. As H12 
was used as low-melting point lipid, the extruder was heated to 40 °C to allow 
softening. However, only with triarachidin a convenient extrusion procedure could be 
established. Substituting tristearin by tripalmitin rendered filling of the extruder 
possible, but no extrusion occurred. To increase the pressure within the barrel the 
extruder was cooled down to 35 °C. Afterwards extrusion could also be performed 
with the triplamitin material.  
Irrespective of the formulation the extrudates revealed a uniform methylene blue 
distribution. In Figure 81 extrudates comprising a H12/tristearin blend and extrudates 
based on trilaurin/tristearin are exemplarily illustrated.  
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Figure 81: Appearance of extrudates based on 10 % PEG, 10 % HP-β-CD placebo lyophilisate, 
64 % tristearin and 16 % H12 (A) or 16 % trilaurin (B), respectively. Figure C represents a 
magnification of A. 
 
From these formulation studies it was concluded that (1) the combination of solid 
triglycerides and semi-softened fat or oils, or (2) the combination of low- and high-
melting point lipids can be considered as most promising manufacturing strategies 
regarding both, feasibility of the extrusion process and product homogeneity.  
Comparing the mechanical properties of the obtained rods a clear superiority of 
extrudates comprising low-melting point lipids became evident. The forces needed to 
induce longitudinal breakage increased from ~15 to ~37 N, when replacing Miglyol® 
by a low-melting lipid. 
2.2. INFLUENCE OF THE MANUFACTURING PROCESS ON THE LIPID MODIFICATION  
During extrusion the applied temperatures must lead to a melting of the low-melting 
point lipid enabling the mass flow within the barrel. Therefore, manufacturing may 
induce a polymorphic transformation from the stable β- to the α-polymorph.  
As such a transformation can be associated with various problems during storage 
and during release (see Chapter I.3.3) the thermal behaviour of freshly prepared 
extrudates was investigated by DSC experiments.  
These studies were carried out with extrudates consisting solely of the lipid materials 
because the melting points of other excipients as for example PEG (Tm=58.7°C, 
SD=0.87, n=3) may overlap with the transitions temperatures relevant for studying 
the polymorphism of the lipids. In accordance with the formulations described above 
the ratio of low melting point to high melting point lipid was 1 to 4. 
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2.2.1. EXTRUDATES BASED ON A MIXTURE OF MONO-ACID TRIGLYCERIDES 
The polymorphic properties of mixed-acid triglycerides (H12 and E85) are more 
complex than those described for monoacid-triglycerides [193]. Therefore, the effect 
of extrusion was first evaluated for extrudates based on a trilaurin/tristearin blend.  
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Figure 82: Thermal behaviour of mono-acid triglycerides. 
The first heating scan of the used lipid bulk materials tristearin (1) and trilaurin (3) as well as the 
respective second heating scans in 2 and 4. 
In order to determine the melting points and the polymorphic behaviour of the pure 
triglycerides, DSC analysis of trilaurin and tristearin was initially carried out. The 
thermograms of trilaurin and of tristearin revealed one single endothermic transition 
at 45.3 °C (n=2, SD=0.07 °C) and at 70.8 °C (n=3, SD=1.15 °C), respectively 
(Figure 82). Both melting endotherms are characteristics of the stable β-modification 
of trilaurin and tristearin [77]. As the triglycerides re-crystallised from melt firstly in the 
metastable α-form, the second heating scan demonstrated an endothermic peak at 
31.2 °C (n=2, SD=0.21 °C) for trilaurin and an endothermic peak at 52.5 °C (n=3, 
SD=0.75°C) for tristearin. These endotherms were followed by an exothermic 
transition representing the re-crystallisation to the β-modification. Upon further 
heating the melting of the β-modification was observed at 44.3 (n=2, SD=0.21 °C) 
and at 68.5 °C (n=3, SD=0.75°C), respectively. 
In Figure 83 the thermograms of the lipid blend comprising trilaurin and tristearin are 
shown before extrusion (scan 1) and after extrusion (scan 3). In order to illustrate the 
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polymorphic behaviour of the lipid blend the respective second heating scans are 
included. 
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Figure 83 : Influence of the extrusion procedure on the lipid modification.  
In (1) the first heating scan and in (2) the second heating scan of tristearin blended with trilaurin are 
illustrated. The first and the second heating scans of the extrudates based on the trilaurin/tristearin 
blend are shown in (3) and (4), respectively.  
Two endothermic transitions were observed for the blend of trilaurin and tristearin 
(ratio 1 to 4, Figure 83 (1)). The similarities of these peaks to the melting 
temperatures of trilaurin and tristearin alone allowed the assignment of the low-
melting to trilaurin and of the high-melting peak to tristearin. In accordance, the 
extrudates (Figure 83 (3)) also revealed two endothermic transitions presumably 
corresponding to the transitions of trilaurin and tristearin.  
However, the melting points of blended triglycerides were lower compared to the 
melting endotherms of pure trilaurin and tristearin, respectively. In particular after 
extrusion, the first melting event occurred already at 40.2 °C (n=2, SD=0.07 °C), 
whereas pure trilaurin revealed an endotherm at 45.3 °C (n=2, SD=0.07 °C).  
In literature it has been described that the phase behaviour and the crystallisation of 
binary systems comprising saturated mono-acid triglycerides both depend mainly on 
the chain length difference of the triglycerides. Two phase types can be 
distinguished: (1) triglycerides of a similar chemical structure form a miscible solid-
solution phase and (2) triglycerides with different chemical structures form a eutectic 
phase. Polymorphism makes the phase behaviour even more complicated. For 
instance, when triglycerides of a binary mixtures differ in their chain length by two 
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carbons, solid solution phases are formed in the metastable α and β´modification, 
whereas a eutectic phase with a limited region of solid solution is formed for the 
stable β form [192, 193].  
Takeuchi et al. [221] investigated the phase behaviour and the polymorphism of 
binary mixtures based on various mono-acid triglycerides by synchrotron radiation x-
ray diffraction. When the mass content of trilaurin was below 50 % no crystallisation 
of the trilaurin fraction occurred during the heating and cooling process [221]. 
Considering this information the transitions observed in the second heating scan of 
the trilaurin/tristearin blend (Figure 83 (2)) might reflect the transformation of tristearin 
from the α to the β modification.  
However, as illustrated in Figure 83 the cooling curves after heating revealed two 
exothermic transitions, indicating the crystallisation in two distinct phases.  
Bunjes et al. [29] investigated the thermal behaviour of solid lipid nanoparticles 
containing various amounts of trilaurin and tristearin. During heating two melting 
maxima were observed, which were ascribed to the trilaurin and the tristearin 
fraction, respectively. In accordance to the present work, the melting peaks were 
shifted to lower temperatures compared to the pure triglycerides. The authors 
suggested, that this depression of the melting temperatures can be explained by 
eutectic phase behaviour [29].  
Summing up, the main characteristics of the DSC-scans shown in Figure 83 – the 
two crystallisation peaks upon cooling in combination with the depression of the 
melting points – implied the formation of a eutectic phase for the physically mixed 
blends as well as for the extrudates. Due to the fact that trilaurin was completely 
molten during extrusion the depression of the melting point was more pronounced 
after extrusion than after physical mixing.  
Moreover, the first melting endotherms in the second heating scans were followed by 
an exothermic crystallisation peaks (Figure 83 (2) and (4)). This suggests that the 
melting endotherm can be ascribed to the instable α-modification. As the melting 
point of the α-tristearin modification might be depressed due to the formation of a 
solid solution of trilaurin in tristearin [29], a clear distinction whether this transition can 
be ascribed to trilaurin or tristearin fraction is not possible based on the presented 
DSC data.  
However, more important for the present work was the observation that no re-
crystallisation was detectable in the themograms of the freshly prepared extrudates. 
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This clearly indicated that the extrudates comprise both the low- and high-melting 
point lipid in the stable β-modification. 
The absence of the α-modification after extrusion was confirmed by WAXS 
experiments. As shown in Figure 84 the freshly prepared extrudates revealed the 
short-spacings typical for the stable β-modification at 0.46, 0.38 and 0.37 nm [77]. 
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Figure 84: Influence of the extrusion procedure on the lipid modification.  
WAXS analyses of tristearin/trilaurin extrudates directly after twin screw extrusion. 
The presence of both lipids in a stable modification even after melting one of them 
during extrusion might be explained by: (1) crystal seeding effects or (2) by the effect 
of shear stress on the fat solidification. It is known that the presence of seeding 
crystals can control polymorphic transitions [192]. As the high melting lipid is present 
in the stable β-modification during extrusion this might trigger a crystallisation of 
trilaurin into the β-form. On the other hand, it has been reported that shearing of 
hydrogenated cottonseed oil facilitates the crystallisation into stable polymorphs [69]. 
In the cited study mechanical “tempering” was performed by repeated extrusion 
through a sodium press [69].  
2.2.2. EXTRUDATES BASED ON A MIXTURE OF MONO-ACID AND MIXED-ACID 
TRIGLYCERIDES 
In order to confirm the promising results obtained with extrudates containing a 
mixture of trilaurin and tristearin a similar study was performed with extrudates based 
on a mixture of mono-acid and mixed-acid triglycerides.  
As the polymorphic properties of mixed-acid triglycerides are quite complex, they 
need to be evaluated for each individual species. For example, Sato et al. [193] 
Chapter V: Development of improved lipid based delivery systems for pharmaceutical proteins 159 
  
reported for some mixed triglycerides the absence of the β-form. In this case the β´-
form became the most stable modification. However, other mixed-acid triglycerides 
were characterised by the existence of several β forms [193].  
In Figure 85 the thermal behaviour of the triglyceride H12 is illustrated. The bulk 
material revealed one single endothermic peak at 35.6 °C. When cooling down 
(5 K/min) and performing a second heating scan the endotherm shifted to 32.9 °C. 
Moreover, a small exotherm was observed in front of the endothermic peak, 
suggesting that the re-crystallisation during cooling was not complete [157]. 
Contrarily, when H12 was slowly re-crystallised from melt at room temperature the 
exothermic transition was missing and a melting endotherm was detected at 35.6 °C. 
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Figure 85: DSC experiments of H12 bulk material. 
The following thermograms are illustrated: (1) first heating scan of H12 bulk, (2) second heating scan 
(after melting and cooling down during the DSC measurement), and (3) first heating scan of H12 bulk 
material melted and solidified at room temperature.  
In order to supplement the obtained results WAXS experiments were carried out. In 
Figure 86 the corresponding X-ray diffraction patterns for H12 bulk material, for 
molten H12 bulk material cooled down with liquid nitrogen as well as for molten H12 
re-solidified at room temperature are shown.  
For H12 bulk material two short spacings at 0.42 nm and at 0.38 nm (2θ = 21.1° and 
23.4°) were determined, which are characteristic for the orthorhombic chain packing 
of the β’ polymorph [77]. After melting and cooling down with liquid nitrogen the 
typical short spacings of the β’ modification were also measured. However, a 
decrease in the intensity of the reflection was obvious, which can be attributed to a 
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lower crystallinity. In contrast, when molten H12 was slowly solidified at room 
temperature the obtained diffraction patterns were comparable to those of the bulk 
material (Figure 86B). 
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Figure 86: WAXS experiments of H12 bulk material. 
In Figure A the diffraction patterns of H12 bulk material (1) as well as the diffraction patterns of molten 
H12 solidified with liquid nitrogen (2) are illustrated. Figure B demonstrates the diffraction patterns of 
H12 bulk material (1) and of molten H12 solidified at room temperature (2).  
The results of the WAXS analysis suggest that H12 bulk material consists of the β` 
modification. Furthermore, H12 re-crystallised in this modification when the molten 
lipid was slowly solidified. Thus, a polymorphic transformation during extrusion 
became unlikely.  
In order to confirm this assumption the thermal behaviour of a H12/tristearin blend 
before and after extrusion was investigated (Figure 87). In accordance to the results 
observed with the trilaurin/tristearin blend, the compounding resulted in a depression 
of the melting points. Whereas H12 bulk material revealed a melting endotherm at 
35.6 °C, tristearin blended H12 featured an endothermic transitions at 32.3 °C prior to 
extrusion and at 30.0 °C after extrusion. It can be assumed that the reasons for these 
shifts of the melting points are similar to that discussed for the trilaurin/tristearin 
formulation.  
Importantly, no re-crystallisation of unstable modifications was detectable for freshly 
prepared extrudates.  
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Figure 87: Influence of the extrusion procedure on the lipid modification.  
In (1) the first heating scan and in (2) the second heating scan of tristearin blended with H12 are 
illustrated. The first and the second heating scans of the extrudates based on the H12/tristearin blend 
are shown in (3) and (4), respectively.  
In addition, the absence of a polymorphic transformation during extrusion was 
confirmed by WAXS analysis. As illustrated in Figure 88 the admixture of H12 and 
tristearin produced reflections, which were intermediate between those of the pure 
substances. The strong diffraction lines at 2θ=19.6°, 23.4°, and 24.4° correspond to 
the crystal spacings of the β modification of tristearin at 0.46, 0.38, and 0.37 nm. 
Considering the diffraction pattern of pure H12 at 2θ=23.4°, d=0.38 nm an 
overlapping with the β’ modification of H12 occurred at this 2θ angle. In addition, the 
β’ modification of H12 was detected at 0.42 nm (respective at 2θ=21.1°). Importantly, 
the same short spacings were featured after extrusion, leading to the conclusion that 
tristearin was present in the β-modification and H12 in the β’-modification. 
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Figure 88: Influence of the extrusion procedure on the lipid modification.  
WAXS analyses of the tristerain/H12 before (1) and after extrusion (2). 
Since both WAXS and DSC analysis of the lipids after extrusion featured the 
characteristics of the modification of the bulk materials, unforeseeable and hardly 
controllable polymorphic transformations upon storage or during release are 
improbable. The next experiments will, therefore, deal with the second potentially 
critical point of the manufacturing procedure: the effects of extrusion on protein 
stability. 
2.3. INFLUENCE OF THE MANUFACTURING PROCESS ON THE PROTEIN STABILITY  
Potential effects of elevated temperatures on the protein stability were discussed in 
Chapter I.4.4. Based on the literature data presented, it might be possible that 
proteins suspended in molten lipids can resist thermally induced denaturation and 
aggregation at moderate temperatures.  
IFN-α loaded extrudates were prepared based on the formulations presented before. 
In particular, a combination of H12 with tristearin as well as a Miglyol®/tristearin blend 
was used as lipidic matrix material. With the latter formulation extrusion can be 
performed at room temperature and heat will only be generated by friction. Thus, 
potential thermally induced aggregation should be lower than in the case of a 
combination between low and high melting point lipids.  
After extrusion IFN-α was extracted (as described previously [151], see Chapter 
III.2.3) and the samples were analysed by SDS-PAGE with subsequent silver 
staining (Figure 89).  
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The presence of dimer specimen was evident in all IFN-α samples. Furthermore, 
samples extruded in the presence of Miglyol® featured the creation of higher-order 
aggregates (Figure 89, lane 8).  
The dimer fraction detected in all extruded samples was already present in the IFN-α 
bulk material and in the lyophilisates used for extrusion. (In contrast to the 
experiments described before (Chapter IV and V.1, here a different lot of protein 
standard was used.) Thus, the formation of dimers cannot be ascribed to the 
extrusion procedure of the H12/tristearin formulation. Only the extrusion in the 
presence of Miglyol® (Figure 89, lane 8) seemed to compromise protein stability.  
 
Figure 89: SDS-PAGE of IFN-α extracted from lipidic extrudates.  
Lane 1: Molecular weight standard, lane 2: IFN-α standard, lane 3: IFN-α after lyophilisation, lane 4-8: 
IFN-α extracted from lipidic implants. The extrudates formulations were 80 % H12/tristearin ¼, 10 % 
lyophilised IFN-α and 10 % PEG (lane 4 and lane 5 extrudates received at the beginning and at the 
end of the extrusion procedure, respectively) and 70 % H12/tristearin ¼, 10 % lyophilised IFN-α and 
20 % PEG (lane 6 and lane 7 extrudates received at the beginning and at the end of the extrusion 
procedure, respectively). In lane 8 IFN-α extracted from extrudates comprising 80 % of a 
Miglyol®/tristearin ¼ blend, 10 % lyophilised IFN-α and 10 % PEG is shown.  
2.3.1. CHARACTERISATION OF THE SECONDARY PROTEIN STRUCTURE WITHIN THE LIPIDIC 
EXTRUDATE 
FTIR-spectroscopy has been suggested to analyse the secondary structure of 
proteins embedded within controlled release devices [75, 228, 256]. This method 
inheres the benefit that extraction of the protein is not necessary as the protein 
structure is directly studied within the delivery system.  
FTIR-spectra of solid protein can be obtained for instance with the ATR-technique or 
with the transmission-technique using infrared-transparent salts. The main advantage 
of the ATR-technique is that it obviates time consuming sample preparation. In brief, 
the basis of ATR-spectroscopy is a beam of infrared radiation entering an optically 
transparent crystal of a higher refraction index than the sample. At the crystal-sample 
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interface the beam is totally reflected and consequently an evanescent wave 
penetrates the sample located at the crystal surface at the reflections point. In 
comparison, the IR-beam passes directly through the sample when the KBr 
transmission method is applied to collect the spectra [230].  
In a pilot survey the potential of ATR- and transmission-technique to characterise the 
secondary structure of IFN-α embedded in a lipidic powder formulation was 
investigated. In accordance to the extrudate formulations presented in Chapter V.2.1 
a lipid mixture based on H12 and tristearin in a ratio of 1 to 4 was blended with 10 % 
IFN-α and with 10 % PEG. As illustrated in Figure 90 the spectra recorded by the 
ATR-technique revealed a protein signal in the amid l/amid II region. However, better 
signal to noise ratio was obtained in the transmission mode. Thus, it was decided to 
use this technique for further investigations.  
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Figure 90: ATR-spectrum (A) and KBr pellet transmission spectrum (B) of the physically mixed 
lipid, PEG and protein formulation 
 
As many proteins revealed spectral changes upon lyophilisation [33, 230] first the 
KBr transmission spectra of lyophilised IFN-α were recorded. The second derivative 
transmission spectra of IFN-α lyophilised with HP-β-CD and that of the protein in 
solution are shown in Figure 91. 
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Figure 91: Vector-normalised second-derivative spectra of IFN-α.  
The solid line represents the second-derivative spectra of lyophilised IFN-α obtained with the KBr 
pellet method. The dashed line shows the second-derivative spectra native IFN-α in solution.  
Upon lyophilisation the dominant band ascribed to the helical structure was shifted 
from 1654 cm-1 to 1656 cm-1. A shift of the band positions upon lyophilisation may 
indicate variations in the order of the α-helical structure [175]. Furthermore, a broader 
amid I band in the KBr spectra was observed and a new band at 1615 cm-1 arose. 
The occurrence of new bands at 1619 cm-1 upon lyophilisation was related to 
intermolecular β-sheet formation [229]. 
Though Carpenter and co-workers showed that the extent of spectral changes 
occurring upon lyophilisation correlated with the storage stability [33], there is still a 
debate about the reasons for these structural changes. For instance, Van de Weert 
et al. [229] figured out that both structural changes as well as the removal of water 
might induce differences in the absorption characteristics of the amid bond.  
Within the scope of the present work the origin of the spectra differences was not 
further investigated. The spectra of lyophilised IFN-α should only serve as standard 
to evaluate the effects of the extrusion procedure on the secondary protein structure. 
As shown before, the C=O stretch vibrations of the triglyceride matrix material 
occurred at 1737, at 1729, and at 1690 cm-1 (see Figure 90). In particular the latter 
band overlapped with the amid I band of the protein. Hence, it was necessary to 
evaluate the possibility of background correction. These investigations were 
performed with IFN-α blended in a mortar with the lipidic matrix material to exclude 
potential changes of the protein structure. The obtained spectra of the lipid/protein 
powder blend (10 % IFN-α/HP-β-CD co-lyophilisate, 10 % PEG, 64 % tristearin, and 
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16 % H12) were corrected by the spectra of the respective placebo blend. Yang et al. 
[256] suggested as criterion for successful background subtraction a flat baseline in 
the region at 1730 - 1710 cm-1 (final protein spectra obtained after correction with 
PLGA background). However, it was not possible to fulfil this request with the 
lipidic/protein blend studied here (Figure 92).  
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Figure 92: Effect of background subtraction on the KBr pellet transmission spectra of IFN-α 
embedded in a lipid/PEG blend 
 
Variations of the subtraction factor either involved an oversubtraction or an 
undersubtraction of the lipid contributions, leading to negative or positive features in 
the spectrum between 1700 to 1800 cm-1. The same problem was noted by van de 
Weert et al. [228]. In the cited work it was tried to correct the spectra of lysozyme 
embedded within PLGA microspheres by the spectra of the blank PLGA 
microspheres. The fact that the background could not completely cancelled out was 
explained by baseline slopes and distorted peak shapes especially in the carbonyl 
stretch vibration of PLGA due to the compression in KBr pellets. In addition, it was 
suggested that different absorption characteristics of protein–loaded microspheres 
restricted the subtraction of the spectrum of blank PLGA microspheres [228]. 
However, in accordance to the work of van de Weert et al. [228], the peak positions 
below ~1670 cm-1 in the absorbance spectra as well as in the second derivative 
spectra were not markedly affected by the used subtraction factor (Figure 93). 
Importantly, the obtained spectra were quite similar to that of lyophilised protein 
before blending with the lipid matrix material. Taking all together led to the conclusion 
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that the subtraction of the lipid background did not cause spectral artefacts in the 
amid I region below 1670 cm-1 (Figure 93).  
 
-0.2
-0.15
-0.1
-0.05
0
0.05
0.1
0.15
0.2
16001610162016301640165016601670168016901700
wavenumber, cm-1
ab
so
rb
an
ce
substraction factor 1.0
substraction factor 1.14
substraction factor 1.2
lyophilised IFN-α 
A
-0.3
-0.25
-0.2
-0.15
-0.1
-0.05
0
0.05
0.1
16001610162016301640165016601670168016901700
wavenumber, cm-1
ab
so
rb
an
ce
B
 
Figure 93: Vector-normalised KBr-pellet-transmission spectra (A) and respective second 
derivatives (B) of IFN-α embedded in a lipid/PEG blend after background correction. 
 
In Figure 94 the obtained second derivatives of IFN-α after extrusion with a 
H12/tristearin blend are illustrated. Compared to the physical blended protein no 
significant differences in the amid I region below ~1670 cm-1 were detected.  
The formation of intermolecular β-sheets would be detectable by the appearance of 
new bands at 1623-1641 cm-1 and at 1674-1695 cm-1 [230], but there were 
uncertainties in the latter band region with the described KBr transmission technique. 
However, a structural rearrangement should be associated with a decrease in the α-
helical content (compare Figure 54 (FTIR-spectra during thermal induced 
denaturation)). As shown in Figure 94 the band at 1653 cm-1 was largely unaffected 
by the extrusion procedure. Thus, it is highly likely that extrusion of IFN-α embedded 
in a H12/tristearin blend comprising either 10 % or 20 % PEG did not induce 
important changes in secondary protein structure. 
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Figure 94: Second derivative KBr-pellet-transmission spectra before extrusion and after 
extrusion with a lipidic blend based on H12 and tristearin. 
In contrast, the second derivatives of IFN-α after extrusion with a Miglyol®/tristearin 
blend revealed a number of differences compared to the spectra of the physical 
blend (Figure 95). The band arising from α-helical structures was shifted to 1653 cm-1 
with a decrease in the relative intensity. In addition, the absorption bands at  
1635 cm-1 and at 1619 cm-1 gained in intensity. Based on the overall spectral 
perturbations, a modification of the secondary structure of IFN-α could be supposed 
upon extrusion with a Miglyol®/tristearin blend. 
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Figure 95: Second derivative KBr-pellet-transmission spectra before extrusion and after 
extrusion with a lipidic blend based on Miglyol® and tristearin. 
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In summary, SDS-PAGE analysis and FTIR-spectroscopy demonstrated that protein 
integrity was kept during extrusion at 40 °C with a lipid blend comprising H12 and 
tristearin. In contrast, SDS-PAGE analysis and FTIR-spectroscopy of IFN-α 
processed with the Miglyol®/tristearin blend revealed the occurrence of higher-order 
aggregates and significant perturbations of the secondary protein structure even 
though extrusion was performed at room temperature.  
2.4. IN-VITRO RELEASE STUDIES 
In the next step the in-vitro release behaviour of IFN-α from lipidic extrudates was 
investigated. In order to facilitate the creation of an interconnected pore network 
enabling complete protein release the extrudates were loaded with 10 % or 20 % 
PEG, respectively. In addition, the influence of different extrudate diameters on the 
protein liberation was studied. For this, dies of 0.5 mm or 1 mm were fixed in front of 
the normal extruder outlet (diameter 2.0 mm) 
The reduction of the extrudate diameter resulted in an accelerated protein delivery 
(Figure 96). For instance, extrudates comprising 10 % PEG liberated IFN-α in a 
sustained manner over 13 days, when the implant diameter was 0.5 mm. In 
comparison, the use of extrudates with a diameter of 1.0 or 1.9 mm extended the 
release period up to 30 or up to 60 days, respectively. Coexistent to this prolongation 
of the release period the total amount of IFN-α released differed in dependence on 
the implant diameter. Almost complete release (95.40 % (SD=5.51 %, n= 3)) was 
determined with the smallest extrudates, whereas increasing the implant diameter 
resulted in less complete protein release. Extrudates with a diameter of 1.0 mm 
delivered 83.53 % of the incorporated protein within 30 days and a further decrease 
in the overall released amount was observed with extrudates of a diameter of 1.9 mm 
(62.09 % (SD=0.85 %; n=3) within 60 days).  
A similar influence of the extrudate diameter was observed with implants loaded with 
20 % PEG. Here almost complete protein recovery was observed with extrudates of 
a diameter of 0.5 and 1 mm. The delivery of 91.18 % (SD=0.17, n=3) or 93.14 % 
(SD=0.6, n=3) IFN-α from these extrudates was retarded over 10 days and over 
23 days, respectively. Furthermore, extrudates with a diameter of 1.9 mm revealed a 
sustained IFN-α release over 2 month. Compared to extrudates comprising only 
10 % PEG the released fraction of IFN-α rose up to 84.12 % (SD=3.71, n=3). 
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The stepwise decrease of the totally liberated IFN-α by increasing the implant 
diameter, indicated that the incomplete protein recovery from larger extrudates can 
be ascribed to the implant geometry rather than to protein aggregation within the 
extrudates. With increasing the diameter of extrudates the diffusion pathways 
increase. Therefore, it seems that the enlargement of the lipidic matrix required 
higher amounts of hydrophilic drug/excipient to allow the creation of a connected 
pore-network.  
However, further investigations should clarify whether the incomplete release from 
thicker extrudates can be ascribed to non-connected diffusing pathways or to protein 
aggregation within the matrix. For instance, the mechanisms of incomplete protein 
release can be investigated by the extraction of non-released protein with different 
types of incubation media. Solutions of sodium chloride would give information on 
potential electrostatic interactions, whereas the denaturants GdnHCl and SDS would 
dissolve non-covalent aggregates trapped within the matrix. From the comparison of 
the released protein amounts in the presence of GdnHCl and SDS information on 
protein adsorption can be obtained, as the strong surface active SDS can additional 
displace protein molecules adsorbed onto surfaces [52, 119, 164].  
Beside the possibility to adapt the release kinetics by using extrudates with different 
diameters the addition of various amounts of PEG was an effective tool to modify 
IFN-α release (Figure 96). Increasing the amount of incorporated PEG from 10 to 
20 % resulted in a more accelerated IFN-α release. For example extrudates with a 
diameter of 1.0 mm comprising 10 % PEG liberated IFN-α in a sustained manner 
over 37 days, whereas the delivery was only retarded over 19 days when 20 % PEG 
were used as pore former.  
Interestingly, the release kinetics of extrudates with a diameter of 1.9 mm (partly also 
extrudates with a diameter of 1.0 mm) revealed a lag-phase after the initial burst 
release. Extrudates loaded with 10 % PEG released 10.41 % (SD=2.02%, n=3) 
within the first day of incubation. After that, a lag-phase until day 16 occurred. 
Enhancing the amount of admixed PEG to 20 % reduced the burst release to 7.19 % 
(SD=0.65 %, n=3) and shortened the lag-phase to 7 days (Figure 96 C). After the 
lag-period IFN-α was delivered from extrudates with 10 % PEG in a constant manner 
over 30 days until day 53 of incubation. In comparison to that, extrudates with 
20 % PEG revealed a linear phase over 24 days. 
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Figure 96: Effect of PEG content and implant diameter on the in-vitro release behaviour of IFN-
α from lipidic extrudates.  
For extrusion 10 % IFN-α/HP-β-CD co-lyophilisate were blended with 10 % or 20 % PEG and 80 % or 
70 % H12/tristearin ¼. Extrusion was performed with the described twin screw extruder at 40 °C. The 
diameter of the prepared rods was 0.5 mm (A), 1.0 mm (B), or 1.9 mm (C) (average +/- SD; n = 3). 
Such a triphasic release profile (burst, lag-phase, linear release period) was reported 
for protein delivery from degradable matrix systems. As explained in Chapter I.5. the 
burst is ascribed to protein delivery from the surface. The lag-phase is characterised 
by diffusion controlled release and finally, when erosion starts, the release rates rise 
up. However, extrudates based on a H12/tristearin blend maintained there geometric 
dimensions during in-vitro incubation and no mass loss occurred during incubation.  
One explanation for the triphasic release profile might be the in-situ precipitation 
mechanism of IFN-α within PEG-containing delivery systems outlined in Chapter IV. 
Assuming high concentrations of PEG within the implant pores over prolonged 
periods of time this would explain the observed non-release phase.  
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It is evident from Figure 96 that the burst effects from extrudates prepared by twin 
screw extrusion were quite low. Even implants with a diameter of 0.5 mm loaded with 
20 % PEG liberated not more than 27.27 % (SD=4.54, n=3) within the first 24 hours. 
Importantly, thicker extrudates revealed a reduction of the burst release with rising up 
the PEG content from 10 % to 20 %. Such an observation was already described 
before for the protein release from PEG-containing compressed tristearin matrices 
and it was shown that this contradiction to the effects of PEG as porogen could be 
explained well by the reduced solubility of IFN-α within PEG-containing matrices (see 
Chapter IV).  
In order to evaluate whether a reduced protein solubility or even an in-situ 
precipitation is relevant for extrudates prepared by twin screw extrusion the release 
behaviour of lysozyme from these implant systems was investigated. As shown in 
Chapter IV.3.3 lysozyme revealed less distinct precipitation in presence of PEG. 
Thus, if precipitation is really important for the sustained liberation of IFN-α from 
extrudates the substitution of IFN-α by lysozyme should result in an acceleration of 
the release kinetics.  
2.4.1. LYSOZYME AS MODEL PROTEIN 
In order to exclude detrimental effects of the manufacturing procedure on lysozyme 
stability, lysozyme was extracted from the lipidic extrudates and analysed by SDS-
PAGE.  
As shown in Figure 97 lysozyme bulk material contains dimeric protein (quantification 
with SE-HPLC revealed approximately 0.3 % dimer) and an impurity with molecular 
weight of approximately 18 kDa. Such contaminations of commercially available hen 
egg-white lysozyme were already noted before [225]. In addition, SDS-PAGE 
revealed a weak band at a molecular weight of about 6 kDa.  
Importantly, it was shown that no further protein degradation occurred upon 
extrusion, indicating that the developed extrusion procedure did not compromise the 
stability of lysozyme.  
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Figure 97: Effect of the extrusion procedure on the integrity of lysozyme. 
Lane 1: Molecular weight standard, lane 2: lysozyme standard, lane 3: lysozyme extracted from 
extrudates received at the start of the extrusion procedure, lane 4: lysozyme extracted from extrudates 
received at the end of the extrusion procedure.  
In Figure 98 the in-vitro release kinetics of lysozyme from extrudates based on a 
H12/tristearin blend and containing 20 % PEG are illustrated. In accordance to the 
delivery of IFN-α, the reduction of the implant diameter resulted in a less retarded 
lysozyme release. For instance, the amount of lysozyme delivered within the first 
24 hours increased from 23.76 % (SD=5.33 %, n=3) to 69.51 % (SD=3.85 %, n=3) 
when the implant diameter was reduced from 1.9 mm to 0.5 mm.  
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Figure 98: Effect of implant diameter on lysozyme release. 
For extrusion 2.5 % lysozyme was blended with 20 % PEG, 70 % H12/tristearin ¼ and 7.5 % HP-β-
CD. Extrusion was performed with the described twin screw extruder at 40 °C. The diameter of the 
extrudates was 0.5 mm (?), 1.0 mm (?), 1.4 mm (?), or 1.9 mm (?), respectively (average +/- SD; n 
= 3).  
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However, in comparison to the IFN-α release a significant faster lysozyme delivery 
was found for all rods irrespective of the implant diameter. As illustrated in Figure 99 
a lag-time was missed when analysing lysozyme release from extrudates with a 
diameter of 1.9 mm. Furthermore, release of lysozyme levelled off at 81.51 % 
(SD=4.61, n=3) already after 25 days whereas 84.13 % of IFN-α (SD=3.71, n=3) 
were liberated over 60 days. Obviously, the burst effect of lysozyme was significantly 
higher than that of IFN-α.  
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Figure 99: Comparison between lysozyme and IFN-α release from extrudates prepared by twin 
screw extrusion. 
Open symbols indicate the liberation of lysozyme and closed symbols the delivery of IFN-α. The 
investigated extrudate diameters were 1.9 mm (?/?) and 1.0 mm (?/?) (average +/- SD; n = 3).  
In Chapter IV it was shown that reduced burst effects as well as deviations from 
purely diffusion controlled release of IFN-α from PEG-containing compressed 
tristearin matrices were a result of the reduced solubility of IFN-α in the presence of 
PEG. Considering this information the comparison of lysozyme and IFN-α indicated 
that the precipitation of IFN-α in the presence of PEG might be of important for the 
sustained protein liberation from extrudates as well. As lysozyme featured a rather 
high solubility in presence of PEG, high protein concentrations within the implant 
pores would allow lysozyme to diffuse out of the matrix. In contrast, the presence of 
PEG within the implant pores would reduce the protein solubility of IFN-α. As a 
consequence, only a minor fraction of the embedded IFN-α might be available for 
diffusion. This would resulted in low burst effects. Furthermore, the maintenance of 
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high PEG concentration within the pores might restrict the release of IFN-α over 
prolonged periods. This would explain why the burst release (of surface adjacent 
protein) is followed by a non-release period of IFN-α.  
However, in contrast to the release of IFN-α from compressed matrices, a lag-phase 
was observed with extrudates prepared by twin screw extrusion (diameter 1.9 mm). 
Therefore, in the following section the inherent differences of the manufacturing 
methods, which might contribute to the observed differences in the release profiles, 
were discussed. 
2.5. INFLUENCE OF THE MANUFACTURING PROCEDURE ON THE IN-VITRO RELEASE 
KINETICS OF IFN-α 
The influence of the three manufacturing strategies used within the scope of the 
present thesis - ram extrusion, twin screw extrusion and compression - on the 
release of IFN-α was investigated. The lipid/protein mixture comprising 10 % IFN-
α/HP-β-CD lyophilisate, 20 % PEG, and a lipidic powder blend of H12 and tristearin 
in a mass ratio of 1 to 4 was compressed at 19.6 kN for 30 s (see Chapter IV) or 
extruded by means of the ram extruder (see Chapter V.1).  
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Figure 100: Influence of the implant manufacturing method on the in-vitro release of IFN-α. 
In-vitro release kinetics of IFN-α from implants based on a H12/tristearin blend ¼ prepared by 
compression (?), by ram extrusion (?) or by twin screw extrusion (extrudates with a diameter 
1.9 mm (?), 1.0 mm (?), or 0.5 mm (?)). All matrices were loaded with 10 % IFN-α co-lyophilised 
with HP-β-CD and with 10 % PEG (average +/- SD; n = 3).  
As illustrated in Figure 100 the protein liberation occurred in a significantly 
accelerated manner when the manufacturing of implants was accomplished by 
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compression or by ram extrusion. Interestingly, despite of the reduction of the implant 
diameter associated with the change of the manufacturing procedure, twin screw 
extrusion resulted in a more sustained protein delivery. This suggested that twin 
screw extrusion per se causes more delayed protein release. However, it should be 
noted that concomitantly to the reduction of the implant diameter the implant height 
was varied. By compression implants with a height of 2.5 mm were produced, 
whereas extruded rods were cut into pieces of 2.3 cm.  
To get a further insight into the impact of the twin-screw extrusion procedure on the 
release of IFN-α, extrudates prepared by twin screw extrusion were ground and then 
compressed to cylindrical implants. This manufacturing procedure should eliminate 
the influence of the implant geometry on the in-vitro release. If the blending and 
compaction during twin screw extrusion has an influence on the protein liberation the 
release profiles should markedly differ from those obtained from implants prepared 
by compression of the physical protein/lipid/PEG mixture. 
Indeed, release profiles from implants prepared from the extruded lipid/protein blend 
revealed a triphasic release curve (Figure 101). After the burst release a lag-period 
over 9 days was followed. Finally, the delivery rates of IFN-α increased.  
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Figure 101: Influence of the extrusion procedure on the protein release. 
For the preparation of lipidic implants a physical powder blend of 10 % IFN-α/HP-β-CD co-lyophilisate, 
20 % PEG, and 70 % H12/tristearin ¼ was compressed (?). Alternatively the powder was extruded 
with the twin screw extruder, ground and compressed (?). For comparison only the protein release 
kinetics from extrudates with a diameter of 1.9 mm (prepared by twin-screw extrusion) are included 
(?) (average +/- SD; n = 3). 
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Three possible process inherent features might explain the more sustained release 
from extrudates prepared by twin screw extrusion: (1) the intense compaction, (2) the 
fine compounding during extrusion, and (3) the melting of the low melting lipid during 
extrusion.  
As shown in Chapter V.1.6.1 the acceleration of IFN-α release by using different 
triglyceride matrices was associated with a decrease in the compactness of the 
matrix. The change of the manufacturing procedure from ram to twin screw extrusion 
also significantly improved the mechanical stabilities of the extrudates (Table 9). 
Therefore, the more compact matrix structure might be one reason for the more 
sustained protein release from twin screw extrudates.  
 
Table 9: Mechanical properties of implants prepared by various manufacturing methods. 
The implants were based on a lipidic powder blend of H12 and tristearin in a ratio of ¼ (average +/- 
SD; n = 5). 
manufacturing method tensile strenght, N
compression 15.2 +/- 2.3
ram extrusion 10.7 +/- 1.5
twin screw extrusion 37.1 +/- 2.6  
 
In addition, homogeneity studies by the admixture of methylene blue to the extrudate 
formulation showed a uniform staining of extruded rods prepared by twin screw 
extrusion. In contrast, implants of the same formulation processed by compression or 
ram extrusion revealed darker and brighter zones (Figure 102).  
 
 
 
Figure 102: Optical appearance of the different implant systems. 
A lipidic powder blend of H12 and tristearin in a ratio of ¼ was admixed with 1 % methylene blue in 
mortar. The powder blend was (A) compressed at 19.8 kN for 30 seconds, (B) extruded with a ram 
extruder, or (C) extruded with a twin-screw extruder. 
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Based on these observations it can be assumed that the compounding during twin 
screw extrusion accounts for a more finely distribution of PEG and IFN-α within the 
lipidic matrix.  
It has been suggested recently, that the homogeneity of the protein distribution within 
a lipidic matrix correlates with the resulting release profiles [126]. Considering this 
information, the high homogeneity after twin screw extrusion may contribute to the 
more delayed protein recovery from extrudates prepared by twin screw extrusion.  
In addition, in can be assumed that the melting of the low melting lipid during 
extrusion resulted in a welding of the lipid matrix, which in turn would account for a 
very dense structure with a low amount of pores and void spaces. Such effects of a 
melting step during implant manufacturing were reported, for instance, by 
Pongjanyakul [174]. The implants were prepared by casting the molten lipid into 
polyethylene tubes (see Chapter I.3.2.3), which entailed a significantly lower water 
uptake and a lower porosity of the implants compared to compressed implants. This 
was considered as reason for the reduced overall protein release from molten lipidic 
implants [174].  
Taken together – the compaction, the blending and the melting – during twin screw 
extrusion can be considered as complementary reasons for the more sustained 
release of IFN-α from implants prepared by this manufacturing technique. 
Furthermore, assuming that these features of twin screw extrusion might also affect 
the release kinetics of the incorporated excipients, in comparison to ram extrudates 
and to compressed implants, a more sustained release of HP-β-CD and of PEG can 
be expected. As explained above, the latter would contribute to the understanding of 
the observed lag-phase during release studies from twin screw extruded implants. 
The verification of these hypothesises was beyond the scope of the present thesis. 
However, further studies should investigate the release of the excipients from the 
implants prepared by twin screw extrusion. In addition, it would be interesting to 
explore the matrix morphology of twin screw extruded implants before and after in-
vitro release and to compare those observations with the morphology of compressed 
(Chapter IV) and of ram extruded (Chapter V.1) implants. Finally, in order to evaluate 
whether the uniform distribution of the model compound methylene blue is 
conferrable to the distribution of IFN-α within the implant, a staining of the protein 
embedded within the lipidic matrix should be performed. For instance, van de Weert 
et al. revealed that the use of the red dye Ponceau S allowed a visualisation of 
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lysozyme embedded within PLGA microspheres [228]. Alternatively, FTIR-
microscopy or the incorporation of a model protein labelled with fluorescent dyes 
could provide further information on the drug distribution [126]. 
2.6. PROTEIN STABILITY DURING RELEASE 
In Figure 103 the monomer content of released IFN-α versus incubation time is 
illustrated. Over the entire liberation period the IFN-α monomer content remained at a 
high level (>95 %). Beside monomeric IFN-α only dimer specimen were detected by 
SE-HPLC. Mostly, the released protein resembled between 0.5 % and 2 % dimer. 
Extrudates with a diameter of 1.0 mm delivered an increased amount of dimer of up 
to 5 % after 16 days. In comparison to that, implants prepared by ram extrusion or by 
compression revealed a higher integrity of released protein. The delivered dimer 
fraction from these kinds of implant was smaller than 1.5 %.  
As protein destabilisation during the manufacturing procedure is unlikely, one reason 
for this more pronounced deterioration of the protein might be a destabilisation during 
release. Such a destabilisation during release is mostly associated with a time-
depended decrease in the monomer content. However, such a dependency of the 
protein stability on the incubation time was not observed. Considering that the protein 
raw material used for twin screw extrusion already comprised a higher content of 
dimer specimen this might further explain the reduced protein integrity. SE-HPLC of 
the reconstituted lyophilisates applied for twin-screw extrusion revealed a dimer 
content of 0.75 %. In comparison, reconstituted lyophilisates processed by ram 
extrusion or by compression revealed in average less than 0.1 % dimeric IFN-α. The 
higher amount of dimer specimen presented within the used raw material used for 
twin screw extrusion potentially triggered further aggregation during in-vitro release 
studies from these implants.  
As shown in Figure 104 lysozyme was delivered almost entirely in its monomeric 
form (>98 %) from extrudates prepared by twin screw extrusion. Size exclusion 
chromatograms of lysozyme revealed a main protein peak with a retention time of 
24.5 minutes. In addition, a small peak with a retention time of 21 minutes was 
detected, which presumable corresponded to dimeric lysozyme. 
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Figure 103: IFN-α integrity during in-vitro release. 
Symbols indicate the total amount of delivered protein from extrudates comprising 10 % (open 
symbols) and 20 % (closed symbols) PEG. The bars illustrate the monomer content of delivered IFN-α 
(brighter bars: extrudates loaded with 10 % PEG, darker bars: extrudates loaded with 20 % PEG) 
Extrudates with a diameter of 0.5 mm (A), 1.0 mm (B) and 1.9 mm (C) were investigated (average +/-
SD; n = 3).  
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Figure 104: Lysozyme integrity during in-vitro release. 
Symbols indicate the total amount of delivered lysozyme from extrudates with different diameters. The 
bars illustrate the monomer content of delivered lysozyme (average +/- SD; n = 3). 
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2.7. SUMMARY AND CONCLUSION 
In the first part of this section various manufacturing strategies to produce lipidic 
implants by means of twin screw extrusion were investigated. Due to the sharp 
melting point of tristearin, implant formulations based solely on tristearin could not be 
processed. By tempering the extruder below the melting point of tristearin clogging of 
the extruder occurred, whereas employing temperatures close to the melting point of 
tristearin failed to increase the pressure within the barrel.  
In order to circumvent these problems a semisolid lipidic mass was prepared by 
admixing of semisolid lipids or oils. The obtained rubbery consistence enabled filling 
and extrusion in a continuous way. Moreover, homogeneity studies using methylene 
blue as model compound featured a uniform distribution of the drug load within the 
lipidic matrix.  
Alternatively, extrudates with an excellent homogeneity of the methylene blue 
distribution could be produced by the preparation of lipidic blends based on low- and 
high-melting point lipids. Due to the selective melting of the low-melting lipid during 
extrusion, clogging was avoided. On the other hand, after extrusion the lipidic matrix 
solidified which resulted in superior mechanical properties of the obtained extrudates 
compared to extrudates produced by the admixing of oils or semisolid fats.  
Using the admixing of low-melting point lipids as manufacturing strategy a broad 
spectrum of lipid combinations can be processed by twin-screw extrusion. An optimal 
percentage of the low-melting fat was found between 16 and 24 %.  
Although the low-melting point triglyceride was molten during extrusion, no 
polymorphic transformation occurred. Both, DSC and WAXS analysis revealed that 
extruded matrices comprised the lipids in their stable modification.  
Furthermore, the extrusion of IFN-α at 40 °C, with a lipidic blend comprising H12 as 
low-melting point component and tristearin as high-melting point fraction did not 
compromise protein integrity. SDS-PAGE analysis of IFN-α extracted from the lipidic 
matrix revealed beside of dimeric IFN-α no further aggregates or fragments. As the 
dimeric fraction was already present within the used protein bulk material before 
extrusion, no detrimental effects of the extrusion procedure could be detected by 
SDS-PAGE. In addition, FTIR-spectroscopy of IFN-α embedded in an extruded 
H12/tristearin matrix indicated that the secondary protein structure was not affected 
by the extrusion procedure.  
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In contrast to these encouraging results, the extrusion of IFN-α with a 
Miglyol®/tristearin blend resulted in the formation of higher-order aggregates as well 
as in conformational changes. Thus, despite the fact that the preparation requires the 
employment of elevated temperatures (40 °C) with respect to protein stability a clear 
superior of extrudates based on H12 and tristearin can be stated.  
As neither lipid modification nor protein stability were affected by the preparation 
methods the prerequisites for a successful sustained release system based on lipids 
were fulfilled and in-vitro release studies were carried out.  
The manufacturing of extrudates with different diameters was shown as an effective 
tool to adjust protein release kinetics. By increasing the implant diameter from 
0.5 mm to 1.0 mm and finally to 1.9 mm the liberation of IFN-α occurred in a 
prolonged manner over 15, 40, or 60 days. 
In addition, the release kinetics could be tailored by varying the amount of 
incorporated PEG. Elevation of the admixed amounts of PEG from 10 % to 20 % 
resulted in a more accelerated protein liberation. Furthermore, extrudates with a 
diameter of 1.0 mm or 1.9 mm revealed a virtually complete protein recovery when 
increasing the PEG content. Importantly, IFN-α was mainly delivered in its 
monomeric form. Over the entire incubation period for all investigated extrudates the 
relative amount of released monomeric IFN-α did not fall below 95 %. Beside the 
monomer fraction only dimeric IFN-α was detectable in the release medium using 
SE-HPLC.  
Interestingly, IFN-α release from extrudates with a diameter of 1.9 mm revealed a 
triphasic profile, consisting of a burst- and a lag-period and a nearly linear release 
phase. Since the implants were geometrically stable during the entire incubation 
period, matrix erosion as reason for the triphasic liberation patterns can be excluded 
(see Chapter I.5.2)  
Bearing in mind the in-situ precipitation of IFN-α within PEG-containing tristearin 
implants prepared by compression, it might be possible that such a scenario also 
contributes to the occurrence of a lag-release period.  
The assumption that protein precipitation might be of importance, was backed by the 
observation that the burst release from extrudates was rather low. For extrudates 
with a diameter of 1.0 mm and 1.9 mm the admixing of higher PEG quantities even 
resulted in a reduction of the burst effect. Such contradictions to the effects of PEG 
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as a porogen described in literature [40, 108, 138, 174] were shown to be a result of 
the postulated in-situ precipitation mechanism (Chapter IV).  
In order to investigate the relevance of in-situ precipitation for the sustained release 
from extrudates, IFN-α was substituted by lysozyme. As lysozyme revealed a less 
distinct precipitation in the presence of PEG the liberation of lysozyme occurred 
markedly accelerated compared to the delivery of IFN-α from the same formulation. 
Moreover, a triphasic release profile was not longer observed and liberation patterns 
of lysozyme featured rather high burst effects.  
Therefore, it can be concluded that the in-situ precipitation mechanism in the 
presence of PEG elucidated for tristearin implants prepared by compression 
(Chapter IV) presumably causes a sustained IFN-α liberation for extrudates prepared 
by twin screw extrusion, as well. 
In the final section of this chapter the three manufacturing methods used within the 
scope of this thesis were compared. A lipidic blend of H12 and tristearin containing 
20 % PEG and 10 % IFN-α/HP-β-CD co-lyophilisate was either processed by 
compression, by ram extrusion, or by twin screw extrusion. Although the implant 
diameter of extrudates prepared by twin screw extrusion was reduced, protein 
delivery was more sustained from this kind of implants. One explanation for this more 
delayed delivery might be the increase in matrix compactness (see Chapter V.1.6.1). 
Furthermore, it is highly conceivable that the melting and re-solidification of the low 
melting lipid filled open pore space of the implant and led to a welding between the 
incorporated compounds and the lipid material. In addition, homogeneity studies 
employing methylene blue as model compound revealed a finer distribution of 
methylene blue within the lipidic matrix. It was shown by Koennings et al. that a more 
homogeneous drug distribution within lipidic implants correlated with a prolongation 
of the release patterns [126]. As twin screw extruded implants revealed the most 
uniform methylene blue distribution, this might further contribute to the more delayed 
release from these extrudates. 
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CHAPTER VI: FINAL SUMMARY 
Two main objectives were to be accomplished within the scope of the present thesis. 
Firstly, it was aimed at an understanding of the mechanisms controlling protein 
release from lipidic implants, and secondly, focus was put on the development of 
new, improved protein delivery systems based on lipids.  
In Chapter I the reader is introduced to the concerns associated with protein delivery 
from polymeric sustained release systems which gave rise to investigate the potential 
of lipids as alternative matrix materials. Screening the current literature increasing 
interest in such lipidic controlled release devices could be stated. However, it turned 
out that the manufacturing strategies for lipidic implants mostly rely on the 
compression of a lipid/protein blend and alternative manufacturing techniques were 
only sparsely investigated for protein-loaded lipidic implants. An overview on the 
currently applied manufacturing strategies for lipidic and for polymeric implants was 
also given, which led to the conclusion that extrusion should be evaluated as 
manufacturing procedure for lipidic implants. Furthermore, the protein release 
mechanisms from degradable and from non-degradable systems as well as the 
respective mathematical models describing release are illustrated in Chapter I.  
Recently, lipidic implants prepared by compression were shown as promising 
platform for the continuous delivery of rh-interferon α-2a (IFN-α). The developed 
implant formulation is based on tristearin as matrix material comprises 10 % IFN-α 
co-lyophilised with hydroxypropyl-β-cyclodextrin (HP-β-CD) and different amounts of 
poly(ethylene glycol) 6000 (PEG) as porogen [151].  
The objectives of the thesis are summarised in Chapter II. 
Materials and Methods that were applied in the present work are listed in Chapter III. 
In order to get insights into the release controlling mechanisms; investigations on the 
in-vitro release kinetics of IFN-α, PEG, and HP-β-CD from the described implants 
system are outlined in Chapter IV.1. The addition of PEG to the lipidic implants 
resulted in a more sustained protein delivery with lower burst effects, whereas the 
liberation of both excipients, HP-β-CD and PEG, was accelerated when increasing 
the initial PEG loading. These different effects of PEG could be ascribed to the 
underlying mass transport mechanisms. As tristearin implants revealed no erosion 
during in-vitro incubation, the experimental release data were analysed with a 
mathematical solution of Fick´s second law of diffusion. Interestingly, the release of 
IFN-α from PEG-free implants was purely diffusion controlled, whereas also other 
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types of transport phenomena were of importance when the release modifier PEG 
was present. In contrast, the release of PEG as well as of HP-β-CD remained purely 
diffusion controlled, irrespective of the presence of PEG.  
In literature the role of PEG within controlled release systems has so far mostly been 
explained by its function as a pore forming agent [40, 108, 138, 174]. Due to an 
increase in the matrix porosity elevated levels of drug were recovered with an 
accelerated release rate.  
As PEG of various molecular weights was reported to precipitate IFN-α [201], it was 
assumed that a reduced protein solubility or even an in-situ protein precipitation may 
explain the sustained release of IFN-α from PEG-containing tristearin implants and 
the observed deviations from pure diffusion control. The assumption was backed in 
Chapter IV.2 where it was shown that IFN-α spontaneously precipitates in the 
presence of more than 3 % (wt/vol) PEG. Importantly, protein precipitation was 
completely reversible. IFN-α was recovered in its monomeric form without chemical 
degradation according to SE- and RP-HPLC measurements after re-dissolving the 
precipitates. Furthermore, FTIR- and fluorescence spectroscopy indicated a 
preservation of the native secondary and tertiary structure after precipitation and re-
dissolution.  
The in-situ precipitation of IFN-α during the delivery from PEG-containing matrices 
was proven in Chapter IV.3. A “macropore model” was developed, which revealed 
that the dissolution of IFN-α in the presence of PEG was the rate-limiting factor for 
protein release. Furthermore, the pH-dependence of IFN-α solubility in the presence 
of PEG was reflected by the protein release kinetics from lipidic implants. Finally, 
evidence for an in-situ precipitation of IFN-α was provided by both the replacement of 
PEG by an alternative porogen as well as by the substitution of IFN-α by lysozyme. 
In summary, the in-situ precipitation mechanism had two main benefits. The 
reversible precipitation of IFN-α in PEG-containing lipidic implants facilitated a low 
burst effect and a sustained protein release with nearly constant release rates. 
Moreover, the precipitation also ensured low concentrations of dissolved protein 
within the implant pores. Therefore, the tendency towards protein aggregation was 
reduced.  
Chapter IV.4 deals with the effects of the second hydrophilic excipient of the matrix 
formulation – HP-β-CD. In brief, the obtained findings indicated that HP-β-CD 
influenced the release of IFN-α rather by increasing the matrix porosity than by 
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protein complexation. In addition, a stabilisation of IFN-α during release can be 
supposed, as thermal protein denaturation studies, monitored with attenuated total 
reflection Fourier transform infrared spectroscopy (ATR-FTIR), figured out that HP-β-
CD reduced the tendency of IFN-α to undergo protein denaturation and aggregation 
at elevated temperatures (50-60 °C). 
In order to overcome the restrictions of administration associated with the large size 
of the above described implant system, various extrusion techniques were evaluated 
regarding their potential to produce small-sized lipidic protein delivery devices 
(Chapter V).  
Initially, the possibilities of ram extrusion were evaluated and an extrusion procedure 
was developed which did neither induced a polymorphic transformation nor 
compromised protein integrity. Moreover, the achieved geometry enabled filling of the 
extrudates in an injection device approved for subcutaneous application of polymeric 
implants.  
However, protein release was only sustained over 16 days and various attempts, 
such as variations in the particle sizes of the used raw materials or the change of the 
lipidic matrix material, did not substantially extend the release period. The less 
sustained protein liberation, compared to compressed implants, can be ascribed to 
the transfer of the manufacturing procedure from compression to ram extrusion, 
which provoked a reduction of the diffusion pathways as well as a decrease in matrix 
density. Since the changes of implant geometry and compactness also affect the in-
vitro release kinetics of the excipients, a more accelerated release of HP-β-CD and of 
PEG occurred from extruded implants. The enhanced leaching out of PEG was, 
furthermore, shown to be associated with distinctions in the underlying drug release 
mechanism between the implant systems. As the actual concentrations of PEG within 
the water-filled pores of extruded implants seemed to be lower compared to that 
generated within compressed implants, IFN-α release was purely governed by 
diffusion irrespective of the initial PEG loading.  
In Chapter V.2 twin screw extrusion was evaluated as alternative manufacturing 
technique. Apart from the initial problems associated with the handling of tristearin 
material, different formulation strategies enabling extrusion were identified. Among 
them the processing of proteins with a combination of low-melting point and high-
melting point lipids was deemed as most promising. Implants with diameters between 
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0.5 mm to 1.9 mm could be prepared, allowing subcutaneous injection via a large 
gauge needle.  
The produced implants based on a blend of the mixed-acid triglyceride H12 and of 
tristearin were shown to contain IFN-α in the quality of the raw material. In order to 
render investigations on the secondary structure of IFN-α embedded within lipidic 
implants, FTIR spectroscopy was utilised. As the obtained absorption spectra in the 
amid I region revealed no significant alterations compared to the lyophilised IFN-α 
prior extrusion, perturbations of the secondary protein conformation due to the 
extrusion procedure could be regarded as unlikely. Moreover, the produced 
extrudates comprised the lipids with their stable modification. Based on these 
positive outcomes regarding protein stability and lipid polymorphism, the main criteria 
for a new lipidic delivery device were met and release studies could be performed on 
a meaningful basis.  
During in-vitro release the developed implant system delivered IFN-α mainly in its 
monomeric form over time periods of up to 60 days. Moreover, the employment of 
small implant diameters or high initial PEG loadings facilitated a complete protein 
recovery.  
Importantly, the in-vitro release profiles could be easily controlled. One option to 
adapt the in-vitro release kinetics of IFN-α was the variation of the implant diameter. 
Protein liberation could be controlled in a prolonged manner over 15, 40, or 60 days 
by producing extrudates with a diameter of 0.5 mm, 1.0 mm or 1.9 mm, respectively. 
Furthermore, protein delivery could be tailored by the admixing of various amounts of 
PEG.  
The comparison of the release of IFN-α and lysozyme pointed out that in-situ protein 
precipitation is again important for the delayed protein liberation from extrudates 
prepared by twin screw extrusion. Although the lysozyme liberation occurred less 
delayed compared to the IFN-α delivery, a sustained lysozyme release over 25 days 
could be achieved. Furthermore, release studies carried out with implants prepared 
either by compression, by ram, or by twin screw extrusion indicated that twin screw 
extrusion per se resulted in more sustained protein delivery. Presumably, the 
blending, melting, and compaction during extrusion may explain this observation.  
Summing up the attainments, twin screw extrusion can be considered as promising 
manufacturing technique for lipidic implants. The developed extrudate formulation 
can be easily manufactured. As twin screw extrusion is commonly applied to produce 
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commercial polymeric implants, up-scaling of the manufacturing appears feasible. It 
was shown that the designed manufacturing procedure did not compromise protein 
integrity. Furthermore, IFN-α as well as lysozyme could be delivered in their 
monomeric form over prolonged periods of time.  
 
In conclusion two major achievements were reached with respect to the development 
of lipid-based sustained release devices for pharmaceutical proteins. First, a novel 
release mechanism based on an in-situ precipitation within inert matrices has been 
identified. Second, a new extruded lipidic implant system has been developed. As 
former concerns regarding implant administration and manufacture were overcome, 
the developed lipidic implant system can be deemed as promising platform for the 
controlled delivery of pharmaceutical proteins. The system was shown to be 
particularly suitable for the delivery of IFN-α, however, the knowledge obtained on 
the mechanisms controlling IFN-α release, should enable to transfer the developed 
system to a variety of other pharmaceutical proteins. 
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